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ABSTRACT

As part of our ongoing efforts to find new drug leads against infectious diseases,
several terrestrial and marine macro- and microorganisms were investigated. Several
bioactive molecules, presented below, were isolated from these natural products.
The mass-screening of dozens of marine Actinomycetes was completed and
several Streptomyces with interesting biological activity profiles identified. A few
examples are the Streptomyces code H747 and the Streptomyces code H668, a
bacterium from which a new (5) and two known polyethers, the antimalarial agent K41-A
(6) and its C-29 analog (7) were isolated.
Five new six-membered ring cyclic peroxides: plakinastreloic acid A (8), methyl
plakinastreloate A (9), the C-12 epimers of methyl 13, 14-epoxyplakinastreloate (10 &
11), and plakinastreloic acid B (12) were isolated from a marine sponge of the genus
Plakinastrella. Compounds 8 and 9 exhibited antifungal activities against Candida
albicans (IC50 = 6.5 µg/mL and 3.5 µg/mL, respectively), Aspergillus fumigatus (IC50 =
4.0 µg/mL and 9.0 µg/mL, respectively) and Cryptococcus neoformans (IC50 = 4.0
µg/mL and 9.0 µg/mL, respectively). A moderate antimalarial activity against CQresistant and CQ-sensitive strains of Plasmodium falciparum was observed, as well. It
was also established that 8 possesses anti-HCV (Hepatitis C Virus) activity.

ii

Two other compounds were isolated from HCV active methanol extracts of Inga
fagifiolia (twigs) and Diplostephium rhodendroides (leaves). These compounds were
identified as 2,3,4,5,6-pentahydroxy-2-(hydroxymethyl)hexanamide (14), the amide of a
known molecule and 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2yl)oxy] pentanoic acid (15). The bioassay-guided approach used for their isolation and
structure elucidation is reported here.
The potential of scCO2 to inactivate bacteria trapped in the gut of oysters was
studied. It was established that exposing oysters to CO2 at 100 bar and 37 °C for 30
minutes and at 172 bar and 60 °C for 60 minutes induced 2-log and 3-log reductions in
the APC loads, respectively. The decrease in the microbial load as a result of treatment
with scCO2 was found to be significant (P = 0.002). A blind study allowing sensory
analysis of treated vs. untreated oysters was also completed; no significant difference in
the physical appearance, smell, or texture was recorded.
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INTRODUCTION

Each year, millions of lives are claimed by diseases of all sorts. Nine of the top
ten threats to human life are disease related; the deadliest being coronary heart
disease, stroke and other cerebrovascular diseases, lower respiratory infections,
chronic obstructive pulmonary disease, diarrheal diseases, AIDS, tuberculosis and lung
cancer. Several of the diseases that burden the world population presently are
extremely old. There are for instance reports of malaria and tuberculosis going back to
antiquity [1, 2]. Yet after centuries of fight to see to their eradication, many are still
major public health issues.
Malaria, for instance, is a leading cause of death and morbidity in third world
countries; this disease claims the life of a child every 30 seconds. One of the major
hindrances towards taking full control of this disease is the emergence and rapid
spread of strains of the parasite that are resistant to major antimalarial drugs currently
marketed. Tuberculosis (TB), Multi Resistant Staphylococcus aureus (MRSA)
infections and AIDS are other major infectious illnesses that burden our world.
Tuberculosis (TB) is a pandemic and the leading cause of death among people
suffering from AIDS [3]. It is caused by Mycobacterium tuberculosis, which presently
infects about one third of the world population. One of the major barriers to fully control
the disease is the emergence of MDR strains; about 450,000 new cases of MDR-TB
are reported worldwide annually [3]. Like tuberculosis, MRSA which can cause fatal
1

invasive infections constitutes a serious public health issue faced by countries all over
the world. MRSA infections are of particular concern in hospital environments. The
emergence of vancomycin resistant strains is cause for greater concern, as
vancomycin is currently the drug of choice in the fight against MRSA related infections.
The incidence of several of these diseases is on the rise. These menaces put an
unprecedented amount of pressure on the necessity to discover new drugs/drug leads.
Multidrug resistance is not the only concern that threatens public health today;
pharmaceutical drug companies facing major problems with their pipelines is another
matter. As research and development (R&D) spending has grown exponentially over the
years, a steady decline in the number of NCE approved has been noted instead. It is
important to point out that combinatorial chemistry had failed to solve this issue. It has
been speculated that increase in attrition, longer R&D timelines, and increased costs for
some key R&D components (novel technologies for instance) were, among others, the
factors that drive R&D costs [4-6]. Because the decline in the number of approved NCE
had paralleled the reduced interest of pharmaceutical industries in natural products
related research, several experts believe that there is a correlation between these two
events [4].
Because of the exceptional contribution made, nature stands out in the drug
discovery arena. According to a recent report [7], of the 974 small molecules new
chemical entities reported between 1981 - 2006, 63% can be traced to nature, either as
a natural or a synthetic compound inspired from a naturally occurring molecule (Figure
0-1). An impressive number of currently marketed antibiotics were derived from
Actinomycetes.
2

The first project was to screen a set of marine Actinomycetes previously isolated
by one of our collaborators, namely Dr. Russell Hill - University of Maryland, Center of
Marine Biotechnology (COMB).

Several bacteria with interesting biological activity

profiles were identified. One of these bacteria was a streptomyces code H747 which
crude extract had outstanding anti-MRSA and anti-HIV activities. Four known bioactive
molecules, three diketopiperazines (1, 2 and 3) and a pyrrolobenzodiazepine (4) were
isolated from the crude extract of this bacterium.

Another Streptomyces with outstanding bioactivity against the malaria parasite
Plasmodium falciparum and MRSA was identified during a different screening program.
The bioassay-guided approaches used for the isolation of anti-infective metabolites from
this bacterium and several other marine and terrestrial organisms are presented below.

3

Figure 0-1. All small molecule new chemical entities, 01/1981-06/2006, by sources
(N974)
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Chapter 1 : POLYETHER IONOPHORES: BROADSPECTRUM AND PROMISING BIOLOGICALLY
ACTIVE MOLECULES FOR THE CONTROL OF DRUGRESISTANT BACTERIA AND PARASITES

Published in Expert Opinion on Drug Discovery, 2009, 4 (2):1-36
Authors: Kevin II DA, Meujo DA, and Hamann MT

Background: As multidrug-resistant (MDR) pathogens continue to emerge, there
is a substantial amount of pressure to identify new drug candidates. Carboxylic
polyethers, also referred to as polyether antibiotics, are a unique class of compounds
with outstanding potency against a variety of critical infectious disease targets including
protozoa, bacteria and viruses. The characteristics of these molecules that are of key
interest are their selectivity and high potency against several MDR etiological agents.
Objective: Although many studies have been published about carboxylic
polyether antibiotics, there are no recent reviews of this class of drugs. The purpose of
this review is to provide the reader with an overview of the spectrum of activity of
polyether antibiotics, their mechanism of action, toxicity and potential as drug
candidates to combat drug-resistant infectious diseases.
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Conclusion: Polyether ionophores show a high degree of promise for the
potential control of drug-resistant bacterial and parasitic infections. Despite the long
history of use of this class of drugs, limited medicinal chemistry and drug optimization
studies have been reported, thus leaving the door open to these opportunities in the
future.
Scifinder and PubMed were the main search engines used to locate articles
relevant to the topic presented in this review. Keywords used in our search were
specific names of each of the compounds presented in the review, as well as more
general terms such as polyethers, ionophores, carboxylic polyethers and polyether
antibiotics.

1. Introduction
Polyether antibiotics or carboxylic ionophores [8, 9] represent a unique class of
compounds reported as potent antibiotics. They belong to the larger family of naturally
occurring ionophores. First used in 1967, the term ionophore refers to the molecule’s
ability to bind a metal ion and facilitate its transport across cellular membranes. This
chemo-physiological property has made polyether ionophores a useful tool in the study
of cation transport mechanisms and has been the rationalization for their biological
activities [9, 10].
Polyether antibiotics are believed to affect their targeted cells by modification of
the permeability of cellular membranes to cationic metal species. Polyether ionophores
6

possess distinctive structural features that are crucial to their ability to interact with
metal species. These features include an exterior alkyl backbone that confers their
lipophilic characteristics, and an oxygen-rich internal cavity that can bind metal ions [8,
11, 12].
Naturally occurring ionophores are grouped into three categories with regard to
the mechanism through which membrane permeability is altered. The first group is the
mobile carriers that bind the metal species in an internal polar cavity, thus shielding their
charge. The second group is the quasi-ionophores. These molecules form transmembrane hydrophilic channels that permit the flow of metal ions. The last group
consists of the neutral ionophores that facilitate the diffusion of cations across
membranes according to the membrane potential [8, 13].
Naturally occurring carboxylic ionophores are relatively high in molecular weight,
500 – 1,000 amu, and are lipid soluble compounds that display a high affinity for cations
such as K+, Na+, Ca2+, thus yielding mobile cation complexes that can freely travel
across biological membranes [9]. With the exception of lasalocid, (16) all naturally
occurring carboxylic ionophores possess an affinity for Na+ and K+. Lasalocid (16) forms
dimers and divalent complexes with Ca2+ and Mg2+. This metal complex formation
results in a paracyclic complex as a result of the head-to-tail hydrogen bonding.
The normal physiologic steady state of most living cells is dependent on the
establishment of intracellular and extracellular concentration gradients of Na+ and K+
[14]. These ion concentration gradients are essential for cell function. Carboxylic
ionophores can easily penetrate cellular membranes owing to their lipophilic properties
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[14-16] and perturb the intracellular cation balance. Carboxylic ionophores thus present
significant biological interests not only for their therapeutic utility but also for the
possibility of using these chemo-physiological dynamics in combination with traditional
or current therapeutics [10, 16, 17].
A total of 53 bacteria of the Streptomycetaceae family are reported to produce
carboxylic ionophores. These microorganisms belong to three genera, Streptomyces,
Actinomadura and Dactylosporangium. Streptomyces sp. are the main producers of
these types of compounds and ~ 50% of the known carboxylic ionophores are derived
from two Streptomyces species (Streptomyces hygrocropicus and Streptomyces albus)
[9]. Industrially, these highly active molecules are produced via fermentation by
microorganisms; the cost of production is generally low [10, 18, 19].
2. Biological activity
Polyether antibiotics show a broad spectrum of bioactivity including antibacterial,
antifungal, antiparasitic, antiviral and tumor cell cytotoxicity. In addition to the previously
mentioned biological activities, several studies have investigated the herbicidal [20] and
anti-inflammatory activities [21] of these molecules, as well as their effect on the CNS
and immunoregulatory systems (Table 1-1) [22, 23].
2.1 Antibacterial
The antibacterial potential of carboxylic ionophores is widely documented;
reports on the discovery of these compounds typically mention their activity against
some fungi and Gram-positive and Gram-negative bacteria. From these reports, it can
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be gathered that carboxylic polyethers are molecules of outstanding potency against
numerous pathogenic bacteria (drug-sensitive and drug-resistant). The fact that their
potency against serious threats such as MRSA and VRE rivals that of clinically used
drugs such as vancomycin and oxacillin, adds to their potential utility. At this point, it is
difficult to fully assess the true value of these molecules as potential antibacterial
therapeutic agents simply because none of these molecules has been tested on animal
models.
2.1.1 Activities against drug-sensitive bacterial strains
A similar inhibitory pattern, namely, a strong selectivity towards Gram-positive
bacteria, emerged from reports on the antibacterial potential of carboxylic polyethers [9,
11, 15, 16, 19, 24-28]. Monensin (17), narasin (18), salinomycin (19), nigericin (20),
lenoremycin (21), septamycin (22), carriomycin (23), X-14766A (24), noboritomycin A
(25), alborixin (26), ionomycin (27), A23187 (28), X-14547A (29), lysocellin (30) and
lasalocid (16) were all evaluated against eight Gram-positive bacteria, seven Gramnegative bacteria, and four fungal species. All but ionomycin (27) showed potent activity
against Gram-positive bacteria (MIC varying in the range 0.006 – 12.5 µg/mL). In
contrast, not one of these compounds displayed activity against the tested Gramnegative bacteria (MIC > 100 µg/mL). Several other carboxylic ionophores are reported
as having a similar biological activity profile against Gram-negative and Gram-positive
bacteria. These are grisorixin (31) [18], ionomycin (32) [27], octacyclomycin (33) [25], X14931A (34) [28], dianemycin (35) [16], ionomycin B (36) [19] and C (37) [19], antibiotic
6016 (38) [26], inostamycin (39) [29], inostamycin B (40) [29] and leuseramycin (41)
[30].
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Not all carboxylic polyethers show this selectivity towards Gram-positive
bacteria. Compounds such as septamycin (22), noboritomycin A (25) and B (42)
stand out for their ability to target not only Gram-positive bacteria but also Gramnegative bacteria. The reported MIC of septamycin (22) against Escherichia coli was
0.1 µg/mL [31]. Noboritomycin A (25) and B (42) inhibited the growth of Neisseria
pharyngi with an MIC of 0.01 µg/mL [32]. The MIC of mutalomycin (43) against the
same pathogen was 0.3 µg/mL [33]. Not all carboxylic ionophores possess significant
activity against Gram-positive bacteria. For example, laidlomycin (44) was reported
as inactive against Staphylococcus aureus [34]. Although in general anaerobic
bacteria are more resistant to carboxylic polyethers, a few Clostridium sp,
Eubacterium sp, Propionibacterium sp and Peptococcus sp are reported as
extremely sensitive to compounds such as nigericin (20), monensin (17), dianemycin
(35), lysocellin (30), lasalocid A (16) and A23187 (28) with MIC values as low as
0.049 µg/mL in many cases [9]. Carboxylic ionophores have a broad spectrum of
activity against Gram-positive but not Gram-negative bacteria. Guyot et al. [35]
attributed this overall differential selectivity to the presence of an outer membrane in
Gram-negative bacteria. The outer membrane is believed to be impermeable to
hydrophobic compounds. These authors came to this conclusion while using
autoradiography; they could show that only Bacillus cereus, not E. coli, could
incorporate the radiolabeled calcimycin (28) [36].
2.1.2 Activities against multidrug-resistant strains of bacteria
Carboxylic polyethers were reported as potent agents against a variety of
MDR strains of pathogenic bacteria. Lycocellin (30), for instance, was reported as
10

active against a streptomycin-, erythromycin-, chloramphenicol and penicillinresistant strain of S. aureus , MIC 4 µg/mL [15]. The MIC for the Na+ salt of the
antibiotic No 6016 (38) against a similar strain was reported to be 1.56 µg/mL [26].
Noboritomycin A (25) and B (42) were also reported as being active against several
resistant strains: penicillin-resistance strains of S. aureus, MIC 0.01 µg/mL,
tetracycline-resistance strains of Micrococcus sp, MIC 0.01 µg/mL, aminoglycosideresistant strains of Streptococcus faecalis, MIC 0.01 µg/mL and macrolide-resistant
strains of Sarcina lutea , MIC 0.01 µg/mL [32].
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Table 1-1. Overview of reported bioactive naturally occurring polyethers (from 1967-1994*), sources, and their
reported in vivo and in vitro testings

Name (acronyms),
molecular formula,
molecular weight

Organism from which
it was isolated

In vitro activities

Tested in vivo

Availability
of crystal
structure

Discove
ry (year,
journal,
authors
)

Lasalocid A (16),
C34H54O8
590.8

Streptomyces
lasaliensis
NRRL 3382

Antimicrobial and/or
antiparasitic effect
[43-47]

[48]

[48]

Monensin A (17),
C36H62O11
670.9

Streptomyces
cinnamonensis ATCC
15413

Antiparasitic [37-39],
antiviral [40], antibacterial
[9, 41],
antifungal [9, 42]
Antiparasitic [37, 49-53],
antiviral [40, 54],
antibacterial [55, 56],
antifungal [9],
antiproliferative/apoptotic
[55, 57]

Antimicrobial and/or
antiparasitic
effect [37, 44, 58],
immunoregulatory
effect [59],
cardiovascular
effect [60, 61],
antiviral [62]

[63]

[63]

Narasin A (18),
C43H72O11
765.0

Streptomyces
aureofaciens NRRL
5758

Antibacterial [9, 56, 64],
antifungal [9] ,
antiparasitic [37, 51, 52]

Antiviral [62],
antiparasitic [64]

[64]

Salinomycin (19),
C42H70O11
751.0

Streptomyces
lasaliensis

Antiparasitic [38, 51, 52],
antiviral [40], antibacterial
[9, 56],
antifungal [9]

Antimicrobial and/or
antiparasitic
effects
,immunoregulatory
effect [40, 44, 47, 58,
65-68]

[69]

- 12 -

Nigericin (20),
C40H68O11
725.0

Streptomyces
hygrocopicus

Lenoremycin (21),
C47H77O13Na,
873.1

Antiparasitic [37, 53, 70],
antiviral [40, 71, 72],
antibacterial [9],
antifungal [9],
antiproliferative/apoptotic
[57, 73]

Antimicrobial and/or
antiparasitic effect
[37, 74-76], effect on
CNS tissues [23, 77],
antitumor [73],
antiherbicidal/insecti
cidal [20], Antiviral
[62]

Antibacterial, antifungal
[9, 39]

Septamycin (22),
C48H82O16
915.2

Streptomyces
hygroscopicus
NRRL 5678

Antibacterial, antifungal
[9, 31],
antiproliferative/apoptotic
[31]

Antiparasitic[16, 31],
antiviral [31]

Carriomycin (23),
C47H80O15
885.2

Streptomyces
hygroscopicus

antiproliferative/apoptotic
[57],
antibacterial, antifungal
[80]

Antimicrobial and/or
antiparasitic effect
[72, 81]

Antibiotic X-14766A
(24),
C43H62ClO14 Na
861.4
.

Streptomyces
malachitofuscus
subsp. downeyi

Antibacterial antifungal
[83]

Noboritomycin A (25),
C43H63O14Na
827.0

Streptomyces
Noboritoensis NRRL
8123

Antibacterial [32]

- 13 -

Antibacterial [32]

[78]

[78]

[79]

[79]

[31]

[82]

[82]

[84]

[84]

[32]

Alborixin (26),
C48H84O14
885.9

Streptomyces albus

Antibacterial [9], antiviral
[85], antiparasitic [51, 52,
86],
anticocicidal [50]

Antimicrobial and/or
antiparasitic
effect [37, 39, 87],
cardiovascular effect
[18]

Ionomycin (27),
C41H70CaO9
747.1

Streptomyces
conglobatus ATCC
31005

Immunoregulatory
effect [92-96],
effect on CNS
tissues [22]

Calcimycin (A23187)
(28),
C29H37N3O6
523.6
X14547 A (29)

Streptomyces
Chartreusensis

Antiparasitic [51],
antibacterial, antifungal
[9, 89],
antiproliferative/apoptotic
[90, 91]
Antiparasitic [51],
antibacterial,
antifungal [9, 36]

Lysocellin (30),
C34H59O10 Na.1/2H2O
659.8

Streptomyces cacaoi

antiproliferative/apoptotic
[57], antibacterial [15]

Antimicrobial and/or
antiparasitic effect
[81]

[99]

[99]

Grisorixin (31),
C40H68O10
709.0

Streptomyces griseus

Antiparasitic [51],
antibacterial [18]

Antimicrobial and/or
antiparasitic
effect [52],
cardiovascular
effect [100-102]

[35]

[35]

Lonomycin A (32),
C44H76O14
829.1

Streptomyces
hygrocopicus

Antibacterial [27],
antiproliferative/apoptotic
[57],
antiparasitic [37, 51]

Antimicrobial and/or
antiparasitic effect
[103],
cardiovascular effect
[104]

[88]

[89]

[97]

Antiparasitic [51]
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[88]

[97]

[98]

[27]

Octacyclomycin (33),
C52H88O19
1,016

Streptomyces sp.

Antibacterial, antifungal,
antiproliferative/apoptotic
[25]

[25]

X-14931A (34),
C40H66O11
723.0

Antibacterial [28, 105],
antifungal [28]

Antiparasitic [28]

[28]

[28]

Dianemycin (35),
C47H78O14
867.1

Antiviral [40],
antibacterial [16],
antiproliferative/apoptotic
[57]

Anti-inflammatory
[21]

[106]

[106]

Lonomycin B (36),
C44H75O14Na
851.1

Streptomyces
ribosidificus TM-481

Antibacterial and
antifungal [19]

[19]

Lonomycin C (37),
C43H73O14Na
837.0

Streptomyces
ribosidificus TM-481

antiproliferative/apoptotic
[57], antibacterial [19]

[19]

Antibiotic 6016 (38),
C46H78O16
887.1

Streptomyces albus

Antibacterial,
antiparasitic [26]

[107]

[107]

Inostamycin (39),
C38H68O11,
700.9

Streptomyces sp.
MH816-AF15

antiproliferative/apoptotic
[24], antibacterial [29]

[108]

[108]

Inostamycin B (40),
C37H66O 11
686 M+

Streptomyces sp.
MH816-AF15

Antibacterial, antifungal
[29]
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[29]

Leuseramycin (41),
C47H78O13
851.1

Streptomyces
hygroscopicus
TM-531

Antibacterial, antifungal
[30]

Noboritomycin B (42),
C44H65O14Na
841.0

Streptomyces
Noboritoensis NRRL
8123

Antibacterial [32]

Mutalomycin (43)
S-11743
C 41 H 69 O 12 Na,
755.0

Streptomyces mutabilis

Antiparasitic [33]

[33]

Laidlomycin (44) AB78
C37H62O12
698.9

Streptoverticillum
eurocidium

Antiproliferative/apoptotic
[34, 57]
antibacterial [34, 41, 56],
antiviral [85]

[34]

X-14885 (45 ),
C27H31N2O7 Na·H2O
536.57

Streptomyces sp. X14885

Antibacterial, antifungal
[109]

Cationomycin A (46),
C45H70O15
850.5

Actinomadura azurea
sp Nov

Antiparasitic [51],
antibacterial [9, 110]

Antiparasitic [110]

AntibioticX-206 (47),
C47H82O14
870

Streptomyces sp

Antiparasitic [111]

Antimicrobial and/or
antiparasitic
effect [111-113]
cardiovascular effect
[114]
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[30]

Antiparasitic [32]

[32]

[109]

[109]

[110]

[115]

[115]

K-41-A (48),
C48H82O18
947.2

Streptomyces
gypseum
NRRL 11168

Antiparasitic [116],
antibacterial [117]

Hawaiimycin I (49),
C36H64O12Na
711.4

Streptomyces sp.

Antiparasitic [120]

Maduramicin (50)
C47H80O17
917.1

Actinomadura rubra

Antibacterial [121],
antiparasitic [52, 122]

Antimicrobial and/or
antiparasitic effect
[44, 87, 123]

CP-82,009 (51),
C49H84O17
945.2

Actinomadura sp.
(ATCC 53676)

Antibacterial [124]

Antiparasitic [124]

[124]

[124]

CP-84,657 (52),
C45H78O14
843.1

Actinomadura sp.

Antibacterial [93]

Antiparasitic [93]

[93]

[93]

CP-80,219 (53),
C47H78O14
867.1

Streptomyces
hygroscopicus

Antibacterial [125]

Antiparasitic [125]

[125]

[125]

Kijimicin (54),
C37H 64O11
684.9

Actinomadura sp
MI215-NF3

Antibacterial [126],
antiviral[40, 127, 128],
antiparasitic [129]

Antiparasitic [126]

[126]

[126]

Endusamycin (55),
C47H77O14Na
889.1

Streptomyces endus
subsp. aureus
(ATCC39574)

Antibacterial [130]

Antiparasitic [130]

[130]

[130]

X-14868A (56 ),

Nocardia X-14868

Antibacterial,

Antiparasitic [131]
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Antiherbicidal/insecti
cidal [118]

[119]

[117]

[120]

[121]

[131]

C47H80O17
917.13

antifungal [131]

X-14868B ( 57 ),
C48H82O17
931.2

Nocardia X-14868

Antibacterial,
antifungal [131]

SF 2361 (58),
C48H82O16
915.2

Actinomadura sp. SF2361

Antiviral [40],
antiproliferative/apoptotic
[57]

[132]

Antiviral [40, 43],
antiproliferative/apoptotic
[57]

[133]

SF2324 ( 59 ),
C52H88O19
1017.2

Antiparasitic [131]

[131]

SF 2487 ( 60),
C42H63O12Na
805

Actinomadura sp
SF2487

Antibacterial [134]
antiviral [40, 134],
antiproliferative/apoptotic
[57],
antiparasitic [129]

Monensin B (61)
C35H60O11
656

Streptomyces
cinnamonensis ATCC
15413

Antiviral [9]

A 28695B (62)
C48H82O17 Na
953.5

Streptomyces albus
NRRL 3883

A-204 (63)
C49H84O17
945.2
Deoxy-(0-8)salinomycin (64),

Streptomyces albus

Antiviral [9]

[135]

[135]

Streptomyces albus
ATCC 21838

Antibacterial, antifungal
[114]

[114]

[114]

[134]

[134]

[112]

Antiparasitic [16],
Antiviral [62]
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[16]

C42H70O10
734
CP-91,243 (65),
C50H83O18Na
995.1

Actinomadurra
roseorufa

CP-120,509 ( 66 ),
C45H76O17
889.1

Actinomadura
roseorufa

Antibacterial,
antifungal [137]

Iso-lasalocid ( 67 ),
C34H54O8
590.8

Streptomyces
lasaliensis

Antibacterial [138]

20-Deoxynarasin
(68),
C43H72O10
748

Streptomyces
aureofaciens
NRRL 11181

Antibacterial, antiviral
[82]

Antiparasitic [82]

[82]

20-deoxy-epi-17narasin ( 69 )
C42H70O10
735.0

Streptomyces
aureofaciens
NRRL 11181

Antibacterial, antiviral
[82]

Antiparasitic [82]

[82]

Moyukamycin (70),
C47H75O13Na
871

Streptomyces
hygroscopicus
TM-581 (FERM-BP
274)

Antibacterial, antifungal
[139]

(Deoxy-(O-8)3)-epil7salinomycin (71),
C42H70O10

Streptomyces albus
ATCC 21838

Antibacterial, antifungal
[114]

Antibacterial,
antiparasitic,
antifungal [136]
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[136]
Antiparasitic
[137]

[137]

[138]

[137]

[138]

[139]

Hypertention [140]

[114]

[114]

735.0
CP-54,883 (72),
C41H61O12Cl2
838

Actinomadura routienii
Huang sp.

Antibacterial,
antiparasitic [141]

X-14868C (73),
C46H78O17
903.1

Nocardia X-14868

Antibacterial,
antifungal [131]

X-14868D (74),
C47H80O17
917.1

Nocardia X-14868

Antibacterial,
antifungal [131]

Abierixin (75),
C40H68O11
725.0

Streptomyces albus
NRRL B-1865

Antibacterial,
antifungal [142]

Antiparasitic,
[142]

[142]

Martinomycin (76),
C49H84O17
967.5

Streptomyces salvialis

Antibacterial [143]

Antiherbicidal/insecti
cidal [143]

[143]

Portmicin (77),
C44H76O14
828

Nocardiopsis sp No.
6270

Antibacterial,
antifungal [144]

Antiparasitic [144]

[144]
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[141]

Antiparasitic [131]

[131]

[131]

X-14667 A (78),
C44 H88NO12Na
826.0

Streptomyces
cinnamonensis

Antibacterial, antifungal
[145]

[145]

X-14667 B (79),
C45H70NO12Na
840.0

Streptomyces
cinnamonensis

Antibacterial, antifungal
[145]

[145]

CP-96,797 (80),
C47H80O17
917.1

Streptomyces sp

Antibacterial, antifungal,
[146]

UK-58, 852 (81)
C52H88O18
1000

Actinomadura
roseorufa Huang sp.
nov., ATCC 39697

Antiparasitic [146]

Antiparasitic,
antibacterial [147]

- 21 -

[146]

[146]

[147]

The sodium salt of septamycin (22) was also reported as effective against
several MDR bacterial strains. These included a penicillin-resistant strain of
Staphylococcus
Micrococcus

sp.

aureus
(MIC

(MIC 0.31
0.31

µg/mL),

µg/mL),

an

a

tetracycline-resistant

strain

of

aminoglycoside-resistant

strain

of

Streptococcus faecalis (MIC 0.1 µg/mL) and finally, a macrolide-resistant strain of
Sarcina lutea (MIC 0.31 µg/mL) [31]. In 2007, Yoo et al. [56] published a report on the
potential of several carboxylic polyethers, namely, laidomycin (44), monensin (17),
salinomycin (19) and narasin (18), to inhibit VRE and MRSA [56]. In the case of MRSA,
the MIC of these compounds varied from 0.5 to 4 µg/mL; in the case of VRE, it varied
from 8 to 16 µg/mL against. Narasin (18) was the most potent compound. All these
compounds were more potent than vancomycin and oxacillin. The MIC of vancomycin
against VRE was 64 µg/mL and that of oxacillin against MRSA was > 32 µg/mL [56].
2.2. Antifungal
In general, fungi are more resistant to carboxylic ionophores. Several authors
have reported MIC values greater than the highest tested concentration [9, 15, 18, 25,
27]. There are some exceptions: several species of fungi, namely, Paecilomyces
variotii, Candida albicans, Saccharomyces cerevisiae and Penicillium digitatum were
reported as moderately sensitive to some carboxylic polyethers. These included for
example, grisorixin (31) [18], monensin (17) [9], narasin (18) [9], salinomycin (19) [9],
lenoremycin (21) [9], carriomycin (23) [9], alborixin (26) [9], A23187 (28) [9], dianemycin
(35) [11] , lysocellin (30) [9], X-14931A (34) [105] and leuseramycin (41) [30] , with MIC
values varying in the range of 20 – 100 µg/mL. P. variotii, C. albicans, S. cerevisiae and
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P. digitatum were quite sensitive to several other carboxylic polyethers (lysocellin (30)
[9], A23187 (28) [9], lenoremycin (21) [9] and nigericin (20) [9]). The MIC values for
these compounds were < 2 µg/mL. More recent studies about the antifungal capacities
of carboxylic ionophores have focused on opportunistic infections caused by
Pneumocystis carinii [46]. Lasalocid (16) and nigericin (20), two common carboxylic
ionophores, were found to possess a significant inhibitory effect on the growth of P.
carinii in vitro [42, 46].
2.3 Antiparasitic
2.3.1 Plasmodium sp
The emergence and spread of resistant strains of the malaria parasites to several
of the antimalarial drugs marketed at present, especially CQ, constitute a serious
public health threat [148-151]. To address this issue, combination therapy, i.e., the
simultaneous use of more than one drug known to have different mechanisms of action
(MOAs) is important. Such an approach slows the development of resistance to
individual drugs, thus limiting the spread of resistant strains [152]. The success of
combination therapy is dependent on the availability of molecules with unique MOA. In
recent years, a great deal of effort has been dedicated to the discovery of new
antimalarial agents. Among the potential candidates reported thus far are carboxylic
ionophores. From the reports we gathered, it emerges that these molecules stand out
as potential antimalarial drug candidates for several reasons.
First, carboxylic ionophores are potent in vitro antimalarial agents, with IC50
values in the nanomolar and picomolar range [51, 111]. Carboxylic ionophores are
23

typically organized into three subclasses. The first category includes compounds
specific to monovalent cations such as alborixin (26), lonomycin A (32), nigericin (20),
grisorixin (31), narasin A (18), salinomycin (19), cationomycin (46) and monensin A
(17). The second group includes molecules that are specific to divalent cations; few
examples are calcimycin (28), X14885 A (45) and X14547A (29) (Figure I-1). The third
category includes molecules that show no particular specificity; among these are
lysocellin (30), lasalocid A (16) and ionomycin (27). Of these three subgroups,
carboxylic ionophores specific to monovalent cations are reported as the most potent
with IC50 values in the range of 0.6 – 1.5 ng/mL. Cationomycin (46), IC50 = 35 ng/mL, is
an exception.
Second, carboxylic ionophores are also reported to have potent activity in vivo.
The in vivo antimalarial potential of alborixin (26), ionomycin A (32), nigericin (20),
narasin (18) and monensin A (17) was recently evaluated using rats infected with
Plasmodium chabaudi and Plasmodium vinckei petteri [37] . Alborixin (26), ionomycin
A (32), nigericin (20), narasin (18) and monensin A (17) showed significant in vivo
antimalarial activity, decreasing the parasitemia by ≥ 70% by day 5 in P. chabaudi and
P. vinckei petteri infected mice. Overall, the ED50 varied between 0.4 and 4.1 mg/kg.
Carboxylic ionophores that are specific to monovalent ions including alborixin (26),
lonomycin A (32), nigericin (20), narasin (18) and monensin A (17) seemed to be the
most potent. The therapeutic index using the intraperitoneal route of administration for
lonomycin A (32), nigericin (20), narasin A (18), monensin A (17) and lasalocid A (16)
ranged from 2 to 6 [37]. A similar study was completed by Adovelande and Schrevel
who assessed the in vivo antimalarial activity of monensin (17) and nigericin (20) on P.
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vincke petteri infected mice. The ED50 and ED90 values for monensin (17) were 1.1 and
3.5 mg/kg, respectively. The ED50 and ED90 for nigericin (20) were 1.8 and 4.6 mg/kg,
respectively. Monensin (17) seemed more effective at curing mice than nigericin (5);
100% of mice that received 10 mg/kg of monensin (17) were cured. Only one-third of
mice that received a similar dose of nigericin (20) were cured [74].
Third, according to several studies, these molecules act in a selective manner.
The threshold of toxicity varies from one subclass of carboxylic ionophores to the next.
Gumila et al. [51] reported the in vitro differential ionophore activity between P.
falciparum and normal mammalian cells (Human Jurkat lymphoblasts and U937
macrophage cell lines). It appeared that mammalian cells were only affected by
compounds such as nigericin (20), alborixin (26), lonomycin (32), narasin (18) and
monensin (17) at concentrations that are significantly (i.e., at least 35-fold) higher than
the IC50 against the malarial parasite [51]. While the IC50 of narasin (3), monensin A
(17) and nigericin (20) against the malaria parasite varied in the range 0.6 – 1.5 ng/mL,
the LD50 against against U937 macrophage, varied between 23.5 and 305 ng/mL. The
LV50, LD50 against Jurkat lymphoblast, varied between 45 and 500 ng/mL [51]. Gumilla
et al. [37] assessed the acute and subacute toxicity of these compounds using rats
infected with P. chabaudi and P. vinckei petteri and determined that alborixin (26), LD50
= 1 mg/kg, was the most toxic. Overall, carboxylic ionophores such as alborixin (26),
lonomycin (32), nigericin (20), narasin (18) and monensin A (17) that are specific to
monovalent ions appeared to be more toxic; the reported LD50 values for those
molecules were in the range 4 - 30 mg/kg. The LD50 values for polyethers specific to
divalent metal ions on the other hand varied in the range of 30 – 80 mg/kg [37].
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Fourth, two carboxylic ionophores were reported to be significantly more potent
than CQ. Adovelande and Schrevel assessed the antimalarial activity of monensin (17)
and nigericin (20) alongside that of CQ and showed that in vitro, these were 25- and
30,000-fold more potent, respectively [74].
Fifth, several carboxylic ionophores were recently reported as having outstanding
activity against chloroquine-resistant strains of P. falciparum. Otoguro et al. [111, 153]
published two reports in 2001 and 2002 in which the effects of several carboxylic
ionophores were evaluated against chloroquine-resistant and sensitive strains of P.
falciparum alongside several drugs marketed at present. These antimalarial agents
were artesunate, artemisin, CQ, pyrimethamanine, amodiaquine, quinine and
trimethoprim. These studies revealed that carboxylic ionophores such as X-206 (47),
lonomycin A (32), nigericin (20), narasin (18), salinomycin (19), dianemycin (35),
monensin (17) and lysocellin (30) were extremely potent against CQ-resistant strains of
P. falciparum with IC50 values varying in the range 0.15 – 6.4 nM (most potent). These
molecules seemed to be more potent than the standard drugs mentioned earlier. The
IC50 values for these drugs varied from 7.6 to values > 100,000 nM. Artemether (IC50 =
7.6 µg/mL) was the most potent of these standard compounds. The cytotoxicity against
mammalian cells, a human diploid embryonic cell line, was also assessed. Lasalocid A
(16), octocyclomycin (33) and X-206 (47) displayed high selectivity indexes. The
highest selectivity index was that of X-206 (47), that is, 3,673 against the CQ-resistant
strain and 1,080 against the CQ-sensitive strain. These compounds showed higher
potency and selectivity towards CQ-resistant strains when compared to CQ-sensitive
strain [111]. Lastly, these authors performed a comparative assessment of the in vivo
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effect of X-206 (47), artesunate and artemether in Plasmodium berghei infected mice.
X-206 (47) showed a narrow therapeutic window and had an ED50 = 0.53 mg/kg but
this compound was toxic at 3 mg/kg. In 2002, these authors reported another
compound, K-41 (48), as active in vitro against a CQ-resistant strain of P. falciparum.
K-41 (48) (IC50 = 8.5 nM) showed an activity similar to that of artemether and
artesunate and was more potent than artemisinin, CQ and pyrimethamine. K-41 (48)
had a moderate selectivity index in vivo; it was active orally against the CQ-resistant
strain used; the ED50 (7.0 mg/kg) was close to that of artemether, CQ and artesunate.
As far as acute toxicity of K-41 (48) is concerned, an LD50 > 100 mg/kg was reported
[153].
Finally, carboxylic ionophores are believed to affect the malaria parasite by
means of a mechanism that is distinct from that of drugs available at present. It is
important to point out that there is some conjecture over this subject. Adovelande and
Schrevel believe that the mechanism of action of carboxylic ionophores is similar to
that of CQ [74]. The latter acts by increasing the internal pH of the food vacuole and by
binding to ferriprotoporphyrin, thus preventing its crystallization into hemozoin.
Hemozoin will then accumulate to a toxic level inside the vacuole [74, 154, 155]. It is
generally accepted that carboxylic ionophores act via anti-transport of cation with H+
after inserting themselves in cellular membranes, acting as ion channels. According to
Adovelande and Schrevel, this anti-transport of cations with H+ will result in the
alkalination of the food vacuole of the parasite in a similar manner as CQ [74]. Gumilla
et al. [51] have a different point of view. According to these authors, the anti-transport
of cations with H+ cannot justify the outstanding potency of these compounds, for the
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simple reason that changes that occur in the plasma membrane of infected
erythrocytes reduce the efficiency of ion shuttling across the membrane. These authors
believe that carboxylic ionophores are completely internalized [51, 156]. Once inside
the cell and in close proximity with the parasite, they can inhibit its development either
by altering its ion content or by disturbing the pre-established ionic gradient between
the host and parasite cytosol [51]. The parasite is reportedly more sensitive during the
shizont stage [37].
A polyether isolated from the marine Streptomyces sp. H668 and named
hawaiimycin-I (49) [120] reinforced the critical role of certain key structural features
including the terminal carboxylic group on the bioactivity of carboxyl ionophores.
Hawaiimycin-I (49) is close structurally to a set of carboxylic ionophores reported as
potent antimalarial [37, 153], that is, monensin A (17 ), K-41 (48), nigericin (20),
lonomycin (32) and grisorixin (31). These molecules share a unique skeleton: five
interconnected tetrahydrofuran and pyran rings. The key difference between
hawaiimycin-I (49), established to have only a weak antimalarial activity (IC50 = 100 –
200 ng/mL against P. falciparum) [120], and these molecules is the absence the
terminal carboxylic group. Crystal structures of this type of compounds reveal that the
terminal carboxylic moieties can either be implicated in ion coordination or be involved
in hydrogen bonding with distant OH groups [8, 11].
Toxicity concerns remain the primary hindrance in the development of carboxylic
polyethers into antimalarial drugs. Apart from this issue, it can be gathered from the
literature that carboxylic polyethers posses a great potential as antimalarial drug
candidates and leads for further optimization. Carboxylic polyethers owe their
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outstanding potency, in vitro and in vivo, to their unique MOA. Studies published by
Gumilla et al. [37] illustrate that it is possible through semisynthetic modification of
these molecules to generate better drug candidates. These authors reported that the
therapeutic index could be improved in the case of monensin (17) and lasalocid A (16);
the therapeutic index of monensin A (17) is 5 p.o. but that of its synthetic analog,
monensin A methyl ether, is 12 i.p. The therapeutic index of lasalocid A (16) is 3.3 i.p.
but that of its analog, 5-bromo lasalocid A, is 22 i.p. [37, 65, 123, 157].
2.3.2 Eimeria sp
Eimeria sp are apicomplexan protozoan parasites and etiological agents of
coccidiosis, a disease affecting cattle and poultry. In an attempt to control these
diseases, anticoccidial drugs are generally added to the feed of these animals. Several
carboxylic polyethers are among the drugs that are now approved for use as control
therapeutics for coccidiosis. The first approved application of veterinary carboxylic
ionophores was in the prophylactic and therapeutic treatment of coccidiosis in poultry
[65, 123, 157]. Carboxylic ionophores are reported to also have a positive impact on the
growth of these animals [59, 92]. Maduramicin (50), salinomycin (19), narasin (18),
lasalocid (16) and monensin (17) are the most prevalent of the feed additives marketed
at present [9, 59, 92, 93]. Several other carboxylic ionophores are also reported to have
anticoccidial utility in chickens and turkeys. Although these are the most common
additives used now, there are several other carboxylic ionophores reported to be more
effective than additives marketed at present [65, 131].
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Dirlam et al. [124] performed a comparative study of the anticoccidial activity of
CP-82,009 (51), salinomycin (19) and maduramicin (50) in chickens infected with
several pathogenic strains of Eimeria: E. tenella, E. necatrix, E. acervulina, E. maxima
and E. brunette. CP-82,009 (51) at doses of 5 or 10 mg/kg of feed showed a broader
spectrum and tolerance [124]. These same authors reported in 1990 that another
carboxylic polyether, CP-84,657 (52) had outstanding anticoccidial potential. This agent
at dosage ≤ 5 mg/kg cured chickens infected with different types of Eimeria sp. CP84,657(37) was more potent than several marketed molecules, such as salinomycin
(19), narasin (18), lasalocid (16) and monensin (17) [93]. CP-80,219 (53) was reported
to have an anticoccidial effects against E. tenella in chickens at dosages of 30 and 120
mg/kg of feed [125].
Kijimicin (54), tested along with monensin (17) and salinomycin (19) in chicken
infected with E. tenella, was more effective than several marketed drugs. Its
anticoccidial index (ACI) was 156.8 versus 144.1 for monensin (17) sodium salt and
127.1 for salinomycin (19) sodium salt [126]. Endusamycin (55) showed a protective
effect on chicken infected with E. tenella and E. acervulina at doses of 10 – 40 mg/kg of
feed [130]. The toxicity of this compound in rats was analyzed; when administered to
rats orally, the LD 50 was 7.5 mg/kg [130].
Liu et al. [131] reported that X-14868A (56) and X-14868B (57) were potent
anticoccidial agents for chickens infected with E. tenella . Doses of 7 and 15 mg/kg of X14868A (56) and X-14868B (57), respectively, were estimated to be protective
quantities against coccidiosis. These agents are more potent than well-known
coccidiostats agents; required doses for monensin (17), lasalocid (16) and salinomycin
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(19) are 98 – 121 mg/kg, 75 – 125 mg/kg and 60 – 100 mg/kg, respectively [131]. Smith
and Strout suggested an MOA for the coccidiocidal effect of carboxylic ionophores
[157]. They suggested that anticoccidial agents act, either by inhibiting the development
of intracellular parasites or by inducing destruction of intracellular sporoizoids [157].
2.3.3 Cryptosporidium parvum
Cryptosporidium parvum infections in immunocompetent individuals are generally
self-limiting. In immunocompromised patients, particularly in AIDS patients, these
infections are severe and are becoming increasingly prevalent [158-160]. Although
many drugs are used for the clinical treatment of C. parvum, effective treatments for
infected AIDS patients are scare [158, 159]. The screening of several anticoccidial
molecules has led to the in vitro and in vivo examination of several carboxylic
ionophores [38, 39, 44, 53, 58, 161]. Monensin (17), maduramicin (50), salinomycin
(19), alborixin (26), and lasalocid (16) were all evaluated for their respective activity
against C. parvum [38, 39, 44, 53, 58, 87, 121, 161]. When compared with control
anticoccidial agents, monensin (17) reduced the development of C. parvum by > 90%
[53]. The administration of maduramicin (35) and Alborixin (26) to severe combined
immune deficient (SCID) mice inoculated with 106 oocysts (bovine) oral gavage,
beginning 4 weeks post infection at 3 mg/kg/day for 3 weeks, has resulted in a 96%
reduction in fecal parasite load (p < 0.003) (case of maduramicin (50)) [87]; this
correlated with significant reductions in parasite loads in cross-sections of small
intestine tissue (p < 0.000002) and colon (p < 0.000006). Alborixin (26) showed less
effective results with oocyst reduction at 71% after 3 weeks [87]; some toxicity was
observed [87].
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2.3.4 Toxoplasma gondii
T. gondii is best known for its neurological effects and its particularly hearty cystic
stage; it infects a wide variety of organisms [75, 162-164]. T. gondii’s most deleterious
activity is its induction of toxoplasmic encephalitis, thus causing fatal CNS lesions. T.
gondii is an opportunistic pathogen in AIDS patients [49, 70, 162, 164, 165]. Treatment
for toxoplasmic encephalitis is typically a combination therapy involving pyrimethamine
and sulfadiazine. However, this type of chemotherapy is not effective against the cystic
stage of T. gondii, thus, reactivation of the bradyzoites is chronic, especially in the CNS
[23, 76].
Previous data has demonstrated that several polyether antibiotics are highly
active against the tachyzoite stage of T. gondii [49, 73, 77, 78, 164]. In vitro and in vivo
studies on the bradyzoites stage revealed under immunofluoresence and electron
microscopy that very low dosages, 0.0001 µg/mL, of monensin (17) significantly altered
the cytological physiology, that is, swollen cysts and large numbers of vacuoles, of T.
gondii [49]. Temporal, in vivo mouse brain T. gondii bradyzoites, evaluations of a 6- and
48-h exposure yielded significant antiparasitic activity [124, 129]. Six-hour single dose
treatment of 0.1 µg/mL of monensin (17) effectively eliminated the viability or lysed the
cells completely. In a similar 48-h trial with concentrations of as small as 0.0001 µg/mL,
the bradyzoites were swollen or lysed, and at a concentration of 0.01 µg/mL all
parasites seemed permanently altered beyond viability under electron microscopic
evaluation [49]. Apart from carboxylic ionophores antibiotics only two other drugs have
shown activity against the bradyzoites stage, atovaquone [166] and 2′,3′-dideoxyinosine
(ddi) [167]. In vitro and in vivo tests have shown that these other molecules take a
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significantly longer time to have the same activity as monensin (17) [78, 129, 137, 164].
2.3.5 Neospora canium
The coccidian parasite N. canium is often misdiagnosed as T. gondii. The
antimicrobial potential of several compounds, including, a few carboxylic polyethers
against this pathogen was recently investigated. To examine the inhibition of tachyzoite
multiplication, a 2-day treatment monoclonal antibody-based enzyme immunoassay
(EIA), and a 5-day treatment cell culture flask lesion-based assay were developed. In
this study 43 chemotherapeutics, sulfonamides, dihydrofolate reductase/thymidylate
synthase

inhibitors,

macrolides,

lincosamides,

pentamidine

analogues,

eight

miscellaneous antiprotozoal and six carboxylic polyethers were evaluated for use in
treating Neospora canium infections. This assay determined that five out of the six
ionophores evaluated, that is, lasalocid (16), maduramicin (50), narasin (18), monensin
(17) and salinomycin (19), caused 100% reduction in tachyzoite induced lesions at
concentrations of 0.000001 µg/mL in the CCF assay. Alborixin (26) was toxic to host
cells at these concentrations [52].
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Figure 1-1. Structures of carboxylic polyethers
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Figure 1.1. (cont.) Structures of carboxylic polyethers
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Figure 1.1. (cont.) Structures of carboxylic polyethers
2.4 Antiviral activity

From the literature reviewed, it can be gathered that carboxylic polyethers
possess several features that could qualify them as promising anti-HIV-1 leads.
Although none of the reports reviewed assessed the potency of these molecules
alongside clinically used drugs the reported IC50 values against HIV-1 targets are
significant. These molecules are also reported to have the potential to inhibit the
replication of the virus in key cells such as CD4-expressing lymphoid cells and
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mononuclear phagocytes. In addition, carboxylic polyethers have proven to be effective
against acute, as well as chronic infections in vitro. The effective dose and toxicity level
varied from molecule to molecule but a few molecules have proven effective at nontoxic
concentrations. As a group, carboxylic polyethers do not belong to a specific class of
known anti-HIV drugs. Some carboxylic polyethers such as monensin (17) and kijimicin
(54) were evaluated as protease inhibitors, with respect to their interference with
posttranslational modifications of HIV-1 proteins. It is well established that HIV-1, which
mutation rate is extremely high, readily develops resistance to protease inhibitors by
altering the active site of the targeted protease enzyme. Whether carboxylic polyethers
that interfere with posttranslational modifications of HIV-1 proteins will share this fate is
not well established at this time due to the limited understanding of the exact sequence
of events through which compounds such as monensin (17) and kijimicin (54) impair
posttranslational modifications. None of the studies reviewed investigated the
effectiveness of these carboxylic polyethers in an animal model.
2.4.1 Activity against HIV-I-AIDS
Several reports describe the potential of carboxylic ionophores: monensin (17),
salinomycin (19), lasalocid (16), nigericin (19), dianemycin (35), alborixin (26), kijimicin
(54), SF2361 (58), SF2324 (59), SF2487 (60) and Laidomycin (44) as anti-HIV agents
[86-91] [40, 54, 127, 128, 168, 169].
Nakamura et al. [40] assessed the effect of 10 carboxylic ionophores, monensin
(17), salinomycin (19), lasalocid (16), nigericin (19), dianemycin (35), alborixin (26),
kijimicin (54), SF2361 (58), SF2324 (59) and SF2487 (60), on the replication of HIV-1.
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All but SF2324 (59) showed a dose-dependent inhibition of the virus replication. Apart
from SF2324 (59), the concentration that inhibited reverse transcription activity, viral
replication, by 50%, EC50, varied in the range 0.40 - 0.040 to 7.12 - 4.4 µg/mL. The IC50
and EC50 of SF2324 (59) in H9 cells (primary infection) was determined to be > 100
µg/mL, the highest tested concentration. The IC50 of the remaining compounds varied in
the range 6.98 ± 2.9 to 78.40 ± 4.7 µg/mL (Table 1-2). For these compounds, an
inhibitory effect at nontoxic doses was observed. The ratio IC50 /EC50 varied in the
range 3.18 – 76.72 (Table 1-2). The chronically infected cells, U937, were sensitive to
all but SF2487, but a higher cytotoxicity was observed as shown by the low IC50 /EC50
ratio, which varied here from 1.18 to 8.32 (Table 1-2) [40, 127].
It is believed that all carboxylic ionophores do not share a common MOA against
HIV. These compounds target different stages of the HIV infective cycle, that is, the preand post-absorption steps [40, 54, 127, 128, 169]. Nakamura et al. [40] using a time of
addition design partitioned these agents in two main groups on the basis of their MOA.
These authors exposed H9 cells to these molecules before, during and after viral
absorption. The first group, believed to inhibit viral absorption was made of lasalocid
(16), dianemycin (35), SF2361 (58), SF2324 (59), SF2487 (60) and alborixin (26). The
second group, believed to interfere with post-viral adsorption events, was made of
monensin (17), salinomycin (19), lasalocid (16), nigericin (20), Dianemycin (35),
alborixin (26), kijimicin (54), SF2361 (58), SF2324 (59) and SF2487 (60) [40]. Yamauchi
et al. [128] working specifically with kijimicin (54), tested at concentrations of 0.08 – 10.0
µg/mL confirmed its lack of ability at interfering with the absorption step, as well as early
stage of the replication, such as integration. It was proposed that kijimicin (54) acted by
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decreasing the infectivity of the virus, which was possibly accomplished by means of
incomplete glycosylation of gp120 [128].
A dose-dependent study of the effect of monensin (17) on chronically infected
MOLT-3/HTLV-IIIB revealed a marked inhibitory effect on the proteolytic processing of
gpl60 to gpl20, after 7 h of exposure at 10 µM [54]. This effect was specific as no
change on the protein level of gag proteins Pr53 gag and p24 was noted. No effect on
the expression of tat, vif and nef gene products was observed, as well. Monensin (17)
also showed a marked reduction in the formation of syncytia at concentration > 3 nM
when MOLT-3/HTLV-IIIB cells were co-cultured with CEM cell. Both effects were
reversible upon removal of monensin (17) [54]. All these findings were later confirmed
by a second group [169]. Laidlomycin (44) was also reported to induce a dosedependent inhibition of HIV replication. The MOA of laidlomycin (44) was proposed to
be via inhibition of gp120 expression. Laidlomycin (44) also induced an inhibitory effect
on syncithium formation at concentrations as low as 1 µg/mL [85].
2.4.2 Activity against other types of viruses
Many carboxylic ionophores are reported to be active against several other DNA
and RNA viruses: monensin (17), monensin B (61), nigericin (20), narasin (18),
lasalocid (16), X-206 (47), septamycin (22), A 28695B (62) and A204 (63) were tested
against transmissible gastroenteritis coronavirus, Newcastle disease virus (NDV),
infectious canine hepatitis virus and infectious bovine rhinotracheitis virus [9]. All these
agents showed a significant activity against transmissible gastroenteritis coronavirus,
MIC ranging from 0.005 to 0.25 µg/mL. Nigericin (20), narasin (18) and A28695B (62)
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were effective against NDV with MIC ranging from 0.02 to 2.0 µg/ml. Only septamycin
(7) was active against infectious canine hepatitis virus (MIC = 0.32 µg/mL). Monensin B
(61), nigericin (20), narasin (18), X-206 (47), septamycin (22) and A204 (63) were
effective against the infectious bovine rhinotracheitis virus, MIC ranging from 0.005 to
0.08 µg/mL [9].
2.5 Cytotoxicity and anticancer
Resistance to chemotherapy is a common clinical problem in patients with
cancer. During treatment, tumor cells are often found to be refractory to a variety of
drugs with different structures or modes of actions. These cancers are referred to as
MDR forms. Most multidrug resistances are caused by trans-membrane xenobiotic
transport proteins belonging to the superfamily of ATP-binding cassette (ABC)
transporter efflux pumps [170, 171]. Carboxylic polyethers are interesting antineoplastic
drug candidates for several reasons; they possess potent anticancer activity in vitro and
in vivo. Some carboxylic polyethers such as nigericin (5) have proven to be selectively
cytotoxic, inhibiting DNA replication of tumor cells in vivo. Another feature that makes
carboxylic polyethers even more appealing as antineoplastic drug candidates is their
ability to reverse multidrug resistance in human carcinoma. Carboxylic polyethers are
reported as chemosensitizing agents. These molecules selectively increase the
sensitivity of cancerous cells, but not normal cells, to several cytotoxic agents of which
the clinically used anticancer drug paclitaxel [172].
Kawada et al. [57] evaluated the effects of several carboxylic ionophores on
colchicine resistance in human carcinoma MDR KB-C410 [57]; these compounds were
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inostamycin (39), lysocellin (30), laidlomycin (44), monensin (17), dianemycin (35),
leuseramycin (41), nigericin (20), lonomycin A&C (32 , 37), carriomycin (23), desoxysalinomycin, antibiotic 6016 (38), SF2324 (59), SF2361 (58) and SF2487 (60). It was
discovered that the cancer cells responded better to colchicine when some polyethers
were added simultaneously. Laidlomycin (44), monensin (17), dianemycin (35) and
leuseramycin (41) led to > 100-fold potentiation of colchicine cytotoxicity. The most
potent compound was laidlomycin (44); at 0.3 and 1 µg/mL, it potentiated the
cytotoxicity of KB-C4 cells by ~ 725-fold [57]. Compared to tumor cells, the potentiation
of normal cells was negligible; the ratio of IC50 in the absence of polyether versus the
IC50 in the presence of polyether only varied in the range 0.4 – 2.4 µg/mL. Inostamycin
(39) was also reported to have a chemosensitizing effect on paclitaxel in Ms-1 cell,
small cell lung carcinoma.
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Table 1-2 HIV-1 infectivity and cytotoxicity

Acute infection (H9)

Chronic (U937)

EC90
(µg/mL)

IC50 (µg/mL)

IC50/EC90

EC90 (µg/mL)

IC50 (µg/mL)

IC50/EC90

Monensin (17)

4.22 ± 2.6

13.44 ± 2.8

3.18

0.5 ± 0.25

0.59 ± 0.19

1.18

Salinomycin (19)

0.4 ± 0.04

6.98 ± 2.9

17.63

0.09 ± 0.02

0.28 ± 0.05

3.14

Lasalocid (16)

2.37 ± 2.9

48.80 ± 4.7

20.63

0.2 ± 0.2

1.35 ± 0.35

6.92

Nigericin (20)

0.68 ± 0.46

14.46 ± 8.0

21.26

0.05 ± 0.33

0.4 ± 0.007

8.32

Dianemycin (35)

7.12 ± 4.4

78.40 ± 4.7

11.01

1.1 ± 0.14

1.1 ± 0

1.00

SF2361 (58)

0.64 ± 0.36

49.10 ± 4.6

76.72

1.35 ± 0.49

2.1 ± 0.14

1.56

SF2324 (59)

> 100

> 100

> 1.00

3.7 ± 0.71

10.1 ± 0.14

2.73

SF2487 (60)

0.49 ± 0.18

7.8 ± 1.3

15.92

0.03 ± 0.15

1.85 ± 0.28

64.91

Alborixin (26)

2.5 ± 1.1

13.50 ± 3.1

5.4

0.12 ± 0.04

0.80 ± 0.28

6.53

Kijimicin (54)

1.63 ± 1.9

18.62 ± 11

11.41

0.1 ± 0.007

0.55 ± 0.07

5.79

Dextran Sulfate

<1

> 100

> 100

NT

Compounds

EC50: Concentration that inhibits reverse transcription activity by 50% (viral replication); IC50: Concentration that decreases cell viability by 50%.
From Nakamura et al., 1992 [40].
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This effect was specific to these types of cells and to paclitaxel, as no
potentiation was noted with the other tested agents, driamycin, vinblastine,
methotrexate, cisplatin, etoposide and camptothecin [172]. Inostamycin (39) was also
reported to reverse multidrug resistance in these cell lines. Using radiolabeled
vinblastine, Kawada et al. [57] established that MDR cells treated with inostamycin (39)
(0.5 – 2 µg/mL) accumulated the drug. Inostamycin (39) (1 µg/mL) acted by inhibiting
drug efflux [57].
Baibakov et al. [73] and Margolis et al. [173] studied the antineoplastic MOA of
nigericin (20) and established that nigericin (20) was a unique type of cytostatic agent.
The

compound

(20)

acts

not

by

interfering

with

spindle

microtubules

or

transcription/translation processes directly, but rather by altering intracellular pH [73,
173]. Nigericin (20) showed anticancer potential (cytostatic agent) in Ehrlich ascites
carcinoma cells. The proposed MOA related to its ability to acidify the intracellular
environment, a consequence of its H+ /K+ anti-transport ability [173]. It is believed that
by decreasing the pH, DNA synthesis is halted. Nearly 100% inhibition of the DNA
synthesis was achieved at 0.5 µM nigericin (20), with the pH of the incubation medium
being 7.0 [173]. An in vivo method, using tridimensional histocultures of human lung
tissues, with normal cells present in the same histoculture, determined that this
antineoplastic effect of nigericin was selective. At 1µM of nigericin (20) neither the
histology of normal cells nor their DNA synthesis was negatively affected. In cancerous
tissues however, the same concentration of nigericin (5) halted the DNA synthesis in
67% of the cases, induced pyknotic nuclei and dystropic alteration in 27% of tumors
exposed to nigericin (20) and necrosis in 13% of cases. Another carboxylic polyether,
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ionomycin (27), is also reported to possess antineoplastic properties. It induced
inhibition of the growth of a human bladder cancer cell line, HT1367, in vitro in a dose
(0.1 – 100 µg/mL), and time dependent manner. The MOA here is reported to be the
induction of apoptosis by means of the downregulation of Bcl-2 and upregulation of Bax.
Ionomycin (27) was also effective in vivo, as it inhibited HT1367 tumor’s growth [90].
2.6 Cardiovascular effects
Several carboxylic polyethers were reported to show ionotropic, chronotropic and
hemodynamic properties. Because of the critical role of Ca2+ in cardiovascular
contractile systems, this was predictable at least for those carboxylic polyethers that are
selective for this ion, such as lasalocid (16) and A23187 (28). It is well established that
lasalocid (16), also known as X-537A, is a positive ionotropic agent. In canine studies,
lasalocid (16) was able to increase the contractility index of the heart by approximately
threefold at 2 mg/kg [10, 13]. X-537A is also reported as a positive ionotropic and
chronotropic agent in dogs. In barbiturated dogs, at dosage 2 mg/kg, it caused a
threefold increase in the contractility, as well as a modest rise in aortic pressure and
heart rate. It also induced a drop in total peripheral resistance followed by a drastic
increase in blood flow through the coronary arteries of the left ventricle [10]. The exact
MOA through which these carboxylic polyethers induce contractility of cardiac muscle is
still unclear. Initially, it was believed that this could be the result of their ability to shuttle
Ca2+ and catecholamine across membranes. This was refuted after the discovery that
carboxylic polyethers specific to monovalent cations were able to induce, even more
effectively, this type of response. Nonetheless, it is believed that catecholamine is
partially involved because the effect of these molecules on the cardiac muscle is
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suppressed by α adrenergic inhibitors.
Several other carboxylic ionophores were reported to possess a cardiovascular
effect. Monensin (17) reportedly induced an increase of arterial blood pressure,
myocardial contractility and total peripheral resistance when administered intravenously
to anesthetized cats at a dose of 0.075 – 0.375 mg/kg [60]. A similar effect was
observed when 0.125 – 2.00 mg/kg were administered via the same route to
anesthetized dogs [60]. Monensin (17) was also effective on isolated organs; it showed
a vasoconstrictor effect on isolated rabbit aortic strips at concentration ≤ 7 µg/mL and a
myocardial stimulation effect in isolated rabbit hearts [60].
Three other carboxylic ionophores, grisorixin (31), alborixin (26), lonomycin A
(32), are reported to have similar effects. Grisorixin (31) induced a coronary vasodilator
effect in dogs at doses of 60 µg/mL; this was associated with a marked increase in the
coronary blood flow, which reached a maximum at this concentration. At doses of 125 –
500 g/kg, further inotropic and hypertensive effects were observed [174]. Grisorixin (31)
was also reported to have a cardiotonic effect on isolated perfused rat hearts [100]. In
guinea pigs, grisorixin (31) and alborixin (26) 4 mg/kg/min i.v. are reported to increase
blood pressure. The MOA is believed to be linked to their intrinsic ionophorous potential:
the ability of the molecules to alter the blood concentration of cations such as K+ and
Na+ [101]. Moins et al. [175] working with anesthetized dogs reported similar findings,
as 2 mg/kg of grisorixin (31) and 1 mg/kg of alborixin (26) increased the ventricular
contractile force and systolic and diastolic arterial pressures. This was associated with
an increase in the plasma concentration of K+ followed by a decrease in the
concentration of Na+ [175]. Because it has been reported that compounds such as
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grisorixin (31) are able to induce the release of catecholamine, the physiological
response associated with the release of catecholamine was also proposed as a
possible justification of the cardiovascular effects of these compounds[174]. Lonomycin
A (32), another carboxylic polyether, was also reported to induce a coronary
vasodilatation effects in dogs. Its MOA was proposed to be the stimulation of the Na+,
K+-ATPase activity [105].
As stressed by Pressman, and despite their toxicity, carboxylic polyethers are
important drug leads for control of various cardiovascular conditions. Their value lies in
their outstanding ionotropic, chronotropic and hemodynamic potentials. These
molecules could prove life-saving tools in controlling conditions such as failure from
myocardial infarction and other similar forms of shock. Carboxylic polyethers such as
lasalocid (16) (1 mg/kg) were proven effective at restoring dogs in cardiogenic shock.
Similar data were reported for salinomycin (19) (0.15 mg/kg). According to Pressman,
the narrower the transport spectrum of a molecule, the fewer the number of associated
undesirable effects [10].
2.7 Other biological activities of carboxylic polyethers: immunoregulatory,
herbicidal and anti-inflammatory
2.7.1 Immunoregulatory activity
Two measures are usually adopted to protect poultry against a variety of
etiological agents such as Angara disease virus (ADV) and Newcastle disease virus
(NDV), and to promote growth. These include vaccination and addition of substances
such as antibiotics, coccidiostat and vitamins to feed. Among additives currently
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approved for use are several carboxylic polyethers (lasaloicid (16), monensin (17),
salinomycin (19) and manduramycin (50)). There have been some recent concerns over
the possible implication of additives in vaccine failure in poultry. A few reports have
actually proven that therapeutic agents such as cyclophosphamide and corticosteroids
possess immunomodulatory properties. Munir et al. in 1994 and 2007 studied the
immunomodulatory effects of salinomycin (19) and monensin (17); specifically, the
effects of these molecules on the protective immune response in NDV and ADV
vaccinated

chickens

[59,

176].

These

authors

established

that

unlike

cyclophosphamide, salinomycin (19), at a dosage of 0.1 g/kg, did not adversely affect
the bursal, splenic, thymic and liver weight gain [176]. It was also established that NDV
vaccinated chickens that received salinomycin (19), 60 mg/kg of feed, had higher
antibodies titers at days 14, 21, 28, 35, 42 compared to unmedicated chickens [59, 176]
or vaccinated chickens that were medicated with monensin (17) 12 mg/kg instead [59].
These salinomycin medicated chickens also gained significantly more weight, p < 0.05,
compared to all the other groups evaluated. These chickens were challenged with both
ADV and NDV after vaccination. No post-ADV or post-NDV challenge mortality was
observed in vaccinated chickens that received salinomycin (19) and no clinical sign of
the disease was observed [59, 176].
From these studies, it seemed that far from causing vaccine failure, carboxylic
polyether such as salinomycin (19) actually seem to have a boosting effect on the antiNDV and anti-ADV immune response [59, 176]. Another carboxylic polyether reported
as having immunoregulatory potential was ionomycin (27), a calcium-specific ionophore.
Ionomycin (27) interferes with physiological processes by increasing the intracellular
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level of calcium, an effect that could have several implications on key cells of the
immune system such as neutrophils and macrophages. They exert their action by
production of microbicidal species such as superoxide anions via an NADPH-dependent
process known as ‘respiratory burst’ in response to in situ triggers such as inflammatory
agents. Ca2+ is documented as an enhancer of NADPH oxidase activity. Finkel et al.
[177]

reported that ionomycin (27) at a concentration of 1 – 10 nM can prime

neutrophils to release approximately sevenfold more superoxide anions during
stimulation. Ionomycin (27) was also reported to induce T cell activation [177] .
2.7.2 Herbicidal activity
It has been reported that nigericin (20) also possess herbicidal properties. A
concentration-dependent study of the effect of nigericin (20) on the growth of the radicle
of garden cress seed showed a dose-dependent inhibitory effect. A 50% reduction in the
elongation was achieved at 1.3 – 2.0 µg/mL; the maximum inhibition was reported at ~
3.33 µg/mL. Nigericin (5) did not induce browning or necrosis of tissues in the process
[20].
2.7.3 Anti-inflammatory activity
Dianemycin (35) was recently reported as having topical anti-inflammatory
potential on several animal models for cutaneous inflammation. In a croton-oil induction
of ear edema, dianemycin (35) had a comparable activity to prednisolone, a potent
steroidal anti-inflammatory. In the UV-induced erythema test or in the delayed type
sensitivity test, no anti-inflammatory activity was observed. Additionally, no acute
toxicity was observed with topical application ≤ 10 mg/ear [21].
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3. Toxicity
Acute toxicity of the naturally occurring polyether ionophores is relatively specific
to the affected organism. It is clear that minimal exposure to these very active
compounds initiates some type of physiological response [13]. In the case of higher
organisms and specifically mammals and birds, these effects are almost equally diverse
[9]. For example, a common poisoning scenario is a horse consuming a small quantity
of feed prepared with a ruminant’s polyether antibiotic and dying rather quickly, or wild
turkeys consuming anticoccidial chicken feed and dying. Although the ionophoric
specificity of molecules can be predicted, respective acute toxicity values are diverse
and unpredictable. For example, LD50 ± SE values for an acute oral dose of monensin
(17) were: mouse (m) 70.0 ± 9.0 mg/kg, (f) 96.0 ± 12.0 mg/kg; rat (m) 40.1 ± 3.0 mg/kg,
(f) 28.6 ± 3.8 mg/kg; dog (m) > 20.0 mg/kg, (f) > 10.0 mg/kg; rabbit 41.7 ± 3.6 mg/kg;
monkey > 160.0 mg/kg; chicken 200.0 mg/kg; cattle 26.4 mg/kg; sheep 11.9 ± 1.2
mg/kg; goat 26.4 ± 4.0 mg/kg; swine 16.7 ± 3.57; horse 2 – 3 mg/kg; trout > 1000.0
mg/kg [9, 13].
Dogs given a daily oral dose of 0, 1.25, 2.5, 5, or 7.5 mg/kg of monensin (17) for
1 year survived with no evidence of toxicity in the two lowest dose groups. Four
generations of rats were continuously maintained on diets containing 0, 33, 50, or 80
ppm of monensin (17)… except for a decrease in body weight gain, there were no
compound-related effects on reproduction or observed teratogenic effects” [77]. These
same dosing conditions were evaluated for a 2-year period, with respect to the skeletal
and cardiac muscles, with no increase in chronic lesions or neoplasms being detected
[77]. Despite these maverick chemo-physical qualities of the ionophores, considerable
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numbers of toxicology studies have attempted to illustrate/translate the specific
toxicology and pharmacology of the most common polyether ionophores to human
health utilization [13].
4. Cardiac toxicity
Whether a monovalent or divalent ionophore is used, these molecules will disrupt
the Ca2+ concentrations, either forming Ca2+ complexes or depolarizing the membrane
potential, changing the H+ concentrations in the mitochondria [12]. It is clear that Ca2+ is
an essential ion in the physiological activities of composite functionality in the entire
human body’s daily functions. Cardiac function is especially sensitive to the roles of
Ca2+ owing to the intrinsic functions of the ion and its role in muscular contractions; so,
expectedly, potent effects of polyether antibiotics have been observed in mammalian
cardiac studies [10, 73, 78, 106, 126, 129]. Canine studies are accepted as the
translative animal model for human cardiac response and for the effects of carboxylic
polyethers. These studies have shown that as little as 2 µg/kg i.v. can induce coronary
dilation [86, 106]. The concern for clinical applications of these ionophores is that
people with coronary heart disease who have coronary arterial dilation, as part of the
hearts own auto regulatory response to occlusion of coronary arterial vessels, will dilate
the affected vessels further in the presence of an indiscriminate vasodilator. The
unaffected vesicles would dilate further and the already maximally dilated obstructed
vessels would divert the blood supply away from the ischemic regions of the
myocardium. This phenomenon is called ‘coronary steal’ and has been observed in the
administration of the drug dipyridamole, a thrombus inhibitor and chronic vasodilator
[88, 101]. As a high percentage of the population is affected by coronary heart disease
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these concerns have validity, although this phenomena was experimentally evaluated
and the coronary steal was not observed [88]. Only recently have the in vitro tools been
available for cardiac toxicity evaluations with respect to interaction on the hERG (human
Ether-a-go-go Related Gene) gene and the associated Kv 11.1 potassium ion channel
that depolarizes the IKr current in the cardiac action potentials. The polyether antibiotics
have not yet been critically evaluated in hERG assays. The drug interactions related to
hERG ion channel were not mandated by ICH guidelines until November 2005
(mandate #CHMP/ICH/423/02). Consequently, the effects of carboxylic polyether
ionophores on the QTc, with respect to the interaction with hERG have not yet been
evaluated.
5. Conclusion
Carboxylic polyethers are broad spectrum antibiotics. They are active against a
wide range of biological targets: bacterial, fungal, protozoan, viral, neoplastic and
cardiovascular. A few authors have also reported carboxylic polyethers as
immunomodulating agents. In vitro, these molecules have proven to be effective at very
low concentrations. The malaria parasite (P. falciparum) is especially sensitive to
several of these compounds with IC50 values in the nanomolar range. Based on the
reports in this review it can be argued that carboxylic polyethers are highly selective.
Unlike Gram negative bacteria or fungi for instance, Gram positive bacteria tend to be
extremely sensitive to these antibiotics. Moreover, the IC50 values of several of these
molecules against mammalian cells tend to be significantly higher, when compared to
the IC50 against targeted etiological agents.
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Despite these interesting features, the only current application for carboxylic
polyethers is in veterinary medicine, where they are used as controls for coccidiosis and
feed absorption efficiency. The main obstacle for the use of carboxylic polyethers as
drugs to control human diseases seems to be the issue of toxicity.

Carboxylic

polyethers possess some interesting qualities against serious threats such as MRSA
and VRE and have proven to be more effective (in vitro) than drugs that are currently
used clinically, such as vancomycin and oxacillin. They have also shown to be effective
against several other resistant bacterial strains including penicillin resistant strains of S.
aureus, tetracycline resistant strain of Micrococcus sp, aminoglycoside resistant strain
of Streptococcus faecalis, and macrolides resistant strain of Sarcina lutea. Carboxylic
polyethers have also proven effective at nanomolar range against CQ resistant strains
of P. falciparum and are more potent against these resistant strains than several
currently marketed antimalarial drugs. Their mechanism of action against the malaria
parasite appears uniquely different from that of the currently utilized drugs. This makes
them possible candidates for use in combination therapy.
6. Expert opinion
On the basis of our assessment of the literature, polyether ionophores show a
high degree of promise for the potential control of drug-resistant bacterial and parasitic
infections. Many of these infectious diseases fall under the umbrella of neglected
disease with limited options for therapeutic intervention. Furthermore, recent decades
have emphasized the importance of combination therapies for the long-term control of
disease and mitigation of resistance. The long history of the utilization of polyether
ionophores as growth promoting antibiotics by the agricultural industry validates the
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potential cost-effective use of these antimicrobial agents for other applications. The
polyether antibiotics seem to provide reasonable oral availability, half-life, metabolic and
general stability, absence of a UV sensitizing chromophore combined with significant
potency. Despite the long history of use of the class very limited medicinal chemistry
and drug optimization studies have been reported leaving the door open to these
opportunities in the future. In many instances, the potency and in vivo efficacy for the
control of bacterial and parasitic infections is truly remarkable.
However, concerns about toxicity need to be addressed with further optimization
and preclinical evaluation. On the basis of the available literature, there is still
insufficient data to clearly classify these molecules as either too toxic or safe as a class.
Several carboxylic polyethers have indeed been shown to be too toxic in animal models
for malaria, but the results cannot be generalized to the entire class. Using an in vivo
model for cancer, nigericin (20) was recently reported to be highly selective in targeting
cancerous cells, broadening the scope of possible utility for this class [80]. As a result,
an organized and carefully orchestrated identification and optimization of leads using in
vitro models followed by an in vivo assessment of toxicity and efficacy would seem to
yield viable drug candidates for the control of drug-resistant infectious diseases and
cancer with a reasonable understanding of pharmacokinetics, stability and cost of
goods. The reported toxicity for monensin (17) of > 160.0 mg/kg (LD50) in primates and
frequent utilization of this drug in agriculture makes the polyether class an attractive
group of molecules for optimization and development of human health applications for
the control of drug-resistant diseases such as malaria and MRSA.
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Chapter 2 : ANTIMALARIAL, ANTI-MTB AND ANTIMRSA METABOLITES FROM A MARINE
STREPTOMYCES
PART 1 - A NEW ANTIMALARIAL POLYETHER FROM
A MARINE STREPTOMYCES SP. H668

Published in Tetrahedron Letters, 2008, 49 (44): 6282-6285
Authors: Na M, Meujo DA, Kevin D, Hamann MT, Anderson M, Hill RT

ABSTRACT - The antimalarial-guided fractionation of the crude extract of the
marine Streptomyces sp. strain H668 led to the isolation of a new polyether (5). This
new metabolite showed in vitro antimalarial activity against the CQ-susceptible (D6) and
resistant (W2) clones of Plasmodium falciparum, without cytotoxicity to normal cells
(Vero) making it a promising drug lead.
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Malaria is a tropical infection caused by four different species of protozoa of the
genus Plasmodium transmitted to humans by the Anopheles mosquito. During past
decades, CQ and other aminoquinolines have been utilized as frontline antimalarial
agents. However, an increase in drug resistance in Plasmodium falciparum has made it
essential to develop new chemotherapeutic agents in addition to combination therapies
utilizing available antimalarial drugs with different modes of action [178]. Recently, some
specific polyether antibiotics have been reported to have potent antimalarial activity [37,
51, 111, 153]. K41-A, a carboxylic acid containing polyether antibiotic produced by
Streptomyces hygroscopicus has been reported to exhibit nanomolar range in vitro
antimalarial activity against the P. falciparum strains K1 (drug resistant) and FCR3 (drug
sensitive) [153]. Furthermore, it showed high selectivity in vivo against P. berghei strain
N and P. yoelii strain NS-infected mice, when administered orally [153]. Several other
polyethers from this class (ionomycin A, nigericin, and monensin, among others) have
been identified as potent antimalarial agents, as well [37, 51].These compounds are
classified as ionophores due to their potential to interact with ions (cations); this is
believed to be their putative mechanism of action [37, 51]. There are two main classes
of ionophores: mobile carriers or true ionophores which bind cations into an oxygen rich
pocket in order to facilitate their transport across the cell membrane and quasiionophores which, instead, form trans-membrane channels through which cations flow.
Compounds of the latter group possess a polycyclic alkyl backbone which confers their
lipophilic character. They also possess a terminal carboxylic group which plays an
important role in the formation of the oxygen rich internal cavity which interacts with
metal ions [37, 51, 179].
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Bacteria, especially Streptomyces sp. isolated from soil samples are reported as
the primary producers of this type of compounds, with at least 21 producer strains
reported thus far [180]. Reports concerning the isolation of these compounds from
marine Streptomyces are scarce; a few examples include aplasmomycin [181], arenaric
acid, and oxolonomycin [182, 183].
H668 was isolated from Hawaiian marine sediments and cultured in ISP2
medium. It was established that its crude extract possessed potent in vitro activity
against P. falciparum and no significant cytotoxicity to Vero cells. H668 was identified as
a Streptomyces sp.

by 16S rRNA analysis. A bioassay-guided fractionation of the

EtOAc-soluble fraction of the H668 culture led to the isolation of a new polyether
metabolite. In this report, we describe the isolation and structure elucidation of this
metabolite.
The antimalarial active fraction eluting with 70% MeOH in H2O using reversed
phase C18 VLC was further fractionated by preparative HPLC [Phenomenex C8 column
(21.2 × 250 mm); flow rate 5 mL/min] using a gradient from 50% to 100% MeOH in H2O
over 80 min. The active fractions were further purified by preparative HPLC
[Phenomenex C18 column (21.2 × 250 mm) at 5 mL/min] eluting with a gradient from
70% to 100% MeOH in H2O, to afford a semipure metabolite. Purification of this
semipure compound by HPLC [5 micron C18 (10 × 250 mm); flow rate 3 mL/min] using
an isocratic solvent of 75% MeOH in H2O gave 3.0 mg of the pure metabolite 5.
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The

1

H NMR spectrum of 5 indicated the presence of eleven oxymethine

hydrogens (3.1 – 4.3 ppm), four methoxy groups (3.2 – 3.6 ppm), eight methyls (0.9 –
1.3 ppm), and five methylene (1.2 – 2.2 ppm). This was supported by the 13C and DEPT
NMR spectroscopic data. In addition, two oxygenated quaternary carbon signals at δC
82.8 and 78.4, as well as two ketal (or hemiketal) signals at δC 100.9 and 106.2 were
observed. Four independent spin systems were identified by a COSY experiment, in
which a sequential correlation from H-12 to H-23 and two methyl signals at C-26 and C27, were observed, along with correlations for H-9 and H-10, H-3 through H-7, and H-1
and one methyl group at C-1. Several ambiguous correlations in the methylene area of
the COSY data were identified based on the analysis of HSQC data. From the HSQC
data, each protonated carbon for the partial structures could be assigned as shown in
Table 1-1. The HMBC data of 5 revealed correlations from H-12 (δH 3.89) to C-14 (δC
28.2) and C-15 (δC 81.7) and from H-15 (δH 3.74) to C-12 (δC 81.9), suggesting a
structure of a tetrahydrofuran ring (ring C). In a similar fashion, HMBC correlations
assisted in identifying ring D. Ring E was deduced from the HMBC analysis, where both
the methyl protons at δH 0.97 (3H, d, J = 6.4 Hz, H-27) and 1.01 (3H, d, J = 6.4 Hz, H26) showed correlations with C-22 (δC 74.6), and H-22 (1H, t, J = 10.0 Hz) exhibited 2and 3-bond correlation with C-20 (δC 75.3), C-21 (δC 40.9), C-23 (δC 47.8), and C-24 (δC
100.9), along with a correlation from the methyl signal at δH 1.30 (3H, s, H-25) to C-24.
Moreover, the HMBC correlations from H-12 to C-11 (δC 82.8) and C-10 (δC 94.8), as
well as from neighboring protons (H-10, H-9, H-7, and H-6) to the ketal carbon at δC
106.2 facilitated the construction of a spiroketal analog linked with ring C. These results
suggest that compound 5 is a polyether type metabolite. Comparison of the NMR data
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of 5 with those of polyether compounds previously reported supported the NMR
assignments for the rings A – D [146, 182, 184, 185]. However, the residual part was
quite different from reported polyethers. The biggest difference was the lack of a
carboxylic group in 5. COSY data confirmed the linkage of H-3 (δH 4.29, 1H, d, J = 10.0
Hz) and H-4 (δH 4.10, 1H, br s), and of H-1 (δH 3.45, 1H, m) and H-32 (δH 1.02, 3H, d, J
= 6.4 Hz). The HMBC correlations from H-3 to C-2 (δC 78.4), as well as to the methyl
carbon at δC 11.6 revealed the connection from C-1 to C-3 bearing two methyl groups
(C-31 and C-32). In addition, two methoxy groups at δH 3.54 and 3.39 were identified
and attached at C-1 and C-2, respectively, by the HMBC data analysis. Taken together,
the structure of 5 was determined as shown in Figure 2-1, and all the 1H and

13

C NMR

data were assigned as in Table 2-1. The relative configuration of 5 was determined on
the basis of ROESY NMR data. NOE correlations were observed as described in Table
2-1, which indicated that 5 has the same relative configuration in rings A-E as those of
K41-A (Figure 2-2).
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Figure 2-1. Spin system 1H-1H COSY data (―) and HMBC correlations of 5
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The antimalarial activity of the new metabolite (5) was evaluated against both the
CQ-susceptible (D6) and -resistant (W2) clones of P. falciparum, and their toxicity was
tested against Vero cells. Compound 5 showed antiprotozoal activity against both the
D6 and W2 clones, with IC50 values ranging from 100 − 200 ng/mL. Although the in vitro
antimalarial activity of 5 was significantly less than the original extract, no cytotoxicity
was observed at 4.75 µg/mL, the highest concentration tested. The high index of
selectivity (SI = IC50 Vero/IC50 P. falciparum) of 5 indicates that the polyether metabolite 5 is
highly specific to the parasite. As discussed earlier, the mechanism of action for
ionophores (quasi-ionophore as mobile carier) is via alteration of normal membrane
permeability to cationic species [37, 51, 186]. Ionophores (mobile carriers) possess
unique structural features which are crucial to their ability to interact with metal species
such as Na+, K+, and Ca2+ [37, 51, 56]; these include (1) an alkyl backbone (2) an
internal oxygen rich pocket and (3) a terminal carboxylic group [179]. A few examples of
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mobile cariers are: monensins A, B, C, nigericin, laidlomycin, grisorixin, mutalomycin,
lonomycins A, B, X-206, alborixin, lenoremycin, dianemycin, carriomycin, septamycin,
etheromycin, A-204A, K41-A, K41-B, and A-601612. All these compounds possess a
terminal carboxylic moiety [186].
The polyether 5 isolated from the marine Streptomyces sp. H668 clearly belongs
to a unique class of compounds. Although it is closely related to several members of
the mobile carriers group, the fact that it lacks the carboxylic functionality, suggests that
the mode of action against the parasite might be unique; this warrants additional
investigation.
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Table 2-1 NMR assignment of 5 in CD3OD
δ Ca

HMBC

ROESY

C-2, 1-OMe
/
C-2, C-31
/
C-7
C-4, C-8
C-5, C-8, C-30
/
C-8, C-10, C-29
C-9, C-12, C-28, C-29,
10-OMe
/
C-10, C-11, C-14, C-15,
C-28
C-11, C-12, C-15

H-3
/
H-1, 2-OMe
/
/
H-7
H-6, H-29, H-30
/
H-10, H-29, H-30
H-9, H-28, H-29

1
2
3
4
5
6
7
8
9
10

81.8c
78.4
66.6
61.4
32.2
78.6
36.7
106.2
45.6
94.8

δH mult. (J in
Hz)b
3.45, mc
/
4.29, d (10.0)
4.10, br s
1.40, mc
3.34, m
1.71, m
/
2.06, m
3.43, d (9.6)c

11
12

82.8
81.9c

/
3.89, t (7.2)

13

26.0

14

28.2

15

81.7

1.99, m
1.83, mc
1.71, mc
1.87, mc
3.74, q (6.4)

16
17

81.9c
28.5

18

24.8

19
20

79.9
75.3

3.99, q (6.4)
2.06, m
1.83, mc
2.00, m
1.91, mc
4.20, dt (6.4, 2.8)
3.40, mc

21
22

40.9
74.6

1.25, m
3.08, t (10.0)

23

47.8

1.40, m

C-19, C-20, C-22, C-27
C-20, C-21, C-23, C-24,
C-26, C-27
C-22, C-24, C-25, C-26

24

100.9

/

/

/

25

21.2

1.30, s

C-23, C-24

H-23, H-26

C-12, C-15, C-16
C-13, C-12 (or C-16),
C-17
C-14, C-19
C-15, C-19
C-16, C-19, C-20
C-20
/
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/
H-13a, H-15, 10-OMe
H-13a, H-14b, H-28
H-12, H-13b
H-13b, H-14a, H-16
H-14b, H-15
H-12, H-14a, H-16, H17a
H-14b, H-15, H-17b
H-16, H-17a
H-15, H-17b, H-18a
H-18a, H-21
H-17a, H-18b, H-20
H-20, H-27
H-18a, H-19, H-22, H27
H-18b, H-23, H-27
H-20, H-26, H-27
H-21, H-25, H-26

26

11.5

1.01, d (6.8)c

C-22, C-23, C-24

H-22, H-23, H-25

27

12.3

0.97, d (6.4)

C-20, C-21, C-22

H-19, H-21, H-22

28

24.7

1.37, s

C-10, C-11

H-10, H-13b

29

10.5

0.97, d (6.4)

C-9, C-10

H-7, H-9, H-10

30

12.0

0.95, d (6.8)

C-6, C-7

H-7, H-9

31

11.6

1.10, s

C-2

H-32

32

11.2

1.02, d (6.8)c

C-1, C-2

H-31

1OMe

60.0

3.54, s

C-1

/

2OMe
6OMe

49.1

3.39, sc

C-2

H-3

56.9

3.28, s

C-6

/

10OMe

59.6

3.41, s

C-10

H-12

a

Assignments based on DEPT, HMQC, and HMBC NMR data (100 MHz). bAssignments based on COSY
and HMBC NMR data (400 MHz)
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Figure 2-3. 1H NMR spectrum of 5 in CD3OD
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Figure 2-4. 13C NMR spectrum of 5 in CD3OD
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Figure 2-5. DEPT spectrum of 5 in CD3OD
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Figure 2-6. 1H-1H COSY spectrum of 5 in CD3OD
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Figure 2-7. HSQC spectrum of 5 in CD3OD
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Figure 2-8. HMBC spectrum of 5 in CD3OD
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Chapter 2: ANTIMALARIAL, ANTI-MTB AND ANTI-MRSA
METABOLITES FROM A MARINE STREPTOMYCES
PART 2 - EPIGENETIC STUDIES YIELDING POTENT
ANTI-MYCOBACTERIUM TUBERCULOSIS AND ANTIMRSA POLYETHERS IN A MARINE STREPTOMYCES
SP

ABSTRACT—Two known polyethers (6, 7) were isolated from a marine Streptomyces
sp whose crude extract previouly showed potent antimalarial and anti-MRSA activities.
It was established that metabolites responsible for these activities were the antibiotic
K41-A (6) and its C-29 OMe (7) ether analog. It was also established that etherification
at C-29 has a negative impact on the bioactivity of K41-A. In this chapter, we report the
outstanding bioactivity of these molecules against two important pathogens:
Mycobacterium tuberculosis and MRSA. Several other commercially available
ionophores were assayed, as well.
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1. Introduction
Tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA) infections
are both serious conditions that can be transmitted from livestock and other animals to
humans. According to the WHO, about 1/3 of the world’s population is currently affected
by TB [3]. In 2007, the CDC reported that an animal MRSA strain is currently
responsible for >20% of MRSA cases reported in the Netherlands [187]. As the
incidence of these two diseases continues to increase there is an unprecedented
demand for the discovery of new drugs leads.
Nature has played a tremendous role in the drug discovery arena for decades
with a wide range of bioactive metabolites reported thus far. Among these molecules
are ionophores, a unique class of compounds with outstanding potency. Polyethers and
peptides are often classified as ionophores; the peptide gramicidin D, has proven to be
one of the most potent compound of this class. Due to limitations associated with
cytotoxicity, none of these molecules is currently utilized beyond topical applications as
a treatment to address human illnesses. It is however important to point out that
ionophores are widely used in veterinary medicine. They have proven valuable tools for
the control of coccidiosis, a serious problem in poultry and cattle [188].
In a continued effort to identify new drug leads, a bacterium (H668) was isolated
from Hawaiian marine sediments. Based on the 16S rRNA analysis, it was established
that H668 is a new species. It is related to Streptomyces cacaoi AB 184183 and
Streptomyces violaceoruber AY999815. The ethyl acetate extract of the fermentation
broth of this bacterium showed outstanding potency against MRSA, IC50 = 0.55 µg/mL.
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Due to a frequent loss of bioactivity from batch to batch, a bioassay-guided epigenetic
study was completed to explore which external stimuli had the most significant impact
on active metabolite production. This was followed by a bioassay guided isolation of the
active metabolites.
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Figure 2-9. Growth pattern of H668 (A) and variation of the antimalarial activity of
the crude extract as a function of the number of days of incubation (B)
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Figure 2-10. Variation of the antimalarial activity of crude extract of culture of
H668 as a function of the temperature of incubation

Initial epigenetic studies involved the inoculation of 50 mL of ISP2 medium with
an H668 spore suspension followed by incubation at different temperatures (20 - 30 ˚C)
and for different periods of time (2, 5, 7, 12 days). It was determined that the best
conditions for active metabolites production were long incubations (~12 days) and
temperatures within the range 25 - 30 ˚C. These conditions were applied to generate
enough crude extract for the isolation of bioactive secondary metabolites. The
generated crude extract was first fractionated on C18 material (VLC) to generate a
bioactive fraction (80% MeOH in H2O) which was further purified by HPLC on a silica
gel column. This bioassay-guided approach revealed that the bioactive metabolites
were the polyether K41-A (5) [117] and its C-29 methyl ether (6) [189].
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Figure 2-11. Structure of K41-A (6) and its C-29 OMe Ether (7)
Though an OMe, instead of an OH, was the only difference between the flat
structures of 6 and 7, their NMR data varied considerably. Based on the NOESY data,
the main difference between both compounds resided in their 3D structure, instead. In
fact, in the case of 6, long range correlations between atoms at opposite ends of the
molecule were detected (Figure 2-12). This was not the case with 7 (Figure 2-13) and
was interpretated as an indication of the chelation of a cation. It is important to point out
that a new polyether was previously isolated from this same bacterium [120]

Figure 2-12. Key NOESY correlations of 6
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The effects of these molecules along with several other standard ionophores
including gramicidin D were evaluated against several disease targets. These included
Gram negative bacteria (Escherichia coli, Pseudomonas aeruginosa), Gram positive
bacteria (Mycobacterium intracellulare, Mycobacterium tuberculosis and Methicillinresistant

Staphylococcus

and

aureus)

fungi

(Candida

albicans,

Cryptococcus

neoformans, and Aspergillus fumigatus). K41-A and its methyl ether showed selectivity
and outstanding potency against Gram-positive bacteria. The IC50s (µg/mL) against
MRSA were 0.065 and 0.55, respectively for K41-A and its methyl ether. Corresponding
MICs (µg/mL) were 1.25 and 5.00, respectively, for K41-A and its methyl ether. The IC50
and MIC (µg/mL) values of K41-A against M. intracellulare were 0.15 and 0.31,
respectively.
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Figure 2-13. Key NOESY correlations of 7
K41-A, its methyl ether and several other ionophores (monensin, nigericin,
calcimycin, gramicidin D, and valinomycin) were also tested again M. tuberculosis [190].
In the primary assay, the inhibition potential of all but valinomycin ranked between 99
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and 100%. The MICs (µg/mL) of monensin, gramicidin D, K41-A and its ether were 0.88,
7.68, 3.70 and 5.96, respectively. Pending further investigations, these molecules are
interesting drug leads for the control of zoonotic tuberculosis and MRSA.
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Table 2-2 NMR assignment of 6 and 7 in CD2Cl2
Hawaiimycin B (6)

Hawaiimycin C (7)

δ Ca

δH mult. (J in Hz)b

δ Ca

1.
2.
3.
4.
5.
6.
7.

174.9
72.9
99.9
38.8 c
85.0
78.3
68.5

/

178.7
71.6
98.8
38.6
85.0
78.1
66.5

8.
9.
10.

33.5
61.7
32.5 c

11.

79.4
c

4.82 br s
2.90, m
4.09 ud
/
4.60, dd (1.8, 12.0)
2.31, m
4.70, m
2.84 , m
1.89, m
4.17, m

32.6
61.3
31.1

2.60, m

δH mult. (J in
Hz)b
/
3.79, m
/
2.04, m
3.29, br s
/
3.80, m

79.8

1.54, m
3.93, m
1.14, m/2.07,
m
3.38d

36.8
107.0
46.1
94.6
83.4
83.6

1.81, m
/
2.12, m
3.53, m
/
3.75, m

25.5

1.93m, /1.77m

23.0

1.77, m

79.5
79.4

3.94, m
4.43, m

12.
13.
14.
15.
16.
17.

37.6
107.0
48.3
95.6
82.4
84.8

18.

25.9c

19.

29.2c

20.
21.

81.4
81.8

22.

30.5c

2.92, m
2.47, m

29.2

1.44, m / 2.00,
m

23.

25.4c

2.66, m

24.1

2.13,
m
1.84m

24.

80.2

4.99, dt (3.0, 7.2)

80.8

4.37, m

25.

76.6

4.19, m

74.2

3.89, dd (2.0,
10.0)

26.

40.1c

2.04m

39.1

1.23, m

2.30, m
4.27, d (9.6)
/
4.43, dd (6.6, 9.6)
2.66, m
2.60, m
2.76, m
2.38 , m
4.35, m
4.88, dd (6.6, 7.4)
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/

27.

83.3

4.06, m

82.7

3.32d

28.

46.6c

2.80, m

47.0

1.42, m

29.

101.5

/

98.3

/

30.

22.2

2.07, s

26.7

1.26, s

31.

11.7c

1.75, m

12.3/12.5/13.0c

Interchc

32.

13.6c

1.79, m

12.3/12.5/13.0c

Interchc

33.

28.5

2.29, s

28.2

1.60, s

34.

13.6c

1.79, m

11.3

1.00, m

35.

12.9c

1.76, m

12.3/12.5/13.0c

Interchc

36.

11.4

1.87, s

10.9

1.09, s

37.

12.2

1.81, d (6.6)

11.8

1.03, d (3.0)

5-OMe

61.4

4.31, s

60.7

3.52, s

6-OMe

51.0

4.11, s

50.4

3.33, s

11-OMe

57.8

4.07, s

59.9

3.44, s

15-OMe

47.8

3.92, s

60.0

3.40, s

29-OMe

60.7

4.17, s

/

/

1’

103.1

5.19, dd (1.8, 9.6)

102.6

4.42, m

2’

31.1c

2.70, m

30.5

1.39, m / 1.93,
m

3’

27.9c

2.95, m

27.3

2.19, m

4’

80.9

3.54, dt (4.2, 10.2)

80.3

2.78, m

5’

75.1

4.02, m

74.4

3.24, m

5’-Me

18.2

1.97, d (6)

18.1

1.20, d (6.0)

4’-OMe

57.1

4.09, s

56.4

3.31, s

5’-Me
a

Assignments based on DEPT, HMQC, and HMBC NMR data (100 MHz). bAssignments based on
c
COSY and HMBC NMR data (400 MHz). Signals partially overlapped.
c
interchangeable methyl assignments, dberried signal
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Figure 2-14. 1H NMR spectrum of 6 in CD2Cl2
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Figure 2-15. 13C NMR spectrum of 6 in CD2Cl2
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f1 (ppm)

Figure 2-16. NOESY spectrum of 6 in CD2Cl2
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Figure 2-17. 1H NMR spectrum of 7 in CD2Cl2
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Figure 2-18. 13C NMR spectrum of 7 in CD2Cl2
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f1 (ppm)

Figure 2-19. NOESY spectrum of 7 in CD2Cl2.
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Chapter 3 : ANTIFUNGAL AND ANTI-HEPATITIS C
VIRUS (HCV) CYCLIC PEROXIDES ISOLATED FROM
A JAMAICAN SPONGE OF THE GENUS
PLAKINASTRELLA

ABSTRACT— Five new six-membered ring cyclic peroxides, plakinastreloic acid
A (8), methyl plakinastreloate A (9), the C-12 epimers of methyl 13, 14epoxyplakinastreloate (10 & 11), and plakinastreloic acid B (12) were isolated from a
marine sponge of the genus Plakinastrella. Their structures and relative configurations
were determined. Compounds 8 and 9 exhibited antifungal activities against Candida
albicans (IC50 = 6.5 µg/mL and 3.5 µg/mL, respectively), Aspergillus fumigatus (IC50 =
4.0 µg/mL and 9.0 µg/mL, respectively) and Cryptococcus neoformans (IC50 = 4.0
µg/mL and 9.0 µg/mL, respectively). A moderate antimalarial activity against CQresistant and CQ-sensitive strains of P. falciparum was observed, as well. It was also
established that 8 possesses anti-HCV activity. The percentage of HCV’s RNA inhibition
at 10 µg/mL was estimated at 88%. Some cytotoxicity was observed, as well.

Marine sponges have proven to be an excellent source of secondary metabolites,
several of which show interesting bioactivity against a variety of disease targets. Among
these compounds are cyclic peroxides, a group of secondary metabolites isolated from
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sponges of the genus Plakortis and Plakinastrella [191]. Examples include plakortide F
[192], plakinic acid F [193], and epiplakinic acid F [193], plakortide Q and its analogues
[194], ethyl plakortide Z, ethyl didehydroplakortide Z, and methyl didehydroplakortide Z,
ethyl seco-plakortide Z, epi-ethyl seco-plakortide Z, and ethyl didehydro-seco-plakortide
Z [195], andavadoic acid [196], nuapapuin A methyl ester [197], nuapapuin B [197].
Cyclic peroxides are bioactives molecules; they are reported to possess antifungal
(primarily against C. albicans and A. aspergillus) [193, 198, 199], antimalarial [199,
200], antineoplastic [194-197, 201, 202] and antiviral (HSV) activities [200].

Figure 3-1. Jamaican sponge of the genus Plakinastrella
In a continued effort to identify new biologically active metabolites from the
marine environment, several sponge samples were harvested from Jamaica (Rio
Buenos Discovery Bay) using closed circuit rebreathers at a depth of - 40 m [203]. We
previously reported the isolation of new peroxylactones from one of these samples
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(Plakinastrella onkodes) [203]. Here, we report the isolation of five new six-membered
ring cyclic peroxides from a liver sponge of the genus Plakinastrella (Figure 3-1) [203].
These include plakinastreloic acid A (8), methyl plakinastreloate A (9), the C-12 epimers
of methyl 13, 14-epoxyplakinastreloate (10 & 11) and plakinastreloic acid B (12).

Plakinastreloic acid A (8) was isolated as a colorless amorphous solid {[α]D = +
38 (c.0.09, MeOH)}. The

13

C NMR spectrum suggested that 8 contained 25 carbons.

Inspection of the 13C and 1H NMR spectra suggested that the molecular formula was
C25H36O4, indicating the presence of eight degrees of unsaturation. A molecular ion of
399.9 was obtained by LCMS analysis under negative ion mode.
are provided in Table 3-1 and

13

C and 1H NMR data

Table 3-2. Resonances attributable to five methyl groups were observed [δH 1.16
(3H, d, J = 6.6 Hz), δH 1.67 (3H, brs), δH 1.36 (3H, s), δH 0.91 (3H, d, J = 6.8 Hz), δH
0.93 (3H, d, J = 6.0 Hz)]. Compound 8 also contained 11 methine, four methylene, and
four quaternary carbons. It was established based on the 1H-1H COSY spectrum
analysis that 8 contained four independent spin systems; these spin systems are
labeled A-D and shown in bold bonds in Figure 3-2; full tables of data are included.

Figure 3-2. Key HMBC and 1H-1H COSY correlations for plakinastreloic acid A (8)
and methyl plakinastreloate A (9)
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These spin systems were connected based on HMBC correlations (Figure 3-2).
First, several HMBC correlations were observed between the methylene protons H-2a
(1H, δH 2.26, m), H-2b (1H, δH 2.68, dd, J = 2.4 Hz, 16.0 Hz) and C-1. Another HMBC
correlation was observed between the methine proton H-3 (1H, δH 4.01, dt, J = 2.8 Hz,
9.6 Hz) and the same carbon (C-1). When taken in conjunction with the molecula
formula and the chemical shift of C-1, this suggested that 8 was a free acid. The
connection of the first and second spin system was made possible by HMBC
correlations between H-7a (1H, δH 1.21, m), H-7b (1H, δH 1.50, dd, J = 2.8 Hz, 14.8 Hz)
and C-6, on the one hand and between H-5a (1H, δH 1.21, m) and C-22 on the other.
The existence of HMBC correlations between H-24 (3H, δH 1.67, brs) and C-9 on the
one hand, and between H-24 and C-11 on the other, allowed the connection of the
second and the third spin system (Figure 3-2). Finally, the HMBC correlation between
H-14 (1H, δH 6.36, d, J = 16 Hz) and C-15 allowed the connection of the aromatic ring to
the third spin system. The structure of 8 was determined to be as depicted in Figure 3-2.
A closely related molecule (13) and its methyl ester were reported in 1980 by
Stierle and Faulkner [204]. These molecules were derived from a sponge of the genus
Plakortis. Compounds 8 and 13 share the same molecula formula and skeleton; in both
molecules, C-10 and C-11 are connected by a double bond. The only difference
between 8 and 13 resides in the location of the second double bond. The second
double bond of 8 connects C-13 and C-14 and in 13 C-12 and C-13, instead. Stierle and
Faulkner reported 13 and its methyl ester as highly unstable compounds that
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“decompose on standing” making data acquisition difficult. Several other reported
peroxides did not share this feature [204].

Based on the NOESY spectrum analysis, it was established that the relative
configuration of 8 is as depicted in Figure 3-3. A strong NOESY correlation was
observed between H-3 (1H, δH 4.01, dt, J = 2.8 Hz, 9.6 Hz) and H-5a (1H, δH 1.21, m). It
is important to note that no NOESY correlation was detected between H-3 and 5b (1H,
δH 1.63, d, J = 4.4 Hz) and that the correlation between H-3 and H-2b (1H, δH 2.68, dd, J
= 2.4 Hz, 16.0 Hz) was weak. Another important NOESY correlation was identified
between H-22 (3H, δH 1.36, s) and H-4 (1H, δH 1.85, m).
The strong NOESY correlations between H-11 (1H, δH 5.07, d, J = 8.8 Hz), H-9a
(1H, δH 1.87, m) and H-9b (1H, δH 1.96, m) suggested an E configuration for the C-10 C-11 double bond. It is important to point out that no similar correlation with H-24 (3H,
δH 1.67, br s) was observed.
Strong NOESY correlations were identified between H-13 (1H, δH 6.17, dd, J =
6.0 Hz, 16.0 Hz), H-14 (1H, δH 6.36, d, J = 16.0 Hz) and the aromatic protons H-16/H20.
This is only possible if H-13 and H-14 are trans-oriented, suggesting an E configuration
of the corresponding double bond; the large coupling constant between H-13 and H-14
(J = 16.0 Hz) confirms this assignment. No other proton had a NOESY correlation with
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the aromatic protons. H-13 and H-14 both showed weak NOESY correlations to H-25,
H-12 and H-11.
Methyl plakinastreloate A (9) was isolated as a colorless amorphous solid {[α] D=
+ 32 (c.0.03, MeOH)}.

13

C and 1H NMR data for 9 are provided in Table 3-1 and 3-2.

Analysis of its NMR spectrum revealed that it was similar to plakinastreloic acid A (8) in
all but one point: the presence of an OMe signal (δH 3.67, δc 51.1); merged NMR spectra
of 8 and 9 are included. This resonance showed an HMBC correlation to C-1 (δc 171.9),
an indication that 9 was the methyl ester of plakinastreloic acid A (8). No difference was
observed between the NOESY spectra of methyl plakinastreloate A (9) and that of
plakinastreloic acid A (8), suggesting that these compounds had the same relative
configuration (Figure 3-3).

Figure 3-3. Relative configuration of plakinastreloic acid A (8) and methyl
plakinastreloate A (9) based on NOESY correlations (↔)
Two additional new molecules, 10 and 11 were isolated after further purification
of the HPLC fraction which eluted with 6:94 H2O/CH3CN [C18 column, 21.2 × 250 mm at
6 mL/min]. These two compounds eluted together, and because of a limited amount of
material, their structures were solved as a mixture. The HRMS analysis (positive ion
mode) of the mixture showed a single peak, an indication that 10 and 11 shared the
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same molecular weight.

13

C and 1H NMR data for 10 and 11 are provided in Table 3-1

and 3-2. Inspection of the 1H and

13

C NMR spectra coupled with HRMS data suggested

a formula of C26H38O5Na for 10 and 11 [(M+ Na) - m/z observed 453.2617], indicating
the presence of eight degrees of unsaturation in each of these molecules.
A comparative analysis of the NMR spectra of 9 with that observed for the
mixture of 10 and 11 suggested that these three compounds share a common moiety
(C-1 through C-11) (Figure 3-4); full tables of data are included. The remainder of the
structure of 10 and 11 was assembled through analysis of the 1H-1H COSY spectrum of
10 and 11 as follows: H-11 was coupled to the methine proton H-12 (δH 2.63 and δH
2.47, for 10 and 11, respectively); this proton was in turn coupled to H-25 (δH 1.06 and
δH 1.1, for 10 and 11, respectively) and H-13 (δH 2.79 and δH 2.86, for 10 and 11
respectively). H-13 was in turn coupled to a methine proton H-14 (δH 3.69 and δH 3.7, for
10 and 11, respectively).

1
5

11

10

8

3

O

O

O

OR

8 R=H
9 R=CH3
10 R=CH3
11 R=CH3

HMBC
COSY

Figure 3-4. Structural moiety shared by 10, 11, 8 and 9
The chemical shifts of C-13 (δC 67.0 and 66.8, for 10 and 11, respectively) and C14 (δC 56.9 and 57.9, for 10 and 11 respectively) are consistent with oxygen substitution
at these positions. When taken in conjunction with the molecular formula of these
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molecules, this suggests the presence of an epoxide ring at C-13 – C-14. The strong
HMBC correlation between H-14 (δH 3.66 and δH 3.77 for 10 and 11, respectively) and
aromatic carbons C-15 and C-16 allowed the incorporation of a phenyl substituent at C14. The aromatic signal (δH 7.1-7.3) integrates for 10 instead of five protons. This further
suggests that we are dealing with a mixture and that the aromatic rings of 10 and 11 are
mono substituted. It was established based on the 1H-1H COSY spectrum analysis that
10 and 11 contained four independent spin systems; these are labeled A-D and shown
in bold bonds in Figure 3-5; full tables of data are included. The planar structures of 10
and 11 are identical and depicted in Figure 3-5.
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Table 3-1.

13

C NMR data for compounds 8 - 12 (600 MHz)

8 (CD3OD)

9
(CD3OD)

10 (CD3OD)a

11 (CD3OD)a

12 (CD2Cl2)

1.

173.7

171.9

171.9

171.9

169.8

2.

36.0

35.8

35.7

35.7

69.6

3.

83.7

83.7

83.7

83.7

43.8

4.

30.3

30.4

30.3

30.4

45.6

5.

42.7

42.8

42.7

42.7

84.4

6.

81.5

81.8

81.7

81.7

51.6

7.

47.0

47.3

47.3

47.3

28.8

8.

26.0

26.2

26.1

26.1

39.0

9.

49.1

49.3

49.1

49.2

27.2

10. 133.2

133.3

135.6

135.8

29.6-30.0u

11. 130.4
12. 35.6

130.6
35.7

126.8
34.5

127.6
35.5

29.6-30.0u
29.6-30.0u

13. 134.7

134.8

67.0

66.8

29.6-30.0u

14. 127.5

127.6

56.9

57.9

29.6-30.0u

15. 137.9

138.1

138.0

138.0

29.6-30.0u

16. 125.6

128.3

125.3

125.4

29.6-30.0u

17. 128.1
18. 126.5

125.8
126.6

128.3
127.8

128.3
127.7

29.6-30.0u
32.1

19. 128.1

125.8

128.3

128.3

22.9

20. 125.6

128.3

125.3

125.4

14.1

21. 16.1

16.2

15.6

16.2

31.1

22. 19.9

20.0

20.0

20.0

28.1

23. 20.9

21.0

20.7

21.0

21.7
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24. 15.1

15.2

15.4

15.6

/

25. 20.3

20.4

16.2

16.7

/

/

51.1

51.1

51.1

/

OMe
u

interchangeable assignments (methylene carbons of the aliphatic chain). a the structures of
compounds 10 and 11 were solved as a mixture; assigned signals are thus interchangeable for any given
position
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Table 3-2. 1H NMR data of compounds 8-12 (600 MHz) δH,mult. (J in Hz)
8 (CD3OD)
/

1.

9 (CD3OD)

11 (CD3OD)a

10
(CD3OD)a

12 (CD2Cl2)

/

/

/

/

2.72, dd (3,
16.2)
2.28, dd (9,
15.6)
3.97, dt (3, 9.6)

2.71, m
2.26, m

2.71, m
2.26, m

/

3.95,m

3.96, m

2.56, dd
(2.4,16.8)
2.39, d (16.8)
1.93, dd (2.0,
14.0)
1.77, d (14.4)
/

2.

2.68, dd (2.4,
16.0)/ 2.26, m

3.

4.01, dt (
2.8,9.6)

4.

1.85, m

1.85, m

1.81, m

1.81, m

5.

1.63, d (4.4)
1.21, m
/

1.63, d (6)
1.21, m
/

1.62, m
1.25, m
/

1.62, m
1.25, m
/

1.50, dd (2.8,
14.8)
1.21, m
1.81, m

1.48, dd (2.4,
14.4) 1.17, m

1.24, m
1.57, m

1.24, m
1.57, m

1.8, m

1.80, m

1.80, m

1.87, m
1.96, m
10. /

1.82, m
1.9, m
/

1.82, m
1.91, m
/

1.82, m
1.91, m
/

11. 5.07, d (8.8)
12. 3.26, m

5.04, d (8.4)
3.24, m

5.00, m
2.63, m

5.00, m
2.47, m

1.27, m
1.27, m

13. 6.17, dd (6.0,
16.0)
14. 6.36, d (16.0)

6.15, dd (6.2,
16.2)
6.33, d (16.2)

2.79, dd
(2.4, 6.0)
3.66, d (2.0)

2.86, dd (2.4,
6.0)
3.77, d (2.0)

1.27, m
1.27, m

15. /

/

/

/

1.27, m

16. 7.32, m

7.24, m

7.20, m

7.20, m

1.27, m

17. 7.27, m

7.30, m

7.30, m

7.30 , m

1.27, m

6.

7.

8.
9.
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1.62, m
1.46, dd (7.0,
15.2)
1.62, m

1.29, m
1.17, m
1.27, m
1.27, m

18. 7.17, m

7.14, m

7.23, m

7.23, m

1.27, m

19. 7.27, m

7.30, m

7.30, m

7.30, m

1.27, m

20. 7.32, m

7.24, m

7.20, m

7.20, m

0.88, t (7.2)

21. 0.91, d (6.8)

0.91, d (6.6)

0.86, m

0.86, m

1.34, s

22. 1.36, s

1.33, s

1.26s

1.29s

1.52, s

0.93, d (6 )

0.81, d (7.0)

0.9, d (7.0)

0.97,d (6.6)

1.64, s

1.64, brs

1.66, brs

/

1.12, d (6.6)

1.06, d (7.0)

1.1, d (6.0)

/

3.67, s

3.67, s

3.67, s

/

23. 0.93, d (6.0)
24. 1.67, brs

*

25. 1.16, d (6.6)
OMe

/

u

interchangeable assignments (methylene carbons of the aliphatic chain). a the structures of
compounds 3 and 4 were solved as a mixture; assigned signals are thus interchangeable for the same
carbon position

Figure 3-5. Key HMBC and 1H-1H COSY correlations for compounds 10 and 11
The next step was to attempt to determine what differentiated 10 from 11.
NOESY correlations appeared to be identical around the double bonds in 10 and 11.
The olefinic proton H-11 (δH 5.00 and δH 5.00, for 10 and 11, respectively) did not show
a correlation to the methyl signal at C-24 (δH 1.64 and δH 1.66, for 10 and 11,
respectively) but did show a correlation to H-25 (δH 1.06 and δH 1.1, for 10 and 11,
respectively) and H-9 (δH 1.82/1.91 and δH 1.82/1.91, for 10 and 11, respectively)
107

leading to an E configuration of these double bonds in both compounds.
As for the configuration around the epoxide ring, H-13 (δH 2.79 and δH 2.86, for
10 and 11, respectively), gave a NOESY correlation to the aromatic proton H-16 (δH
7.20 and δH 7.20, for 10 and 11, respectively). This point added to the fact that there
was no NOESY correlation between the aromatic protons and the olefinic signal H-11
was an indication that the aromatic ring had an α orientation while the C-11 – C-12 bond
had a β orientation (Figure 3-6). The major difference between 10 and 11 is the
chemical shifts of H-12 (δH 2.63 and δH 2.47, for 10 and 11, respectively). This suggests
that 10 and 11 differ in the relative configuration between C-11 and C-12. The epoxide
ring present in 10 and 11 could have resulted from a nonselective epoxidation of the C13 - C-14 double bond of 9.

Figure 3-6. Key identical NOESY correlations for 10 and 11
A fifth compound, plakinastreloic acid B (12), was isolated as a colorless
amorphous solid {[α]D= + 60 (c.0.06, MeOH)}. The inspection of the

13

C and 1H NMR

spectra coupled with the HRMS data suggested a formula of C23H45O4 [(M+H+) m/z
observed 385.4380], indicating the presence of two degrees of unsaturation. The 1H
NMR spectrum indicated the presence of four methyl groups [δH 0.88 (3H, t, J = 7.2 Hz),
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δH 0.97 (3H, d, J = 6.6 Hz), δH 1.34 (3H, s) and δH 1.52 (3H, s)]. Complex signals were
present between δH 1.33 - 1.20 (23 H, m), suggesting the presence of an aliphatic chain.
Based on the HSQC spectrum, these signals could be correlated to complex carbon
signals in the δC 29.6 -30.0 region. This was further confirmed by the DEPT spectrum.
Based on the HSQC spectrum, the methylene protons could be assigned as
follows: 2H attached to C-9, 2H attached to C-19, 1H attached to the methylene carbon
C-8, and finally, 2H attached to C-18. By simple subtraction, it was established that the
remaining 16 hydrogens (eight methylene) belonged to the aliphatic chain. Based on the
HSQC, three additional methylene groups were identified, including C-3, C-4 and C-6. It
was established that the molecule contained three quaternary carbons as well as a
methine signal. All these carbons add up to a 23 carbon molecule.
Analysis of the 1H-1H COSY spectrum showed evidence for the existence of
three independent spin systems; these are labeled A-C and shown as bold bonds in
Figure 3-7; full tables of data are included.
The peroxide ring depicted in Figure 3-7 was assembled based on the following
HMBC correlations: first, the correlations between the methyl protons H-21 (3H, δH
1.34, s) and C-1, C-2, C-3, C-4 and then the correlations between the methyl protons H22 (3H, δH 1.52, s) and the carbons C-5, C-4 and C-6. Because of the existence of an
HMBC correlation between H-6a (1H, δH 1.46, dd, J = 7.0, 15.0), H-6b (1H, δH 1.62, m)
and C-5, it was determined that the spin system that extended from C-6 trough C-8 was
connected to the peroxide ring. Another HMBC correlation was identified between H-8a
(1H, δH 1.17, m), H-8b (1H, δH 1.29, m) and a carbon at δC 27.2 which is part of the
109

aliphatic chain that extended from C-8 to C-20. H-20 (3H, δH 0.88, t, J = 7.2) gave an
HMBC correlation to C-19 and C-18. Based on these correlations, the structure of
plaskinatrealoic acid B (12) was determined to be as depicted in Figure 3-7.

Figure 3-7. Key HMBC and 1H-1H COSY correlations of 12
Based on the NOESY spectrum, it was established that the relative configuration
around the peroxide ring of 12 is as depicted in Figure 3-8. A NOESY correlation was
observed between H-22 (3H, δH 1.52, s) and H-3b; no similar correlation to H-3a was
observed. A weak correlation was also detected between H-23 (3H, δH 0.97, d, J = 6.6)
and H-22. Another NOESY correlation was observed between H-6a (1H, δH 1.46, dd, J =
7.0 Hz, 15.2 Hz) and H-4a; no correlation between H-6a and H-4b was observed.
Finally, there were NOESY correlations between H-21 (3H, δH 1.34, s) and both protons
of the methylene C-3 and C-4, suggesting spin diffusion.

Figure 3-8. Relative configuration of 12 based on NOESY correlations (↔)
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Plakinastreloic acid A (8) and methyl plakinastreloate A (9) showed an
interesting bioactivity profile. The IC50 values for plakinastreloic acid A (8) and methyl
plakinastreloate A (9) against Candida albicans were 6.5 and 3.5 µg/mL, respectively;
against Aspergillus fumigatus, the IC50 values were 4.0 and 9.0 µg/mL, respectively.
Finally, against Cryptococcus neoformans, the IC50 values were 4.0

and 9.0 µg/mL

respectively. A moderate antimalarial activity against the CQ-resistant (strain W2) and
sensitive strains of P. falciparum (strain D6) was also observed for 8 and 9. For
plakinastreloic acid A (8), the IC50 values were 3.8 and 2.7 µg/mL, respectively against
D6 and W2. The selectivity indexes were higher than 1.3 and 1.8, respectively for these
2 strains. For 9, the IC50 values against the malaria parasite were 2.3 µg/mL and 1.8
µg/mL, respectively, for the CQ-sensitive (D6) and the CQ-resistant strains (W2) of P.
falciparum. The selectivity indexes were higher than 2.1 and 2.6, respectively for these
two strains. No cytotoxicity against Vero cells was observed up to 4.7 µg/mL, the
highest concentration tested. Plakinastreloic acid A (8) also exhibited antiviral activity
against the Hepatitis C Virus (HCV) in a dose dependent manner. At the highest
concentration (10 µg/mL), the percentage of HCV’s RNA inhibition was estimated at
88%. It is important to note that a significant reduction in the level of rRNA replicon was
noted as well (Figure 3-9) suggesting that plakinastrella A (8) acts in a non-selective
manner (cytotoxic). The EC50 was 2.2 µg/mL and the EC90 > 10 µg/mL.
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Figure 3-9. Dose-dependent anti-HCV activity of plakinastreloic acid A (8)

2. Experimental
2.1. General experimental procedures
1D and 2D NMR spectra were recorded on a 600 MHz NMR spectrometer
(Varian; 3mm inverse probe with variable temperature control (vtc). Chemical shifts are
expressed in ppm with the residual solvent signal used as standard.
Semi-preparative and preparative HPLC were carried out using a Waters PrepLC
system; Reverse (C18, C8) and normal phase (silica gel) HPLC columns were used
subsequently. The MW of 8 was determined by LCMS analysis under negative (Bruker
Daltonics MicroTOF LCMS). The high resolution mass spectra (HRMS) for 10, 11, and
12 were recorded on a Waters Micromass Q-TOF® Micro mass™ spectrometer
equipped with a NanoLockSpray™ source.
112

2.1.1 Extraction and isolation
A bioassay-guided approach was used for the isolation of all compounds
mentioned in this report. Targeted biological assays included tests against P.
falciparum, HCV and a variety of microbial pathogens (Gram positive and negative
bacteria, as well as, a set of fungi). The initial fractionation of the crude extract was
completed by VLC on silica gel using a n-hexane/acetone gradient. The most active
fraction was further purified by HPLC. The first HPLC was completed on a 100 × 250
mm C8 column. The flow rate was 25 mL/min and the solvent system varied from 100:0
H2O/CH3CN  40:60 H2O/CH3CN over 60 minutes and then from 40:60 H2O/CH3CN 
0:100 H2O/CH3CN over an additional 240 minutes. The fraction collection was UV–
guided (254 nm) and 62 fractions were collected. Two of these fractions that eluted with
100% CH3CN, namely the fraction 44, from which 8, 9, 10, 11 were isolated and the
fraction 58 from which 12 was isolated, were selected for further purification. The HPLC
of fraction 44 using the same column (C8, 100 × 250 mm) but a different solvent system
led to poor separation; solvents were set to vary from 25:75 H2O/CH3CN  20:80
H2O/CH3CN over 40 minutes and then from 20:80 H2O/CH3CN 0:100 H2O/CH3CN
over an additional 80 minutes. Nonetheless, the further purification of a fraction that
eluted with 100% CH3CN by prep-TLC led to the isolation of 9. The solvent system for
the prep-TLC was 80:20 n-hexane-EtOAc. A better separation was achieved by
switching the column to Phenomenex C18 column (21.2 × 250 mm). The solvent system
varied from 25:75 H2O/CH3CN  20:80 H2O/CH3CN (40 minutes) and from 20:80
H2O/CH3CN 0:100 H2O/CH3CN for an additional 80 minutes; the flow rate was 6
mL/min; using this second approach, 8 eluted with 14:86 H2O/CH3CN. The fraction that
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eluted with 6:94 H2O/CH3CN was further purified using a Phenomenex C8 column (10 ×
250 mm). In this particular case, the solvent system varied from 15:85 H2O/CH3CN 
0:100 H2O/CH3CN (25 minutes) and 10 and 11 eluted with 0:100 H2O/CH3CN. The
amount of plakinastreloic acid A (8) derived from 30 mg of fraction 44 was 3.5 mg and
the combined weight of 10 and 11, epimers of 13, 14 –epoxyplakinatreloate, was 1.6
mg; the structure of 10 and 11 was solved as a mixture. The fifth compound
(plaskinastreloic acid B) was isolated from the fraction 58. The amount of plakinastreloic
acid C (12) derived from 40 mg of fraction 58 was 3.5 mg. The purification of
plaskinastreloic acid B (12) was completed using a Luna 10µ silica HPLC column (21.2
× 250 mm). The solvent system varied from 0:100 2-propanol/n-hexane  10:90 2propanol/n-hexane over 45 minutes and then from 10:90 2-propanol/n-hexane  40:60
2-propanol/n-hexane (25 minutes). All these isolations were monitored by UV (254 nm)
and 12 eluted with 14:86 2-propanol/n-hexane.

Plakinastreloic acid A [8]. Colorless amorphous solid; [α]D = + 38 (c.0.09,
MeOH); MS negative mode m/z 399.9 (very weak signal) [M-H] (calcd for C25H35O4,
399.2535); 1H NMR (CD3OD)
Table 3-2 and 13C NMR (CD3OD) Table 3-1
Methyl plakinastreloate [9]. Colorless, amorphous solid; [α]D= + 32 (c.0.03,
MeOH); C26H38O4, calcd = 414.2770; 1H NMR (CD3OD);
Table 3-2 and 13C NMR (CD3OD) Table 3-1
Epimer of Methyl 13, 14-epoxyplakinastreloate [10 and 11] Colorless
amorphous solid. The HRMS m/z 453.2617 [M + Na+] (calcd for C26H38O5Na,
453.2617); 1H NMR (CD3OD);
Table 3-2 and 13C NMR (CD3OD) Table 3-1
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Plakinastreloic acid B [12]. Colorless, amorphous solid [α]D= + 60 (c.0.06,
MeOH); HRMS m/z 385.3318 [M + H+] (calcd for C23H45O4, 385.6033); 1H NMR
(CD2Cl2);
Table 3-2 and 13C NMR (CD2Cl2) Table 3-1
2.2. Material and methods
2.2.1. Antifungal and antibacterial assay
Several strains: Candida albicans ATCC 90028, Cryptococcus neoformans
ATCC 90113, Aspergillus fumigatus ATCC 90906, Methicillin resistant Staphylococcus
aureus ATCC 43300, Escherichia coli ATCC35218, Pseudomonas aeruginosa ATCC
27853, and Mycobacterium intracellular ATCC 23068) were used in these assays.
Positive controls were amphotericin B (for C. albicans, C. neoformans and A. fumigatus)
and ciprofloxacin for the rest the remaining bacteria. This assay was completed in a 96
well plate format [205].
2.2.2. Antiviral assay
The anti-HCV activity was determined in the HCV replicon (Clone B) system
(Huh 7 clone B cells containing HCV RNA). Cells were seeded onto 96-well tissue
culture plates (3,000 cells/well); the compounds were tested in a dose response at
concentrations of 10, 3, 1 uM (triplicate). After addition of test compounds the plates
were incubated for five days (37 °C, 5%, CO2). Afterwards the total cellular RNA was
extracted using the manual Perfect Pure RNA 96 cell Vacki from 5 Prime. The replicon
RNA and the internal control (TaqMan rRNA control reagent, applied Biosystems) were
amplified by RT-PCR. The antiviral potency of the tested molecule was determined by
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subtracting the threshold RT-PCR cycle of the tests compounds from the threshold RTPCR of the negative control (no drug): #CtHCV ( a 3.3 value being considered a 1 log
reduction in replicon RNA level (in other words 90% reduction). The cytotoxicity was
calculated using #Ct rRNA values and RS-446 (2-Me-C) was used as control to
determine the EC50 and EC90 values [206, 207].
2.2.3. Antimalarial assay
The test was based on the determination of plasmodial LDH activity. Suspensions
of red blood cells infected with D6 or W2 strains of P. falciparum (200 µL, with 2%
parasitemia and 2% hematocrit in RPMI 1640 medium supplemented with 10% human
serum and 60 µg/mL amikacin) was added to the wells of a 96-well plate containing 10
µL of test samples diluted in medium at various concentrations. The plate was placed in
a modular incubation chamber (Billups-Rothenberg, CA) flushed with a gas mixture of
90% N2, 5% O2, and 5% CO2 and incubated at 37 ºC, for 72 h. Parasitic LDH activity
was determined according to the procedure of Makler and Hinrichs (1993). 20 µL of the
incubation mixture was mixed with 100 µL of the MalstatTM reagent (Flow Inc., Portland,
OR) and incubated at room temperature for 30 minutes. 20 µL of a 1:1 mixture of
NBT/PES (Sigma, St. Louis, MO) was added and the plate is further incubated in the
dark for 1 h. The reaction was stopped by the addition of 100 µL of a 5% HOAc solution.
The plate was read at 650 nm using the EL-340 Biokinetics Reader (Bio-Tek
Instruments, Vermont). IC50 values were computed from the dose response curves.
Artemisinin and CQ were included in each assay as the drug controls. DMSO (0.25%)
was used as a vehicle control [208].
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Table 3-3. Complete 1D and 2D data of 8 (CD3OD)
13

C

1.

COSY

δ H mult. (J in Hz)

/

/

/

2.

36.0

3.

83.7

2.68, dd (2.4, 16.0)/
2.26, m
4.01, dt (2.8,9.6)

H-3, H-2a, H2b

4.

30.3

1.85, m

5.

42.7

6.

81.5

1.63, d (4.4)
1.21, m
-

7.

47.0

1.50, dd (2.8, 14.8)
1.21, m

H-8

8.

26.0

1.81, m

9.

49.1

1.87, m
1.96, m

H-7a, H-7b, H23, H-9abm
H-8m

10.

133.2

/

/

11.

130.4

5.07, d (8.8)

H-12

12.

35.6

3.26, m

13.

134.7

6.17, dd (6.0, 16.0)

H-11, H-25, H13
H-12, H-14

H-2a, H-2b, H-4

H-3, H-21, H-5a,
H-5b
H-4
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HMBC

NOESY

H-2a,
H-2b,
H-3
/

/

H-21, H2a, H-2b,
H-5a, H5b, H-4
H-21, H-5

H-21, H-5a,
H-2a, H-2b

H-22, H21
H-7a, H7b, H-5a,
H-5b, H22
H-23, H22, H-9a,
H-9b
H-23, H7a, H-7b
H-24, H23, H-7a,
H-7b
H-12, H9, H-24

H-4, H-23

H-25,
H24, H9a, H-9b,
H-12, H14
H-25

H-13, H14,
H-25

H-25, H12

/

H-5a, H-22

H-9a, H-9b

H-7a, H-7b,
H-23
/

H-13, H-14,
H-25
H-11,H-12,
H-16/H-20,
H-25, H-14

14.

127.5

6.36, d (16.0)

H-13

H-13, H12

15.

137.9

/

/

H-14, H13, H-17

16.

125.6

7.32, m

H-17/H-19m

H-20, H14, H-18

H-13, H-14

17.

128.1

7.27, m

H-18, H20/H16m

H-19, H15

/

18.

126.5

7.17, m

H-17

19.

128.1

7.27, m

H-18, H20/H16m

H-17, H15

/

20.

125.6

7.32, m

H-17/H-19m

H-16

H-13, H-14

21.

16.1

0.91, d (6.8)

H-4

22.

19.9

1.36, s

/

H-3, H-2b,
H-4
/

23.

20.9

0.93, d (6.0)

/

H-5a, H5b
H-7a, H7b, H-5a
H-7a, H7b, H-9a,
H-9b

24.

15.1

1.67, br s*

/

25.

20.3

1.16, d (6.6)

H-12

/

H-9a, H9b, H-11
H-11, H12, H-13,
H-14

*assigned as a broad singlet, slightly split at the top but has no COSY correlation,
m
merged signals
w
weak correlations
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H-11,H-12,
H-16/H-20,
H-25, H-13

H-5b, H-9a,
H-9bW, H7a, H-22, H8
H-12
H-12, H-11,
H-13

Table 3-4. Complete 1D and 2D data of 10 and 11 (CD3OD)
13

C
10

13

C
11

δH mult. (J
in Hz) 10

1.

171.9

171.9

/

2.

35.7

35.7

2.71, m
2.26, m

2.71, m
2.26, m

3.

83.7

83.7

3.95,m

3.96, m

4.

30.3

30.4

1.81, m

1.81, m

5.

42.7

42.7

1.62, m
1.25, m

1.62, m
1.25, m

6.

81.7

81.7

/

/

/

7.

47.3

47.3

1.24, m
1.57, m

1.24, m
1.57, m

H-8

8.

26.1

26.1

1.80, m

1.80, m

9.

49.1

49.2

1.82, m
1.91, m

1.82, m
1.91, m

H-7a,
H-7b,
H-9abm
H-8m

10. 135.6

135.8

/

/

/

11. 126.8

127.6

5.00, m

5.00, m

H-12

12. 34.5

35.5

2.63, m

2.47, m

13. 67.0

66.8

2.79,
dd
(2.4, 6.0)

2.86, dd (2.4,
6.0)

H-25,
H-11,
H-13
H-14,
H-12

δH mult. (J in
Hz)
11

COSY

/
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HMBC

NOESY

OMe,
H-2a,
H-2b,

/

/

H-2a,
H2b,H3
H-2a,
H-2b,
H-4
H-3, H21, H5a, H5b
H-4

/

/

H-21, H2a, H-2b,
H-5b
H-21, H5a, H5b

H-21, H5a, H-2a,
H-2b
/

H-4, H-3,
H-21, H22
H-5a, H22
H-22, H23w, H-9a,
H-9b
H-23, H7a, H-7b

/

H-23, H24, H-7a,
H-7b
H-24,
H-9a, H9b, H-12

/

H-9,
H-24,
H-25,
H-12
H-25, H13

H-25,
H9a, H9b,
H13, H14

H-25,
12

H-16/H-20

H-

/
/

/

/

H-14, H24, H-25

14. 56.9

57.9

3.66,
(2.0)

15. 138.0

138.0

16. 125.3

3.77, d (2.0)

H-13

H-15, H16

H-16/H-20

/

/

/

H-14,
16

/

125.4

7.20, m

7.20, m

m

H-14, H20, H-18

H-14,
13

17. 128.3

128.3

7.30, m

7.30 , m

m

/

18. 127.8

127.7

7.23, m

7.23, m

m

H-19,
15
/

19. 128.3

128.3

7.30, m

7.30, m

-m

/

/

20. 125.3

125.4

7.20, m

7.20, m

-m

/

/

21. 15.6

16.2

0.86, m

0.86, m

/

H-5

22. 20.0

20.0

1.26s

1.29s

/

23. 20.7

21.0

0.9, d (7.0)

/

24. 15.4

15.6

0.81,
d
(7.0)
1.64, brs

1.66, brs

/

25. 16.2

16.7

1.1, d (6.0)

/

51.1

51.1

1.06,
(7.0)
3.67, s

H-7a, H7b, H-5a
H-9a, H9b, H-7b
H-11, H9a, H-9b
/

H-2b, H-3,
H-4
H-42b, H4

3.67, s

/

/

OMe
w

d

d

weak signal, m merged
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H-

H-

H-

/

H-12
H-12,
11
/

H-

Table 3-5. Complete 1D and 2D data of 12 (CD2Cl2)
13

C
(CD2Cl2)

COSY

δH mult. (J in Hz)
(CD2Cl2)

1.

169.8

/

/

2.

69.6

/

/

3.

43.8

4.

45.6

2.56, dd (2.4,16.8)
2.39, d (16.8)
1.93, dd (2.0, 14.0)
1.77, d (14.4)

H4b, H3a, H-3b
H3b, H4a, H-4b

5.

84.4

/

/

6.

51.6

7.

28.8

1.62, m
1.46, dd (7.0, 15.2)
1.62, m

8.

39.0

9.

27.2

1.29, m
1.17, m
1.27, m

H-6a, H6b
H-23, H8a, H-8b
/

10.

29.6-30.0u

11.
12.

HMBC

NOESY

-m

H-3a,
H3b, H21
H-21, H-3a, H3b, H-4a, H4b,
H-21, H-4aw,
H-4b,
H-21, H22, H3a, H-3b, H6aw, H-6bw,
H-22, H-4a, H6a, H-6b
H-22, H-23, H4a, H-4bw,
H-23, H-6a, H6b,
H-23, H-6a, H6b,
-m

1.27, m

-m

-m

-m

29.6-30.0u
29.6-30.0u

1.27, m
1.27, m

-m
-m

-m
-m

-m
-m

13.

29.6-30.0u

1.27, m

-m

-m

-m

14.

29.6-30.0u

1.27, m

-m

-m

-m

15.

29.6-30.0u

1.27, m

-m

-m

-m

16.

29.6-30.0u

1.27, m

-m

-m

-m

17.
18.

29.6-30.0u
32.1

1.27, m
1.27, m

-m
-m

-m
H-20

-m
-m

19.

22.9

1.27, m

-m

H-20

-m

20.

14.1

0.88, t (7.2)

-
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H-19-H-9m

/
/

H-21, H-4a
H-3a, H-21, H6a4
/
H-23, H-4a6
/
/
-m

-

21.

31.1

1.34, s

-

22.

28.1

1.52, s

23.

21.7

0.97, d (6.6)

m

merged
interchangeable
*stronger signal
6
Correlation to H-6a
4
Correlation to H-4a
u
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-

H-3a, H-3b, H4a, H-4b,
-

H-3a, H-3b, H4a, H-4b,
H-4b

-

H-6a, H-6b,

H-6a,
H7/H6b, H-22

Figure 3-10. 1H NMR spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-11. 13C NMR spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-12. DEPT spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-13. 1H-1H COSY spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-14. HSQC spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-15. HMBC spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-16. NOESY spectrum of the plakinastreloic acid A (8) (CD3OD)
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Figure 3-17. 1H NMR spectrum of the methyl plakinastreloate (9) (CD3OD)
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Figure 3-18. 13C NMR spectrum of the methyl plakinastreloate (9) (CD3OD)
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Figure 3-19. 1H-1H COSY spectrum of the methyl plakinastreloate (9) (CD3OD)
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Figure 3-20. DEPT spectrum of the methyl plakinastreloate (9) (CD3OD)
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Figure 3-21. HSQC spectrum of the methyl plakinastreloate (9) (CD3OD)

134

Figure 3-22. HMBC spectrum of the methyl plakinastreloate (9) (CD3OD)

135

Figure 3-23. Merged 1H NMR spectra of 8 (green) and 9 (red)
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Figure 3-24. Merged 13C NMR spectra of 8 (green) and 9 (red)
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20.90
20.32
19.93
16.14
15.05

26.01

30.33

35.63

49.16
48.11
47.97
47.82
47.68
47.54
47.40
47.26
47.19
42.68

83.70
81.52

137.92
134.64
133.21
130.46
128.14
127.49
126.51
125.66

f1 (ppm)

Figure 3-25. Merged 1H-1H COSY spectra of 8 (gray) and 9 (orange)
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Figure 3-26. Merged HMBC spectra of 8 (red) and 9 (gray)
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Figure 3-27. 1H NMR of the methyl 13, 14-epoxyplakinastreloate (10 and 11)
(CD3OD)
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Figure 3-28.

13

C NMR spectrum of the methyl 13, 14-epoxyplakinastreloate (10 and

11) (CD3OD)
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Figure 3-29. DEPT spectrum of the methyl 13, 14-epoxyplakinastreloate (10 and
11) (CD3OD)
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Figure 3-30. 1H-1H COSY spectrum of methyl 13, 14-epoxyplakinastreloate (10 and
11) (CD3OD)
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Figure 3-31. HMBC spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 11)
(CD3OD)
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Figure 3-32. HSQC spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 11)
(CD3OD)
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1
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6
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3.5

3.0

2.5

2.0

1.5

1.0

Figure 3-33. NOESY spectrum of methyl 13, 14-epoxyplakinastreloate (10 and 11)
(CD3OD)
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Figure 3-34. 1H NMR spectrum of plakinastreloic acid B (12) (CD2Cl2)
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Figure 3-35. 13C NMR spectrum of plakinastreloic acid B (12) (CD2Cl2)
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Figure 3-36. DEPT spectrum of plakinastreloic acid B (12) (CD2Cl2)
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f1 (ppm)

Figure 3-37. 1H-1H COSY spectrum of plakinastreloic acid B (12) (CD2Cl2)
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Figure 3-38. HMBC spectrum of plakinastreloic acid B (12) (CD2Cl2)
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Figure 3-39. HSQC spectrum of plakinastrelloic acid B (12) (CD2Cl2)
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f1 (ppm)

Figure 3-40. NOESY spectrum of plakinastreloic acid B (12) (CD2Cl2)
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Chapter 4 : BIOASSAY-GUIDED ISOLATION OF HCV
ACTIVE METABOLITES FROM INGA FAGIFOLIA AND
DIPLOSTEPHIUM RHODENDROIDES

ABSTRACT - Two new molecules were isolated from Hepatitis C Virus (HCV) active
methanol extracts of Inga fagifiolia (twigs) and Diplostephium rhodendroides (leaves).
These

compounds

were

identified

as

2,3,4,5,6-pentahydroxy-2-(hydroxymethyl)

hexanamide (14) and 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2yl)oxy]pentanoic acid (15). The bioassay-guided approach used for their isolation and
structure elucidation is reported here.

1. Introduction
Hepatitis C, caused by HCV is a serious condition which, according to the CDC,
currently affects about 3.2 million Americans. HCV targets the liver causing
inflammation. HCV is a highly mutable virus; this property has made it difficult to
address this disease effectively. Consequently, there is an urgent need for new antiHCV drug leads.
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In a continuous effort to find new drug leads against infectious diseases, we
initiated a screening campaign of plant and marine extracts from the National Cancer
Institute repository of natural products. These extracts were screened for their ability to
inhibit HCV. Two extracts with outstanding activity were the crude extracts of the twigs
of I. fagifiolia and the leaves of D. rhodendroides.
I. fagifiolia (Figure 4-0-1), also known as Mimosa fagifolia L., I. tetraphylla (Vell.) Mart,
M. laurina Sw., M. tetraphylla Vell, Feuilleea fagifolia (L.) Kuntze or F. laurina (Sw.)
Kuntze is a well known tree belonging to the order Fabales, family Fabaceae and subfamily Mimosoideae. I. fagifolia is a non climbing perennial tree and not an endangered
species. The reported use of this tree is environmental, being used as a shade tree. The
geographical distribution of this plant is wide. I. fagifolia has been reported in many
countries around the world. These include the Caribbean regions, Central America,
Indian Ocean regions, and South American regions. It possesses a variety of vernacular
names; these include Pois Doux Blanc, Arbre a Miel, Caspiro, Cujincuil, Gina, Jina,
Nacaspiro, Palal, Paternillo, Paternillo and Spanish Oak [209, 210]. Reports concerning
the isolation of secondary metabolites from I fagifolia, especially those of biological
importance are scarce. A few molecules have been isolated from this plant in recent
years. These include a protein inhibitor of trypsin isolated from seeds [209], and three
new galloyl depsides of tyrosine [211] that are abundantly produced in young leaves of
I. Fagifolia. The primary structure of the protein was EVVVDSDGEMLRNGGKYY
LSPANPIGGGAIISAAIRHGDHLCSLAVVS. The structures of these new galloyl
depsides are displayed below [209, 211].

155

156

Inga fagifolia
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Figure 4-0-1. Inga fagifolia
D. rhodendroides, on the other hand, is a flowering plant that belongs to a
subgroup of Diplostephium with characteristic disk flowers. The latter are more or less
clavate and merely bifid; corresponding branches are very short and ovate. D.
rhodendroides has been reported in Ecuador and Columbia. Plants of the genus
Diplostephium are believed to have evolved from Aster, another genus of the familly
Asteraceae, by adapting to extreme paramos’ conditions. Among other evolutionary
variations was the development of tomentum under leaves and on branches. About 110
species (trees and shrubs) have been reported to belong to the genus Diplostephium.
Plants of this genus are mainly distributed in Columbia. Several species have been
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reported in several other nearby countries, such as Ecuador, Peru, Chile, Coasta Rica,
Venezuela, and Bolivia [212, 213].
2. Results and Discussion
The crude extract of twigs of I. fagifolia was received from the National Cancer
Institute and fractionated using VLC on silica gel. The percentage of HCV RNA
inhibition for the MeOH fraction was estimated at 99 but this fraction was also cytotoxic.
HCV active and cytotoxic constituents of the methanol fraction were successfully
separated by HPLC using a Phenomenex NH2 column (21.2 × 250 mm). The fraction
that eluted from 100 -107 minutes was active against HCV and showed no cytotoxicity.
This fraction was further separated on a smaller scale using a Phenomenex NH2
column (10 × 250 mm) to yield two well resolved peaks.
The fraction corresponding to the second peak was active against HCV and
showed no toxicity (percentage of HCV RNA inhibition = 96, percentage of rRNA
inhibition = - 54); this fraction contained compound 14. The molecular formula was
determined to be C7H15NO7 based on a pseudo-molecular ion peak at m/z 226.9440 [M
+ H]

+

obtained by HRMS. The odd molecular weight of 14 was interpreted as an

indication that the molecule contains an odd number of nitrogen atoms (nitrogen rule). It
was determined that the molecule contained two quaternary carbons, two methylene,
and three methine (Table 4-0-1). A 1H-1H COSY correlation was observed between the
diastereotopic methylene protons H-7a (1H, δH 3.62/3.47, m) and H-7b (1H, δH 3.62
/3.47, m). Another COSY correlation was observed between the methylene protons H-6
(2H, δH 3.62, m) and H-5 (1H, δH 3.9, m). An HMBC correlation was observed between
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H-3 (1H, δH 3.7, d, J = 10 Hz) and C-5. Another HMBC correlation was detected
between the methylene signals H-7a, H-7b and the quaternary carbon C-2 (Figure
4-0-3). The fact that H-4 was a doublet of doublet, suggested that it was positioned
between the only two other methines of this compound namely C-3 and C-5.

The

presence of a terminal amide group in 14 was determined based on the chemical shift
of C-2, the degree of unsaturation and the molecular weight of the compound. All these
points suggested that the structure of 14 is as depicted in Figure 4-0-2.

Figure 4-0-2. Structure assignment of 14 [2, 3, 4, 5, 6-pentahydroxy-2(hydroxymethyl) hexanamide]
This molecule was identified as 2, 3, 4, 5, 6-pentahydroxy-2-(hydroxymethyl)
hexanamide (14). The free acid analog of 14, 2-hydroxymethyl-D-arabinohexanoic acid,
was reported recently [214-216]. In fact, the potential of various salts of the free acid of
14 to boost the immune response after immunization has been broadly studied. These
studies, which also involved several other similar molecules, have resulted in several
patents [214-216]. These compounds were investigated for use as components of
vaccine adjuvants, a safer, less toxic alternative to cholera toxin [214-216].
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H2N HO
O
HO

OH OH
OH
OH

Figure 4-0-3. COSY (↔) and HMBC (→
→) correlations of 14 [2,3,4,5,6-pentahydroxy2-(hydroxymethyl)hexanamide]
The crude extract of Diplostephium rhodendroides was also received from the
National Cancer Institute and fractionated using VLC on silica gel; solvents included nhexane, DCM, EtOAc and MeOH. The methanol fraction showed promising HCV activity
and was further purified using a 250 × 21.2 mm NH2 column. The resulting ELSD
chromatogram indicated that this fraction was constituted of a large number of minor
metabolites that elute early during the HPLC. The major constituents of this methanol
fraction were simple sugar molecules, none of which possessed anti-HCV activity. Early
fractions that eluted from 10-12 minutes and from 13.9-15.9 minutes were active against
HCV and non toxic. It was determined that the 10-12 minutes fraction was constituted of
a mixture of trace amounts of HCV active molecules predominantly distributed in the
stem and twigs of this plant. The fraction that eluted from 13.9-15.9 minutes was further
purified using a Phenomenex NH2 column (10 × 250 mm). The ELSD chromatogram of
this fraction indicated that, aside from very minor metabolites, it also contained 15;
about 1.5 mg of 15 were isolated from 400 mg of the methanol fraction; compound 15
eluted at around 38 minutes. Based on a pseudo-molecular ion peak at m/z 295.0491
[M - H] – (HRMS, negative mode), its molecular formula was determined to be C11H20O9,
corresponding to two degree of unsaturation. The 11 carbons included a quaternary

160

carbon, a methyl group, a ketal moiety, six other methines, and two methylenes (Table
4-0-2). It was established based on the 1H-1H COSY spectrum analysis that 15
contained two independent spin systems labeled A and B and shown in bold bonds in
Figure 4-0-5. The first involved protons from H-6 (3H, δH 1.52, d, J = 6 Hz) to H-2 (1H,
δH 4.46, m) and the second involved protons from H-2’a (1H, δH 2.73, dd, J = 3 Hz, 18
Hz) and H-2’b (1H, δH 3.02, dd, J = 5 Hz, 18 Hz) to H-5’a (1H, δH 3.67, dd, J = 4 Hz, 11
Hz) and H-5’b (1H, δH 4.12, m).

Figure

4-0-4.

Structure

of

15

[4,

5-dihydroxy-3-{(3,

4,

5-trihydroxy-6-

methyltetrahydro-2H-pyran-2-yl} oxy) pentanoic acid]

The HMBC correlation between H-1 (1H, δH 5.24) and C-5 indicate a six membered ring
involving carbons C-1 through C-5. Similarly, the HMBC correlation between H-1 and C3’ allowed the connection of this ring to the rest of the molecule. Based on these
analyses, it was determined that the structure of 15 is as depicted in Figure 4-0-4.
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Figure 4-0-5. COSY (
) and HMBC (→
→) correlations of 15 [4,5-dihydroxy-3-{(3,4,5trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy}pentanoic acid]
Based on the NOESY spectrum of 15, it was established that its relative configuration
is as depicted in Figure. 4-0-6. NOESY correlations were detected between H-5a' and
H-1, H-3' and H-4'. Another correlation was detected between the methyl protons H-6
and H-3; no such correlation was detected between H-6 and H-4. There was also a
correlation between H-4' and H-5'b. Finally a correlation was detected between H-2 and
H-3.

Figure. 4-0-6. Relative configuration of 15
3. Supporting information
Compound 14. White solid, [α]D = -12 (c.0.03, MeOH); HRMS m/z 226.9440 [M +
H+] (calcd for C7H15NO7, 226.0927);

13

C NMR (400 MHz, D2O) Table 4-0-1; 1H NMR
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(400 MHz, D2O)
Compound 15. Clear solid; [α]D = -40 (c.0.02, MeOH); HRMS m/z 295.0491 [M H] – (calcd for C11H19O9, calcd 295.1029);

13

C NMR (400 MHz, pyridine) Table 4-0-2; 1H

NMR (400 MHz, pyridine) Table 4-0-2
3.1. Experimental Section

3.1.1. Inga fagifolia
The crude extract of twigs of I. fagifolia was initially fractionated using VLC on
silica gel and the methanol fraction showed promising activity. Next, HCV active and
cytotoxicity constituents were separated by HPLC using a Phenomenex NH2 column
(21.2 × 250 mm). Fractions collection was guided by an ELSD detector. The solvent
system was 100/0 DCM/MeOH  75/25 DCM/MeOH (90 minutes), followed by 75/25
DCM/MeOH  0/100 DCM/MeOH (30 minutes). The fraction that eluted between 100 107 minutes was active against HCV and showed no cytotoxicity; this fraction was
further purified on a smaller scale using a Phenomenex NH2 column (10 × 250 mm).
The solvent system was 70/30 DCM/MeOH  30/70 DCM/MeOH (60 minutes), followed
by 30/70 DCM/MeOH  0/100 DCM/MeOH (5 minutes) and the flow rate was 6 mL/min.
The ELSD chromatogram showed two well resolved peaks; corresponding fractions
were collected at 22 and 28 minutes, respectively. The fraction collected at 28 minutes
showed promising HCV activity and displayed no cytotoxicity. The percentage of
inhibitions against HCV RNA and rRNA were estimated at 96 and - 54, respectively; this
fraction contained compound 14; 3 mg were derived from 300 mg of the methanol
fraction.
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3.1.2. Diplostephium rhodendroides
The crude extract of D. rhodendroides was fractionated using VLC on silica gel.
Next, the MeOH fraction was purified using a Phenomenex NH2 column (21.2 × 250
mm). The ELSD chromatogram of this fraction indicated that it was comprised of a large
number of minor metabolites that eluted early during the HPLC. None of the major
metabolites was bioactive. Using the solvent system 50:50 DCM/MeOH (10 minutes) 
0/100 DCM/MeOH (18 minutes) followed by 0:100 DCM/MeOH (5 minutes), minor
metabolites were combined in a few fractions and sent for assay. The fractions that
eluted from 10-12 minutes and from 13.9-15.9 minutes were active against HCV and
non toxic. The 10-12 minutes fraction was constituted of trace amounts of HCV active
molecules predominantly distributed in stem and twigs. About 2 mg of a mixture of these
molecules were derived from 400 mg of the methanol fraction. The fraction that eluted
from 13.9-15.9 minutes was further purified using a Phenomenex NH2 column (10 ×
250mm). The solvent system used was 100:0 DCM/MeOH (10 minutes), followed by
100:0 DCM/MeOH  75:25 DCM/MeOH (40 minutes) and 75:25 DCM/MeOH 0:100
DCM/MeOH (40 minutes). The ELSD chromatogram indicated that, aside from very
minor metabolites, this fraction also contained a metabolite (15); about 1.5 mg were
isolated from 400 mg of the methanol fraction; 15 eluted at around 38 minutes.
3.2. Anti-HCV assay
Antiviral assay
The anti-HCV activity was determined in the HCV replicon (Clone B) system
(Huh 7 clone B cells containing HCV RNA). Cells were seeded onto 96-well tissue
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culture plates (3,000 cells/well). The compounds were tested in a dose response at
concentration 10, 3, 1 uM (triplicate). After addition of test compounds the plates were
incubated for five days (37 °C, 5%, CO2). The total cellular RNA was extracted using the
manual Perfect Pure RNA 96 cell Vacki from 5 Prime. The replicon RNA and the
internal control (TaqMan rRNA control reagent, applied Biosystems) were amplified by
RT-PCR. The antiviral potency of the tested molecule was determined by subtracting
the threshold RT-PCR cycle of the tests compounds from the threshold RT-PCR of the
negative control (no drug): #CtHCV ( a 3.3 value being considered a 1 log reduction in
replicon RNA level (in other words 90% reduction). The cytotoxicity was calculated
using #Ct rRNA values and RS-446 (2-Me-C) was used as control to determine the
EC50 and EC90 values [206, 207].
Table 4-0-1. 1D and 2D data of 14
13

C

δ H mult. (J in
Hz)

COSY

HMBC

1.

/

/

/

/

2.
3.
4.

98.0
67.9
70.1

/
/
/

H-7a, H-7b
/
/

5.
6.
7.

69.5
63.7 or 64.1u
63.7 or 64.1u

/
3.7, d (10.0)
3.81, dd (3.0,
10.0)
3.9, m
3.62, m
3.62/3.47, m

H-6
H-5
H-7a, H-7b

H-6, H-3
/
/
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Table 4-0-2. 1D and 2D data of 15
13

C

COSY

HMBC

NOESY

1

103.1

δ H mult. (J in Hz)
5.24 *

2

73.2

4.46, m

/

/

H-3

3

74.0

4.35, m

/

/

H-6, H-2

4
5
6
1’
2’

74.9
71.4
19.8
178.0
40.1

/
H-6
H-5
/
H-3’

H-6
H-6, H-1
/
H-2’a, H-2’b
/

H-3

3’
4’
5’

70.3
88.6
68.6

4.24, m
4.13, m
1.52 d (6.0)
/
2.73, dd (3.0, 18.0)
/3.02, dd (5.0, 18.0)
4.74, m
4.9, m
3.67, dd (4.0, 11.0)
/4.12, m

H-2’
H-5’
H-4’

H-1

*buried signal, presence inferred based on the HSQC
a
correlation to H-5a
b
correlation to H-5b
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/

/

H-5’a

H-5’a
H-5’ab
H-1a,
H-4’ab

H-3’a,

3.48
3.45

3.71
3.69
3.63
3.60

3.82
3.79
3.79

3.95
3.92
3.90

4.70

Figure 4-0-7. 1HNMR spectrum of
(hydroxymethyl)hexanamide (14) (D2O)
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2,

3,

4,

5,

6-pentahydroxy-2-

Figure 4-0-8. DEPT spectrum of
(hydroxymethyl)hexanamide (14) (D2O)
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2,

3,

4,

5,

6-pentahydroxy-2-

f1 (ppm)

Figure 4-0-9. HSQC spectrum of 2, 3, 4, 5, 6-pentahydroxy-2(hydroxymethyl)hexanamide (14) (D2O)
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f1 (ppm)

Figure 4-0-10. HMBC of 2, 3, 4, 5, 6-pentahydroxy-2-(hydroxymethyl)hexanamide
(14) (D2O)

170

f1 (ppm)

Figure 4-0-11. COSY of 2, 3, 4, 5, 6-pentahydroxy-2-(hydroxymethyl)hexanamide
(14) (D2O)
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Figure 4-0-12. 1H NMR of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro2H-pyran-2-yl)oxy] pentanoic (15) (pyridine)
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1
Figure
4-0-13.
H-1H
COSY
of
4,5-dihydroxy-3-[(3,4,5-trihydroxy-6methyltetrahydro-2H-pyran-2-yl)oxy] pentanoic (15) (Pyridine)
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Figure 4-0-14. HSQC of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2Hpyran-2-yl)oxy] pentanoic (15) (Pyridine)
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Figure 4-0-15. HMBC of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2Hpyran-2-yl)oxy] pentanoic (15) (Pyridine)
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Figure 4-0-16. DEPT of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2Hpyran-2-yl)oxy] pentanoic (15) (Pyridine)
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Figure 4-0-17. NOESY of 4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyltetrahydro-2Hpyran-2-yl)oxy] pentanoic (15) (CD3OD)
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Chapter 5 :
ENVIRONMENTAL TOXICOLOGY
–
ENCYCLOPEDIA OF SUSTAINABILITY SCIENCE AND
TECHNOLOGY "SCIENCE, POLICY, AND RISK
MANAGEMENT: THE CASE OF SEAFOOD SAFETY"
(Book Chapter – Elsevier, in press)

Authors: Meujo DA and Hamann MT
1. Glossary (Definitions of keywords)
“An outbreak involves two or more ill people” – CSPI.
Action levels: “Action levels and tolerances represent limits at or above which the
FDA will take legal action to remove products from the market” - FDA.
Biological contaminants: in the context of this document, these are pathogenic
microorganisms (bacteria, viruses and parasites) found in seafood.
Chemical contaminants: in the context of this chapter, are regrouped under this
denomination, all non-biological contaminants (deleterious chemicals) traceable to
seafood.
Environmental pollutants: seafood-associated deleterious substances traceable to
the environment such as heavy metals and persistent organic pollutants.
Etiological agent: a microorganism responsible for a given disease.
Food safety hazards: according to the Seafood HACCP Regulation, a “food safety
hazard” is “any biological, chemical, or physical property that may cause food to be
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unsafe for human consumption."
Seafood-associated toxins: harmful chemical substances produced either by
seafood-associated bacterial contaminants, cyanobacteria or toxic microscopic
algae (dinoflagellates and diatoms) on which seafood feed.
Seafood: edible marine plants and animals (fish and shellfish) are usually grouped
under the denomination of seafood; in some contexts, these are referred to as “fish
and fishery products” [217] This same term is often given a broader meaning: all
edible aquatic plants and animals.
Tolerance threshold: maximum allowable amount of ubiquitous deleterious
substance in seafood.

2.

Definition of the subject.
In order to function properly, the human body needs a wide range of essential

nutrients, which it gets from food that is ingested on a daily basis. Unfortunately, food
also represents a vector for harmful creatures (bacterial, viral, protozoan pathogens)
and chemical substances (organic toxins as well as toxic metals and various
environmental contaminants). According to the most recent surveys of the Center for
Science for Public Interest (CSPI), for more than a decade now, seafood has ranked
first as the most likely source of foodborne disease outbreaks of established origin [218,
219].

Based on these surveys, seafood-associated hazards that have caused the

largest number of outbreaks are toxins (especially scombrotoxin and ciguatera),
followed by bacteria, the most problematic of which are Vibrio spp, and finally viruses,
especially norovirus. Though food safety is primarily the responsibility of regulatory
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agencies, several other groups are involved. These include industries, consumers and
the scientific community upon which rests the responsibility of developing cutting edge
technologies capable of eliminating seafood-associated biological and chemical
contaminants. The international community also relies on science for the development
of revolutionary technologies for a faster, cheaper, easier and more accurate detection
of seafood-associated health hazards; tools without which enforcing laws and
regulations set forth by regulatory agencies is virtually impossible. In this chapter, we
review different categories of seafood-associated health hazards as well as a few
relevant regulatory and scientific efforts dedicated to reduce the incidence of seafoodborne illnesses.
3.

Introduction.
Seafood constitutes a significant portion of the world’s food supply and is

renowned for its delightful taste. It is a critical component of the human diet because of
its unique nutritional properties. Fish, for instance, is a good source of protein as its
major components are proteins and lipids. All essential amino acids can be derived from
fish consumption. Approximately 40% of the lipids found in fish are comprised of highly
unsaturated long-chain fatty acids. Other outstanding nutritional qualities are reduced
saturated fats and carbohydrates and plentiful essential nutrients. Some fish species
are a valuable source of important nutrients such as vitamins A and D, phosphorus,
iron, calcium, magnesium, selenium and iodine [220, 221].
There are numerous reports of health benefits associated with the consumption
of seafood. Several of these health benefits have been attributed to seafood’s high
content of vital nutrients, such as n-3 polyunsaturated fatty acids (PUFAs), specifically
180

eicosapentaenoic acid (EPA), and docosahexaenoic (DHA). These health benefits
include a reduced risk of developing serious diseases such as depression [222],
myocardial infarction, Alzheimer’s [223], dementia [224] and weight loss [225]. A
number of reports have associated seafood consumption with a reduced risk of mortality
among individuals suffering from coronary heart disease [226] and a reduced risk of
developing diseases such as ischemic and thrombotic strokes, colon and intestinal
cancers as well as others [68, 225, 227, 228]. These positive effects are counted among
the factors that have driven current market trends. There has been a steady increase in
the world’s per capita fish and fishery products consumption for several decades now
[229]. According to the December 2009 Food Outlook Report of the Food and
Agriculture Organization (FAO), the annual per capita fish consumption in the world
during the years 2007 - 2009 was estimated at ~ 17.1 kg. It is important to note that in
the 1970s, 1980s and 1990s, these values were 11.5, 12.8 and 16.4 kg per capita
respectively [230].
As indicated by recent estimates, there has been a net increase in the demand
for seafood in countries around the world [231]. In the United Kingdom for instance, the
seafood retail market has experienced a considerable increase between the years 2003
and 2007, increasing from £2.4bn (retail price) to an estimated £3.25bn in 2007 [229]. A
significant increase in seafood demand in developing countries has been observed, as
well [231]. Millions of tons of seafood are caught each year worldwide to sustain the
current demand. There has been a steady increase in the total world fish production
since the 1950’s, from 19.3 million tons to about 134 million tons in 2002

[232].

According to a 2009 FAO report, the current world production (capture fisheries plus
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aquaculture) is estimated at 144.1 million tons, divided into 98.8 million from capture
fisheries and 54.3 million from aquaculture [230].

Figure 5-1. Variation in the number of reported seafood-borne disease outbreaks
since the 1990’s in the U.S.A.
Unfortunately, seafood consumption is not without risks and food is an important
vector of a wide range of health hazards (Figure 5-1). Foodborne illnesses are a serious
public health concern and according to the Centers for Disease Control and Prevention
(CDC) roughly 76 million foodborne illnesses corresponding to about 325,000
hospitalizations and 5,000 deaths are recorded in the U.S. each year [233]. A recent
survey conducted by the Center for Science for Public Interest (CSPI) [218], revealed
that the food categories that were associated with the largest number of outbreaks in
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the United States during the period 1990-2006 were seafood, produce, poultry, beef and
eggs. Seafood was responsible for 1,140 out of 5,778 outbreaks and therefore, was the
most problematic food (Figure 5-2). Also reported was an increase in the number of
seafood related outbreaks compared to the early 1990s (Figure 5-1). It is important to
mention that the number of reported cases of seafood-borne illness has remained
constant over the years. Though it ranked second as far as number of outbreaks,
produce caused the largest number of cases of illness during that same time frame
[218].

Figure 5-2. Foodborne outbreaks reported during the years 1998 - 2007 by
category of food in the U.S.A.
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4.

“Food safety hazards” associated with seafood
Seafood-associated health hazards can be classified into two main categories:

(1) biological contaminants (includes a long list of bacteria, viruses, parasites) and (2)
chemical contaminants such as environmental pollutants (pesticides, heavy metals,
approved or unapproved drug substances) and finally natural toxins from a variety of
structural classes. According to the CSPI’s 2008 report, the latter category was
associated with the largest number of seafood-borne outbreaks from 1990 through 2006
(Figure 5-3) [218]. Currently known health hazards associated with seafood are either
naturally occurring or from various anthropogenic activities. Seafood becomes
contaminated either as a result of feeding on poisonous phytoplankton species or in
sewage contaminated marine environments. Seafood contamination can also arise from
inappropriate storage or accidental exposures during handling. Certain types of seafood
are more likely vehicles of dangerous substances and pathogenic microorganisms than
others.
Categories of seafood that have been associated with greater public safety risks
are considered a high priority in sampling and surveillance efforts by the Food and Drug
Administration (FDA) [234]. At the top of the FDA’s seafood watch list are products
such as molluscan shellfish from uncertified sources, refrigerated reduced oxygen
packaged products, ready-to-eat seafood, seafood mixes containing cooked, raw or
partially-cooked seafood components, as well as, scombrotoxin (histamine)-forming
fish, aquaculture derived seafood and finally salt-cured or dried uneviscerated finfish
[234]. According to the 2008 CSPI report, based on the number of reported outbreaks,
finfish (such as tuna and grouper) was the most dangerous type of seafood between the
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years 1990 through 2006. Finfish was responsible for 61% of all reported seafood-borne
outbreaks during this period, followed by molluscan shellfish (15%) (Figure 5-4). The
largest number of cases of seafood-borne illness was attributable to molluscan shellfish
(Figure 5-4) [218].

Figure 5-3. Specific health hazards that caused seafood-borne outbreaks reported
during the years 1990 through 2006 in the U.S.A.

4.1.

Seafood associated toxins
Seafood-associated toxins, especially scombrotoxin and ciguatoxin, have been

linked to the majority of seafood-borne outbreaks that occurred during the last decade
and as such, could be viewed as the most dangerous seafood-associated “food safety
hazard” [218, 219]. Scombrotoxin and ciguatoxin alone were responsible for 57% of all
seafood-related outbreaks in the United States reported from 1990 through 2006 [218].
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Seafood-associated toxins have been linked to a wide variety of intoxications.
These include, poisoning associated with shellfish consumption, namely Diarrheic
Shellfish Poisoning (DSP), Paralytic Shellfish Poisoning (PSP), Amnesic Shellfish
Poisoning (ASP), Neurologic Shellfish Poisoning (NSP), AZaspiracid Shellfish Poisoning
(AZP), and, poisonings associated with fish consumption. The latter include Ciguatera
Fish Poisoning (CFP) and puffer fish poisoning [235]. It is necessary to point out that
some seafood-associated biotoxins, namely ciguatoxin and toxins responsible for PSP,
NSP and ASP can be lethal [236]. Seafood-associated toxins are generated either by
bacterial contaminants that freely proliferate when seafood is improperly stored or by
cyanobacteria and toxic microscopic algae (dinoflagellates and diatoms) on which the
seafood feed. The blooms of these latter organisms, which occur from season to
season, forming red tides (Harmful Algae Blooms (HAB) are a subject of public health
and environmental concerns, affecting the tourism and fishing industries [237].
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Figure 5-4. Seafood-borne, outbreaks (A) and cases of illnesses, (B) reported in
the U.S.A. during the years 1990 through 2006 (by category of seafood)

4.1.1. Ciguatera fish poisoning
Ciguatera fish poisoning has been reported in countries around the world
(Europe, Africa, America, Asia, and Oceania). This form of poisoning is frequent
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between the months of April through August and has been linked to the consumption of
certain fish. Some examples are shark, barracuda, snapper, hogfish, horse-eye jack,
red grouper, gray triggerfish, Spanish mackerel, narrowhead gray mullet, chinamanfish,
swordfish and amberjack. Ciguatera fish poisoning is caused by a set of heat resistant
polyether toxins known as ciguatoxins (Figure 5-5), which are the product of in situ
gambiertoxin biotransformation [237, 238]. Ciguatoxin, maitotoxin, palytoxin, and
scaritoxin are members of this group. These toxins are produced by a variety of
organisms; these include Gambierdiscus toxicus, Gymnodinium sangieneum, G.
polyedra, Ostreopsis lenticularis, Prorocentrum concavum, P. mexicanum, and P.
rhathytum among others [235, 239]. Symptoms of ciguatera fish poisoning are mainly
gastrointestinal and neurological. A few therapeutic approaches in case of poisoning
include, but are not limited to, antihistamines, antiemetics (droperidol, prochlorperazin,
metoclopramide), atropine, as well as, intravenous hydration [237].
4.1.2. Scombrotoxic fish poisoning.
Scombroid fish poisoning differs from other types of toxin mediated seafood
poisonings because the responsible toxin is not produced by a microalgae. Instead, it is
generated under improper storage conditions (temperature >20 ˚C). This toxin is the
result of a catalytic reaction involving the conversion of in situ histidine into histamine ().
The enzyme responsible for this conversion, histidine decarboxylase, can be produced
by several types of bacteria. These include various Vibrio sp. Clostridium,
Enterobacteriaceae (such as Morganella morganii and Klebsiella pneumoniae and
Hafnia alvei) and Lactobacillus sp. [240]. Scombrotoxin is stable to both heat and cold
conditions. Scombroid fish (fish containing a high level of free histidine) and non188

scombroid fish have been implicated in this form of poisoning. These include fish such
as amberjack, abalone, tunas, sardines, mackerel, bonito and bluefish, just to name a
few [239]; associated symptoms rank from mild and self-limiting to severe. Groups at
risk for developing the severe form of this disease are people with respiratory and
cardiac conditions or those on medication such as isoniazid and doxycycline that slow
histamine degradation [237, 239, 241].

Symptoms of scombrotoxic fish poisoning

include headache, abdominal cramps, nausea, diarrhea and palpitations among others.
As far as pathophysiology, bioamines other than histamine are believed to play a critical
role; a few examples are spermine, cadaverine, agmatine and putrescine [239, 242].
There are several therapeutic approaches for this type of food poisoning. These include
administration of activated charcoal, diphenhydramine, cimetidine and famodine [241].
4.1.3. Other major seafoodborne poisonings.
Paralytic shellfish poisoning (PSP) can be caused by a wide range of
tetrahydropurine

type

toxins

(carbamate,

N-sulfo-carbamoyl,

decarbamoyl

and

deoxydecarbamoyl) [238] collectively called saxitoxins (Figure 5-5). These are
neurotoxins that act by blocking sodium channels, causing symptoms like numbness,
paralysis and disorientation. Saxitoxins are produced by dinoflagellates and blue-green
algae. Dinoflagellates that have been linked to this form of poisoning include Pyrodinium
bahamense, Gymnodinium catenatum, as well as several organisms belonging to the
genus Alexandrium [235, 238, 243]. Various types of seafood can serve as vectors;
these include clam, crabs, cockles, oysters, salmon, mackerels, scallops, and whales to
name a few [235, 237]. PSP has been reported on all continents. Regrettably, there is
no antidote for PSP, and therapeutic approaches are mostly supportive and include
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respiratory support in a life-threatening situation, gastric emptying, dialysis and
enhancing renal clearance [237].
Diarrheic shellfish poisoning (DSP) has also been reported worldwide.
Diarrhea, nausea, cramps and vomiting are common signs of DSP. It is usually
associated with consumption of contaminated clams, mussels, oysters and scallops.
This syndrome is caused by a group of acidic (okadaic acid and related
dinophysistoxins) and neutral toxins (pectenotoxin). Yessotoxins have also been
reported to cause this form of poisoning (Figure 5-5) [238, 244]. These toxins are
produced by a variety of marine dinoflagellates including Dinophysis spp (D. acuta, D.
acuminate, D. caudate, D. mitra, D. norvegica) as well as Protoceratium spp.,
Prorocentrum spp. Gonyaulax spp. and Phalacroma spp [235].
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Figure 5-5. Toxins involved in seafoodborne intoxications

191

Figure 5-5. (cont) Toxins involved in seafoodborne intoxications
Amnesic shellfish poisoning (ASP) has been reported in various areas around
the world including Europe, North, Central and South America, Asia and Oceania.
Several types of seafood, including anchovies, clams, crabs, oysters, mussels,
mackerels, lobsters, scallops and gastropods are potential vectors. ASP is caused by a
marine biotoxin called domoic acid (Figure 5-5). This toxin is produced by a red-brown
marine diatom called Pseudo-nitzschia pungens. Diarrhea, nausea and abdominal pain
are examples of symptoms that indicate amnesic shellfish poisoning [235].
Neurotoxic shellfish poisoning (NSP) is caused by brevetoxins and its analogs
(Figure 5-5). Occurrences have been reported in countries around the world. This form
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of poisoning has been associated with the consumption of contaminated clams, mullets,
mussels, oysters, tunas and whelks. Fibrocapsa japonica, Gymnodinium breve (Karenia
brevis), Raphidophyceae sp., and Chattonella marina, among others, are examples of
organisms that produce these toxins [235, 238].
Puffer fish poisoning has been linked to the most potent and lethal marine
neurotoxin: tedrodotoxin (Figure 5-5). It is produced by a variety of animals including the
California newt, trumpet shell, the blue ringed octopus and puffer fish, especially a
species known as fugu (present in the liver). Puffer fish is a delicacy in Japan and is the
main vector for this form of poisoning. Once again, there is no antidote. The first case in
Europe occurred in 2009 and involved an individual that had consumed trumpet
shellfish (Charonia sauliae) harvested from the Atlantic Ocean in Southern Europe
[245]. The main therapeutic approach upon poisoning is supportive and includes
respiratory support (life-threatening circumstances). Activated charcoal, atropine,
anticholinesterase agents, and alpha agonists, among others, are also recommended
[246].
AZaspiracid shellfish Poisoning (AZP). Mussels and oysters are known
vectors of toxins responsible for azaspiracid shellfish poisoning. AZP has been reported
in countries around Europe, namely Norway, Portugal, the U.K. and Ireland. AZP is
caused by marine toxins known as azaspiracids (Figure 5-5), which are produced by
Protoceratum crassipes and Protoperidinium. Nausea, vomiting and diarrhea, are a few
symptoms of azaspiracid shellfish poisoning [235, 238].
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Figure 5-6. Structure of biotoxins produced by Karlodinium veneficum. (B) The
absolute configuration of KmTx-2,

Several other marine biotoxins not listed above have been reported. A few
examples

able

to

impair

human

health

are

gymnodimine,

neosurugatoxin,

prosurugatoxin, polycavernoside and debromoaplysiatoxin [235]. It is also important to
note that a number of biotoxin producers (dinoflagellates) has been associated with
massive fish mortality and thus represent a major issue to the seafood and tourism
industry worldwide. Examples in this case are Pfiesteria piscicida and Karlodinium
veneficum however there is growing evidence that P. piscicida associated fish kills in
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the past may have been indeed have been K. veneficum derived. Blooms of K.
veneficum have been linked to various episodes of massive fish kill around the world. In
this particular case, a set of toxins, believed to be the etiological agents, and regrouped
under the denomination karlotoxins or KmTxs, has been isolated [247, 248]. Examples
of such toxins include the karlotoxin-1 (KmTx-1), the 10-O-sulfo-KmTx-1, the KmTx-3,
the 64-E-chloro-KmTx-3, the 10-O-sulfo-KmTx-3, the 65-E-chloro-KmTx-1, and finally,
the KmTx-2 (Figure 5-6) [249], for which the relative and absolute configurations were
assigned only recently [250]. Ongoing work in this area actually began with research by
Abbott and Ballantine in the 1940s and ‘50s [251]. Karlotoxins kill fish by osmotic cell
lysis, a result of the alteration of the ion transport system of the cell membrane. The fish
dies as a result of damage to its vital gill epithelial tissues. These toxins are
environmental pollutants and detectable in water during fish kill episodes. The
ecological role of these toxins was investigated recently and because the toxins
possesses an allelopathic inhibitory effect on competitors as well as a prey
immobilization it was established that the organism produce these toxins in order to
facilitate feeding and control of competition during a bloom [252, 253].
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Figure 5-7. Specific health hazards that caused seafood-borne outbreaks reported
during the years 1990 through 2006 in the U.S.A.
4.2.

Microbial pathogens
Following chemical toxins, pathogenic microorganisms were the most likely

cause of seafood-borne disease outbreaks throughout 1990-2006 (Figure 5-3). The
CSPI’s survey associated bacteria to 24% of reported outbreaks during this period,
trailed by norovirus (10%) [218].
4.2.1. Pathogenic bacteria
Seafood’s bacterial pathogens can be found either in their GI system (bivalve
mollusks) or on their surface (crustaceans). These bacteria have been linked to various
infections and intoxications. Pathogens accumulate in the digestive track of bivalve
mollusks (cockles, mussels, oysters, clams) as a result of filter-feeding in heavily
contaminated water. Seafood associated bacterial pathogens are either indigenous to
the marine environment (case of Vibrionaceae, a source of greater concern) or
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nonindigenous (resulting from fecal contamination). Members of the first category are
pathogenic Vibrio spp. such as V. cholerae, V. parahaemolyticus, V. vulnificus,
Clostridium botulinum (non-proteolytic types B, E, F), Aeromonas hydrophila,
Plesiomonas shigelloides, and Listeria monocytogenes, just to name a few [236, 240,
254]. Diarrhea is a common symptom of infection caused by several of these
microorganisms. V. parahaemolyticus, V. vulnificus, V. hollisae, and V. cholera non O-1
have been also associated with more serious conditions such as septicemia. These
microorganisms are most prolific during summer months as the water temperature rises.
The second category includes bacteria such as Salmonella (nontyphoidal), Shigella,
Campylobacter, Staphylococcus aureus, and Escherichia coli [218]
Proper seafood storage is sufficient to protect against diseases caused by
several of these bacteria. It has been established that their concentration in seafood is
normally low (below the minimum infective dose) and will remain so providing that the
seafood is stored in conditions that are not conducive to bacterial growth, multiplication
or toxin production (refrigerated (4 ºC) and frozen (- 18 ºC)). It is important to note that
this does not apply to mollusks and their predators [242, 255]. While, in several cases, a
low concentration in seafood is tolerated, FDA regulations become more stringent when
it comes to bacteria such as L. monocytogenes, V. vulnificus, Salmonella, C. botulinum
and toxigenic 01 V. cholera. Current regulations require that these be undetectable in
seafood requiring minimal cooking before consumption, for instance [217].
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4.2.1.1.

Vibrio spp.

Vibrio spp, especially V. parahaemolyticus and V. vulnificus, are a cause of
significant concern in the U.S. and several Asian countries (Japan, Taiwan, India and
China). V. parahaemolyticus (Vp), for instance, has been associated to the vast majority
of seafood-borne gastroenteritis in the U.S. This bacterium has been associated with
fewer outbreaks in Europe [254, 255]. The pathophysiology of Vp is centered on several
virulence factors; a few examples in this case are the Thermostable Direct Hemolysin
(TDH) and TDH-Related Hemolysin (TRH), which are encoded by tdh and trh genes
respectively [256]. Healthy individuals are also at risk of developing Vp associated
infection [239]. The FDA can take legal action when seafood products are found to
contain a Vp count ≥ 1 x 104/g [217]. Raw or improperly cooked fish and shellfish are
potential vectors [239]. The minimal infective dose for this pathogen is > 106/g [240]. V.
vulnificus (Vv) infections can also result from consumption of raw or undercooked
seafood. In addition, transmission can occur via wound infection. Though Vv is not a
major issue in healthy individuals, in certain groups, Vv can cause serious infections or
death. People suffering from alcoholic cirrhosis, hemochromatosis/cirrhosis, chronic
hepatitis, post-necrotic cirrhosis, as well as diabetics and alcoholics are at higher risk.
V. vulnificus is the second leading cause of seafood-related fatality in the U.S. [257259]. Vv infections that occur as a result of consumption of contaminated seafood
(especially raw oysters) are primarily septicemia and gastroenteritis. One therapeutic
approach is the use of antimicrobial agents (tetracycline and intravenous doxycycline
with ceftazidime) [258].
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2.2.1.2. Other seafood-associated bacteria
Clostridium botulinum – This bacterium is responsible for a condition known as
botulism, the responsible agent being a toxin. Lightly preserved, semi-preserved, and
fully preserved smoked, fermented, salted and pickled fish products are likely vectors.
Cold-smoked and fermented fish products are of greater risk. Chilling, autoclaving, and
salting are approaches used to prevent botulism [240, 242].
Listeria monocytogenes - Infections cause by this other bacterium can, at
worst, result in septicemia spreading to several organs and even, in the case of
pregnant women, to the fetus. This type of infection can be fatal. Groups most at risk
are pregnant women, neonates, fetuses, and immuno-compromised patients. Shrimp is
an important vector [240, 242, 260]. S. aureus has also been isolated from seafood.
This bacterium is, as C. botulinum, a toxinogenic species. It produces toxins that are
resistant both to enzymes degradation and heat. It is introduced in seafood as a result
of environmental contamination or transferred from an infected worker involved in
seafood handling [240, 242].
Enterobacteriaceae such as Salmonella, Shigella and E. coli have been also
reported in seafood. Enterobacteriaceae usually occurs in seafood as a result of fecal
contamination. Salmonella is responsible for salmonellosis and is especially problematic
for the shrimp industry [260]. Compared to other food categories, seafood is a less likely
vector of Salmonella [239, 240]. The minimum infective dose for Salmonella sp has
been estimated to be in the range of < 102 - >106. Non-bloody diarrhea, fever,
abdominal pain and nausea, just to name a few, are indicators of infection by this
pathogen. Symptoms of a Shigella infection, on the other hand, are bloody stools,
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severe abdominal cramps, fever and dehydration. The minimum infective dose in this
case has been estimated at 101- 102. This is similar to what has been reported for E.
coli, for which the minimal infective dose is 101- 103 [240, 242].
Table 5-1. Safety levels set by FDA for several seafood associated bacteria

Hazards

FDA & EPA
thresholds

Analytical
approach

Targeted
seafood

Higher
populations

Salmonella
sp.

Presence
organism a

All fish

E. coli

MPN of 230/100
grams b
APC
500,000/gram
Presence
of
staphylococcal
enterotoxin, or a
load
≥104/g
c
(MPN)
Presence
of
viable spores or
vegetative cells
or toxin c

Conventional
culture
methods
Hemorrhagic
colitis
agardirect
plating
method
Specific
precipitation
with antiserum

Imported fresh
and
frozen
clams
and
oysters
All fish

Severe
in
the
elderly,
infants,
AIDS patients
All people – most
susceptible
are
young children and
the elderly
All people

All fish

All people

S.aureus

C.
botulinum

of

Mouse
neutralization
test

Compliance policy/programs
Sec 555.300 Compliance Policy Guide [261]
Sec 560.600 Compliance Policy Guide [262]
c
Compliance Program 7303.842 [263]
a
b

4.2.2. Seafood associated viruses

Seafood can also serve as a vector of viruses. Non A, non B enteral hepatitis
viruses, Hepatitis A Virus (HAV), poliovirus, and norovirus, among others have been
associated with seafood-borne outbreaks [239, 240, 264, 265]. Viruses end up in
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risk

seafood as a result of fecal contamination of the marine environment or when handled
by an infected worker. Viruses are one of the most serious seafood-associated threats.
So far, reports of seafood-borne infection outbreaks linked to viruses have emerged
from countries around the world. HAV was associated with the largest seafood outbreak
ever reported. This outbreak, which occurred in 1998, in the Chinese city of Shanghai,
was linked to the consumption of contaminated clams and over 292,000 cases were
reported [265, 266]. Another virus, namely norovirus, a single-stranded nonenveloped
RNA virus, is currently responsible for roughly 50% of all foodborne outbreaks of
gastroenteritis according to the CDC [267]. Norovirus was reported by CSPI as the most
problematic seafood-associated virus during the period 1990 through 2006 (Figure 5-3)
as it caused 10% of all reported seafood outbreaks during that time [218].

It is

important to point out that of the five genogroups of norovirus, GII has been linked to the
majority of infections. Filter feeding bivalve shellfish are important vectors [258].
Norovirus gastroenteritis-associated symptoms are vomiting, watery stools, non-bloody
diarrhea with abdominal cramps, and nausea. It is a fairly resistant virus that can
survive harsh conditions such as chlorine treatments (10 ppm), heating to 60 °C (4
hours), or freezing [267].
4.2.3. Seafood associated parasites
Seafood (raw or undercooked) can also serve as a vector of pathogenic
parasites. These include nematodes, cestodes and trematodes. Anisakis simplex,
Pseudoterranova dicipiens, Gnathostoma sp., Capillaria sp., and Angiostrongylus sp.
are examples of seafood-associated nematodes. Examples of tape worms that can be
isolated from seafood include Diphyllobothrium latum and D. pacificum; Clonorchis sp.,
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Opisthorchis sp., Metagonimus yokagawai, Heterophyes sp., Paragonimus sp. and
Echinostoma sp., on the other hand, are a few examples of seafood-associated
trematodes [240].
Several parasite-infected seafood dishes such as sushi, crab, sashimi, herring
roe and undercooked grilled fish have been associated with illnesses [217]. Compared
to bacteria and viruses, however, parasites are of lesser concern. Trematodes (such as
Paragonimus westermani), cestodes (such as Diphyllobothrium latum, D. pacificum)
and nematodes (such as Angiostrongylus cantonensis, Contraceacum osculatum) have
been associated with domestic fish and shellfish. Several other organisms have been
associated with imported products instead. These include Clonorchis sinensis,
Heterophyes heterophyes, Metagonimus yokogawai, Opisthorchis felineus and
Gnathostoma spinigerum. Some nematodes, cestodes, and trematodes are of greatest
concern as far as seafood safety. These include Anisakis simplex, Pseudoterranova
spp., Eustrongylides spp., Gnathostoma spp., Opisthorchis spp., Chlonorchis sinensis
and Paragonimus spp, just to name a few [217, 264].
4.3.

Toxic heavy metals
Heavy metals are a threat to the environment and public health and are

problematic in regard to their long-term persistence. A variety of heavy metal
contaminants has been reported in seafood. These elements originate from natural
occurrences (marine volcanism, geological and geothermal events) and anthropogenic
activities. Several categories of anthropogenic activities threaten the marine
environment. These include, activities that take place in tanneries, steel plants, battery
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industries, thermal power plants and farms, especially those farms using heavy metal
containing fertilizers and pesticides. Runoff from roadways has also been recently cited
as an important source of contamination [220, 268, 269].
Heavy metals found in seafood include antimony, arsenic, cadmium, chromium,
lead, mercury, nickel, copper, iron, manganese, selenium, zinc, aluminum, silver,
strontium, thallium, and tin. Of these heavy metal contaminants, those of greatest
concern are antimony, arsenic, cadmium, chromium, lead, mercury, and nickel. It is
important to note that elements such as copper, selenium, iron and zinc (known
essential micronutrients) are toxic only at high concentrations [220].
Arsenic can be present under a variety of forms: toxic (inorganic) and nontoxic
(organic). Arsenic is an extremely potent poison in its trivalent form and can cause a
wide range of acute and chronic illnesses. A few examples include cancer, nephritis,
hepatomegaly, peripheral symmetrical neuropathy, and palmar hyperkeratosis, among
others. In seafood, arsenic is mainly present in a nonpoisonous form known as
arsenobetaine or arsenocholine [264]. A compilation of data (about 100,000 results)
received from fifteen European countries revealed that seafood is among the food
commodities with the highest arsenic levels [270].
Methyl mercury is a neurotoxic contaminant. Due to its potential effects on the
fetus, it is one of the most regulated seafood-associated toxic metals.

There are

several related FDA recommendations to nursing/pregnant women, women of
childbearing age, or children when it comes to seafood consumption. CH3Hg+ is present
in nearly all seafood, but some types of fish such as shark, swordfish, king mackerel,
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and tilefish are believed to have a higher content. The FDA and the U.S. Environmental
Protection Agency (U.S.EPA) have recommended being very selective of the type of
fish consumed, limiting uptake to ~ 12 ounces/week as a healthy approach for groups at
risk [221]. This has been supported by scientific data [228, 271, 272]. Several reports
have shown that moderate to high consumption of fish species containing only a low
amount of CH3Hg+ during pregnancy, has a positive effect on fetal brain development.
However, it is also important to note that several other studies, Myers et al. (2003) for
instance, did not support the fact that exposure of pregnant women to methyl mercury
through fish consumption could have deleterious effects on fetal development [228,
273].
Other toxic heavy metals include nickel, chromium, cadmium, selenium and
lead. Cadmium tends to be bio-accumulated by crustacea and bivalves. Clinical signs of
cadmium poisoning include osteoporotic and osteomalacic disease, as well as kidney
damage. Lead poisoning, on the other hand, has been associated with anemia,
convulsions, paralysis and proteinuria. This metal tends to accumulate in cortical and
trabecular bone, kidney, lung, as well as the CNS. Edema, hepatitis, and hemorrhage
are conditions that can result from selenium poisoning, which is also known, to result in
congenital malformations and infertility. Arsenic (As), nickel (Ni) and chromium (Cr) are
carcinogens [264].
4.4.

Other chemical environmental contaminants
Organochlorine compounds. Until recently, organochlorine compounds were

widely used. A wide range of polychlorinated substances can be found in seafood.
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These include various insecticides, agrochemicals, industrial chemicals and byproducts.
Examples of pesticides traceable to seafood include endrin, heptachlor, dieldrin,

γ-1, 2,

3, 4, 5, 6-Hexachlorocyclohexane, chlordane, dichlorodiphenyltrichloroethane and
lindane. Polychlorinated biphenyls and dioxins such as 2,3,7,8-tetrachlorodibenzo-pdioxin, are example of industrial chemicals that contaminate seafood. Prior to 1970,
PCBs were widely used industrially [274]. Because they are non-biodegradable, toxic in
nature and tend to bio-accumulate in seafood, organochlorine compounds now
constitute a major environmental and public health concern. Several of these
substances are known carcinogens (dioxins and polychlorinated biphenyls); but
because seafood-associated health benefits outweigh potential risks, seafood
consumption is recommended [228].

The level of these substances in fish is truly

minimal. However, it is important to note that people whose diet is predominantly made
of seafood are still at risk [274]. Reports on farm raised salmon (especially European
farms) containing higher levels of these contaminants compared to wild type salmon is
believed to have had a serious impact on the consumer acceptance of this type of
seafood [274, 275].
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Figure 5-8. Main causes of rejection or detention of seafood imports into Europe
during the years 1999 – 2002.
Antimicrobial drug contaminants of seafood.

This is a problem mainly

associated with aquaculture, as farmers rely more and more on various drugs and
antimicrobial agents to deal with specific seafood diseases (bacterial, fungal, viral), to
improve the quality of water, and to manage pest-related issues.
There are quite a few reasons why there are concerns over drug residues being
present in seafood. Several antimicrobial agents used in aquaculture have been linked
to various adverse health effects, such as hypersensitivity reactions. In vivo studies, in
animals, have established several others as carcinogens; these include nitrofuran,
malachite green, gentian violet, and fluoroquinolones. Fluoroquinolones have been also
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associated with antibiotic resistance. There are several drugs used to this end in the
U.S. that have been approved by the Center for Veterinary Medicine (CVM) (Table 5-2).
Substances such as ciprofloxacin, erythromycin, tetracyclines, chloramphenicol,
nitrofurans, malachite green, gentian (crystal) violet, and fluoroquinolones have been
frequently reported in seafood imported into the U.S. in recent years [234]. A short,
recent survey by the FDA has shown that imports from China test positive for the
presence of a variety of unapproved substances, such as gentian violet, malachite
green, nitrofuran, and fluoroquinolones. Consequently, these products are the subject of
great concern and the focus of regulatory surveillance [276].
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Table 5-2. Aquaculture drugs approved in the U.S. and action levels
FDA-approved aquaculture drugs
Drug name
Tolerance level in
the flesh
Unapproved drugs
No trace tolerated a
Chorionic Gonadotropinb
Formalin solutionc
Tricaine methanesulfonated

Oxytetracycline

2.0 ppme

Sulfamerazine f
Sulfadimethoxine/
Ormetoprim combination h

Undetectable g
0.1 ppm i

All fish

Brood finfish
Salmon
trout,
catfish, largemouth
bass, and bluegill
Catfish,
salmon
and trout, pike and
perch
Salmonids, catfish,
and lobster
Trout
Salmonids
and
catfish.

Purpose
-

Reproductive
Antiparasitic
and
fungicidal/static
-

Disease control
-

21 CFR 558.582 [282]
21 CFR 556.660 [283]
h
21 CFR 558.575 [284]
i
21 CFR 556.640 [285]

Compliance policy/programs

f

Sec 615.200 Compliance Policy Guide [277]
b
21 CFR 522.1081 [278]
c
21 CFR 529.1030 [279]
d
21 CFR 529.2503 [280]
e
21 CFR 556.500 [281]

g

a

Type of seafood

Similar issues have been reported in Europe. In fact, during the years 1999
through 2002, the presence of residues of antimicrobial drugs, mainly nitrofuran and
chloramphenicol, was one of the main reasons for detention or rejection of seafood
imports into Europe (Figure 5-8) [242]. A handful of aquaculture drugs approved in
Europe are presented in Table 5-3.
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Table 5-3. Aquaculture drugs approved in Europe and action levels
The Council of the European Communities approved aquaculture drugs
Drug name

Maximum Residue Limit (MRL) –
muscle and skin in natural portion

Type of seafood

Trimethoprim
Flumequine
Oxolinic acid

50 µg/Kg *
600 µg/Kg *
100 µg/Kg *

Finfish
Finfish
Finfish

Sarafloxacin

30 µg/kg *

Salmonidae

Tylosin A

100 µg/kg *

Finfish

Thiamphenicol

50 µg/kg *

Finfish

Colistin

150 µg/kg *

Finfish

Deltamethrin

10 µg/kg *

Finfish

Emamectin B1a

100 µg/kg *

Finfish

Oxolinic acid

300 µg/kg *

Finfish

Florfenicol

1 000 µg/kg *

Fish

Thiamphenicol

50 µg/kg *

Finfish

Deltamethrin

10 µg/kg *

Finfish

Compliance policy/programs
*

Council Regulation (EEC) No 2377/90 of 26 June 1990 [286]

5. What are the approaches used to assure public safety?
Regulatory authorities and the scientific community are two groups with
complementary goals that play a key role in ensuring public safety against seafoodassociated health hazards.
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5.1.

Regulatory agencies
Seafood regulatory agencies, via promulgation and enforcement of various laws

and regulations, guidance, and recommendations are usually at the heart of protecting
the public from seafood-associated hazards. Numerous programs have been designed
over the years to this end. In the U.S., the primary responsibility of assuring seafood
safety falls to the FDA, which is in charge of setting the maximum safe levels of
unavoidable toxic substances in seafood [276]. The FDA has the authority to detain and
even refuse import entries into the U.S. A recent related event was the June 28, 2007,
decision of the FDA to detain Chinese farm-raised catfish, basa, shrimp and dace until
they were cleared from containing unapproved drug substances [276]. As for domestic
seafood, the FDA can recommend legal sanctions, which include “warning letters,
seizure of products, injunction against further non-compliant practices, or prosecution of
an individual or establishment” [234]. There are a few other regulatory agencies; these
include the EPA (Environmental Protection Agency) in charge of chemical contaminants
such as pesticides and the National Marine Fisheries Service for instance. In Europe,
the E.U. parliament is at the heart of food safety control. This organization promulgates
food safety related laws, regulations and directives, which are mandatory in all states of
the European Union. The E.U. parliament works in close collaboration with the
European Food Safety Authority, which was established by regulation (EC)
No.178/2002. This latter organization, more science oriented, is in charge of risk
assessment.
There is a long list of guidance and regulations, mostly to seafood industries that
protect the public from dangers associated with seafood consumption. Several of these
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are preventive measures. A few examples in the U.S. are the National Shellfish
Sanitation Program, the Salmon Control Plan, the Low-Acid Canned Food (LACF)
Program, the Hazard Analysis & Critical Control Points (HACCP) Program and the
Good Manufacturing Practice regulation. The latter is intended to assure that
recommended processing conditions were used. The Salmon Control Program, on the
other hand, was designed to assure the safety of salmon consumers and is a
cooperative approach involving the FDA, industries, and various associations. As part of
the Shellfish Sanitation Program in the U.S., the level of various pollutants in coastal
water is to be monitored in order to classify each given area as suitable or unsuitable for
shellfish harvest. As for the HACCP, it applies to domestic as well as imported seafood.
HACCP requires both domestic and foreign processors of fish and fishery products to
understand all concepts behind food safety hazards and through a system of
precautionary control measures to prevent hazards from occurring [234, 276]. The E.U.
parliaments, as well as regulatory agencies of countries around the world, have issued
several similar regulations and directives that apply to domestic and imported seafood.
A few examples of seafood-related regulations promulgated by the European
Parliament include regulations (EC) No. 852/2004 and No. 853/2004, which established
some key hygienic rules for food (including seafood) business operators and regulation
(EC) No. 854/2004 in which key exigencies related to the organization of seafood official
control programs are determined. Several of these regulations elaborate on the
“tolerance threshold” for contaminants present in seafood. Examples of “tolerance
threshold” for seafood-associated health hazards, set by regulatory agencies around the
world are presented in Table 5-1  Table 5-6.
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Table 5-4. Seafood-associated marine biotoxins and action level set by regulatory agencies around the world
Hazards

Detection method (analytical
methods
for
regulatory
purposes)
USA- mouse bioassay

Paralytic
poison

shellfish

Amnesic
poison

shellfish

Neurotoxic
poison

shellfish

Diarrheic
poison

shellfish

Tolerated thresholds

Targeted seafood

0.8
ppm
(80µg/100g)
saxitoxin equivalent a
800ug/Kg (live bivalve
molluscs)
80 mg STX eq/100 g of
meat c & d
80 µg STX eq/100 g
< 80 mg STX eq/100 g
400 MU/100 g
80 mg STX eq/100 g
20 ppm domoic acid (in
general) a
30 ppm (in viscera of
dungeness craba

All fish

Europe - LC method

20 mg/Kg of domoic acid c

Live bivalve mollusks

Canada - LC method
New Zealand - LC method

20 mg DA/kg
20 mg DA/kg
0.8 ppm (20 mouse
units/100 gram) (USA)

EU - mouse bioassay b

160 ug of okadaic acid/Kg

Mussel
Shellfish
Clams, mussels and
oysters, fresh, frozen or
canned
Molluscs, echinoderms,
tunicates and marine
gastropods

EU - mouse bioassay b
Africa - mouse bioassay b
Canada - mouse bioassay b
Asia - mouse bioassay b
Australia – mouse assay b
USA - LC method

c
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Bivalve molluscs
molluscs
Molluscs
Shellfish
Shellfish meat
All fish

Azaspiracids

Ciguatoxin
Histamine

Asia (Japan) mouse bioassay
Australia
USA - mouse or rat bioassay

5 MU/100 g whole meat
16 to 20 µg OA eq/100 g
160
ug
azaspiracid
equivalents/Kg c

Shellfish
Shellfish
Bivalve
molluscs,
echinoderms, tunicates
and marine gastropods

Europe - mouse or rat bioassay

160 µg/kg

Live bivalves

Presence c
50 ppm

Fishery products
Tuna, mahi mahi, and
related fish
Scombridae,
clupeidae, engraulidae
and coryphaenidae

USA- extraction coupled
fluorescence spectroscopy
Europe

to

< 200 ppm e

Compliance policy/programs
a

Compliance Program 7303.842 or Sec 540.250 Compliance Policy Guide [263]
FAO (2004) Marine Biotoxins Food and Agriculture Organization of the United Nations Rome, 2004 http://www.fao.org/docrep/007/y5486e/y5486e00.HTM
available online, retrieved December 30, 2009 [238]
c
Regulation (EC) No 853/2004 (European standards) [287]
d
EU Directive 91/492/EEC[288]
e
council directives 91/493/EEC [289]
b
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Table 5-5. Seafood-associated toxic heavy metals and action level set by the FDA
Seafood Health Hazard

Tolerance threshold

Targeted seafood

Methyl mercury

1.0 ppm a

All fish

Arsenic

86 ppm (76 ppm for crustacea) b

Cadmium

4 ppm (3 ppm for crustacean) b

Chromium

13 ppm (12 ppm for crustacea) b

Lead

1.7 ppm (1.5 ppm for crustacea) b

Nickel

80 ppm (70 ppm for crustacean) b

Clams,
mussels
Clams,
mussels
Clams,
mussels
Clams,
mussels
Clams,
mussels

Compliance Policy/program
a
b

Sec 540.600 Compliance Policy Guide [262]
Appendix 5 - FDA & EPA Safety Levels in Regulations and Guidance [217]
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oysters,

and

oysters,

and

oysters,

and

oysters,

and

oysters,

and

Table 5-6. Seafood-associated environmental pollutants and action level set by
the FDA
Seafood Health Hazard

Tolerance threshold

Targeted seafood

Polychlorinated
Biphenyls (PCBs)
DDT, TDE and DDE

2.0 ppm (edible portion) a

All fish

5.0 ppm (edible portion) b

All fish

Chlordane -

0.3 ppm (edible portion) b

All fish

Chlordecone -

All fish

Mirex

0.3 ppm
crabmeat)b
0.1 ppm b

Diquat

0.1 ppm c

All fish

0.3 ppm b

All fish

Heptachlor
heptachlor epoxide
Glyphosate

and

(0.4 ppm in

All fish

d

Fluridone

0.25 ppm
Shellfish)
0.5 ppm e

3.0 ppm (for

Fin fish

Simazine

12 ppm f

Fin fish

Aldrin and dieldrin -

0.3 ppm b

Fin fish and shellfish

Fin fish and crayfish

Compliance Policy/program
21 CFR 109.30 [290]
Sec 575.100 Compliance Policy Guide [291]
c
40 CFR 180.226 [292]
d
40 CFR 180.364 [293]
e
40 CFR 180.420 [294]
f
40 CFR 180.213 [295]
a
b

5.2.

The Scientific community’s contribution in ensuring seafood safety
Through the development of cutting edge technologies to solve problems at

hand, science has also played a critical role in ensuring public safety against dangers
associated with seafood. A simple literature search with a key word such as “seafood
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safety” in ScienceDirect shows a significant and steady increase in seafood safety
related research effort since 1991 (Figure 5-9). The international community relies on
science, to develop cutting edge technologies and techniques that can rid seafood from
associated biological and chemical contaminants in order to bring a safer product to the
market. The development of cutting edge technologies for faster, cheaper, easier, and
more accurate detection methods of seafood-associated health hazards is another way
scientists have contributed in the protection of consumers against these dangers.

Figure 5-9. Increased interest in seafood safety related research.
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5.2.1. Detection tools for seafood associated health hazards
Detection of biotoxins. Years of effort have yielded a wide range of approaches
for toxin detection in seafood. These include various bioassays (in vivo and in vitro
assays), biochemical techniques (immunoassays), and chemical techniques including
fluorometric and colorimetric techniques, chromatographic techniques, electrophoretic
techniques, mass spectrometry, and finally biosensor-based techniques (Table 5-7). In
countries around the world, the mouse bioassay, despite its numerous shortcomings,
and liquid chromatography are the two official methods recommended for biotoxin
detection in seafood (Table 5-4).
Chromatographic techniques are at the heart of several effective analytical
approaches to biotoxin separation and detection. Compared to animal assays, analytical
techniques present the advantages of higher accuracy and sensitivity. While with animal
bioassays, it is impossible to clearly determine the nature of contaminants, these
techniques, coupled with the appropriate detection methods, will permit not only
separation and accurate identification of incriminated toxins, but also, using a standard
curve, their quantification. A variety of analytical approaches is currently available for
the detection of marine toxins. These include Gas Chromatography (GC), Thin-Layer
Chromatography (TLC), Liquid Chromatography (LC), Liquid Chromatography–Mass
Spectrometry (LC-MS), and Capillary electrophoresis [235, 296]. In addition to
advantages listed above, with chromatography-based detection methods, several toxins
can be monitored simultaneously. A new liquid chromatography–tandem mass
spectrometry method was developed recently [297]. With this method, up to 28 marine
lipophilic toxins can be monitored at the same time. In this case, toxins are separated
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using a gradient of acetonitrile/water at alkaline pH on a new type of C18 column proven
stable under these conditions: a Waters X-Bridge C18 (150 mm × 3 mm, 5 µm) [297].
Biosensor-based detection methods have also been investigated for application
in seafood safety programs. They are not only economical, straightforward and easy to
use, but offer the advantages of high sensitivities/low limit of detection, plus, these
technologies are portable [235]. An example of a recent development in this field is a
new planar interdigital sensor-based sensing system developed by Syaifudin et al.
(2009). This approach involves simple monitoring of variations of reactive impedance of
the planar interdigital sensors. Using this approach, as little as 12.6 µg/g of domoic acid
in mussel meat, for instance, can be successfully detected [298].
ELISA has also been investigated widely for application in seafood biotoxin
detection. An example of a recent development in this field was made by Zhou et al.
(2010), who reported a reliable ELISA-based approach to monitor brevitoxin in mollusks
with reduce interference from the matrices. Oysters and cockles were used in this
experiment. With such a method, the limit of detection of brevitoxin is improved. The
main advantage of immunoassays, which are based on antibody-antigen interactions, is
high specificity [299].
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Table 5-7. Proposed methods for biotoxin detection in seafood [235, 238, 300]

PSP

DSP

ASP

Ciguatera

NSP

Mouse bioassay

Mouse
bioassay
Suckling
mouse
assay
Rat
bioassay
Daphnia
magna
assay
Intestinal
loop assays

Mouse
bioassay

Mouse bioassay
Chicken assay
Mongoose and cat
assay
Brine shrimp assay
Mosquito assay
Diptera larvae assay

Mouse bioassay
Fish bioassay

In vitro assays

In
vitro
hippocampal
slice assay
Sodium channel
blocking assay

Cytotoxicity
assays (rat
hepatocytes,
KB
cells,
fibroblasts)

Receptor
binding
assays
Hippocampal
slice
preparations

Sodium
channel
binding assays for
ciguatoxins

Neuroblastoma
cell assay
Synaptosome
binding assay
Hippocampal
slice assay

Biochemical
techniques

Immuno
(ELISA)

Immunono
assay (RIA
or ELISA)
Acid
phosphatase
assay

Immuno
assay
(ELISA)

Immuno
assay
(Radioimmunoassay
Enzyme-linked
immunosorbent
assay ( ELISA )
Stick tests
Immunoassays
based
on

Immuno
(ELISA)

Bioassays
In vivo assays

assay
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SFP

assay

monoclonal
antibodies
Solid-phase
immunobead assay)

Chemical/analytical
techniques

Fluorometric and
colorimetric
technique, MS
Chromatographic
and
Electrophoretic
techniques.

TLC,GC, LC
MEKC, MS

Amino acid
analysis
TLC,
LC,
CE, MS

Biosensors based
techniques

Sodium channels
based
biosensors

Immuno
sensors

Optical
immuno
sensors

Enzyme
inhibition
based
biosensors

Molecularly
imprinted
polymer
based
biosensors

220

Chromatographic
detection
Nuclear
magnetic
resonance
(NMR)/mass
spectrometry (MS)
Mass spectrometry
Capillary
zone
electrophoresis

Micellar
electrokinetic
capillary
chromatography
detection
Electrospray
LC/MS
Ionspray LC/MS
LC/MS/MS

Chromatography
coupled
with
fluorimetric
detection
or
derivatization
techniques
(TLC,
GC,CE,
HPLC)

Drug residues in seafood. With the rise in demand of fish and shellfish, a large
portion of seafood found in market places around the world comes from aquaculture,
especially from China. As it is the case with any animal husbandry, veterinary drugs are
often heavily used in aquaculture to control pests, infections, or to increase production.
Unfortunately, drug residues, often molecules that have proven harmful to humans, are
found in edible seafood tissues. As previously mentioned, lately in the U.S. as in
Europe, there have been a significant number of alerts regarding seafood imports
contaminated with unapproved drug residues (Figure 5-8). Over the years, through the
dedication of the scientific community, better and more improved detection methods
have been made available. An example in this case is liquid chromatography (LC)
coupled with triple-quadrupole mass-spectrometry (LC–QqQ-MS). Until recently, in a
single run, this sort of method could only analyze related molecular entities.

An

upgraded and more robust version, a multi-component quantitative HRLC–ToF-MS, was
reported recently. This new approach has proven effective at simultaneously monitoring
a wide range of unrelated drugs generally used in aquaculture or found in seafood
tissues [301]. Smith et al. (2009) also developed an LC-ion trap mass spectrometry
approach, effective at detecting several types of veterinary drugs in fish samples. In this
case, the extraction of drug residues from seafood matrixes is completed in acetonitrile
and hexane followed by HPLC separation on a phenyl column. In certain cases,
imidazoles, macrolides, fluoroquinolones for instance, very low concentrations
(0.01 ppm) could be detected using this technique.
studies

included

ionophores,

macrolides,

Other drugs involved in these

nitroimidazoles,

benzimidazoles,

anthelmintics, penicillines, quinolones, sulfonamides, tetracyclines, amphenicols, and
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tranquilizers, among others [301, 302].
Detection of microbial pathogens in seafood. The best approaches for the
detection of microbes in seafood are usually a combination of culture based and
molecular based techniques; the latter being often used to assist in bacterial strain
identification, while culture is required for enrichment purpose. The kind of medium used
to this end is dictated by the type of microorganisms targeted. Over the years, a
tremendous amount of effort has been dedicated to the conception of superior media.
Recommended Standard Operating Protocols for use in microorganism detection, in
seafood, are described in detail in the FDA’s 1998 Bacteriological Analytical Manual
(BAM) [303]. Targets of quality control programs are numerous. These include various
pathogenic bacteria such as Vibrio, Salmonella, S. aureus, L. monocytogenes and E.
coli) as well as indicators of fecal contamination [240].
Several molecular and culture-based methods have been developed to assist in
the detection of V. parahaemolyticus (Vp) and V. vulnificus (Vv), which are major issues
as far as seafood safety is concerned. Commonly used culture-based approaches,
which present the main disadvantages of being time consuming, laborious, and
inaccurate, are the MPN and the ISO cultural methods [254]. Quite a few Vibrio-specific
media has been developed to assist in the isolation of these bacteria from seafood
matrixes; these include TCBS agar (for V. cholera and V. parahaemolyticus) and
modified cellobiose polymyxin colistin (mCPC) and CC agar for V. vulnificus [303]. The
MPN method, coupled with various techniques to assist in the identification of suspect
isolates, is recommended for detection of Vv and Vp in seafood. Examples of
approaches used for these identifications are the establishment of a biochemical profile,
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DNA probes or PCR. In the case of PCR for instance, DNA primers targeting tdh and trh
genes are used to detect virulent strains of V. parahaemolyticus.
Until the advent of real-time PCR, this approach presented the main drawback of being
limited to qualitative evaluation of food samples. Today, faster and quantitative
assessment of Vibrio’s presence in food samples is possible [254]. More sophisticated
methods have been introduced. In 2009 for instance, Espiñeira et al. introduced a
sequential multiplex PCR system for the detection of Vibrio sp that have been involved
in fish and shellfish poisoning, namely V. cholerae, V. parahaemolyticus, V. vulnificus,
V. alginoliticus and V. mimicus. This method, which has been validated, is not only able
to detect problematic Vibrio species, but it can also, using a fragment analysis, confirm
the viable-dead status of these microorganisms and most importantly, probe for the
presence of important serogroups and virulence factors [304]. Genetic markers, a
precious tool for PCR, have been identified for several other seafood-borne pathogens.
These include cytotoxin-hemolysin (V. vulnificus), ctxAB (V. cholerae), oriC,
chromosomal origin of replication (Salmonella spp.), listeriolysin O (hly) and the 16S
rRNA (L. monocytogenes), polymerase gene (Hepatitis A virus) and polymerase gene
for norovirus, just to name a few [303].
5.2.2. Examples of recent technological breakthroughs in efforts to free seafood
from associated contaminants
In recent years, outstanding breakthrough techniques and cutting edge
technologies to aid in freeing seafood from associated contaminants have been
developed. Molluscan shellfish and associated pathogens (especially V. vulnificus and
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V. parahaemolyticus), scombrotoxin, fish safety (especially of cold-smoked salmon) and
bio-preservation of seafood are a few examples of highly investigated topics.
Molluscan

shellfish

and

associated

pathogens.

Nowadays,

seafood

regulatory authorities face major issues with molluscan shellfish. For years now,
molluscan shellfish has been classified as “high risk” seafood by the FDA. They were
responsible for the largest number of seafood-borne illnesses during 1990-2006 (Figure
5-4). Because of their filter-feeding habits, they tend to accumulate a wide range of
etiological agents (pathogenic bacteria, parasites, and viruses) as well as biotoxins. The
emergence of innovative FDA-approved Post-Harvest Processing (PHP) technologies
such as Individual Quick Freezing (IQF), Heat-Cool Pasteurization (HCP), and High
Hydrostatic Pressure (HHP), have revolutionized the industry of seafood, particularly in
regard to oysters. These technologies, which are currently commercially available, have
made it possible to bring raw and healthy products to consumers. An end product of
high quality (fresh taste and superior appearance) is the major advantage of IQF, HCP
and HHP. These processing techniques reduce the level of Vibrio bacteria to
undetectable levels [304]. Though HHP is already approved by the FDA, several
attempts to perfect this technology are currently on the way. In 2008 for instance, using
a pressure resistant strain of Vp (MLT 403) to picture the worst-case scenario, Kural et
al. proposed better pasteurizing conditions. Under such conditions, a 5-log reduction in
the load of the pressure resistant Vp in live oysters could be achieved. These conditions
were as follows: a two-minute treatment at pressure ≥ 350 MPa (1 °C to 35 °C) and a
two-minute treatment at 40 °C (pressure ≥ 300 MPa) [305].
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As far as seafood safety is concerned, HHP processing is an especially
promising technology. Its inactivating effect on a variety of pathogenic agents isolable
from seafood has been documented. These agents include viruses, parasites, and
several other types of seafood-associated bacterial pathogens. The ability of HHP to
inactivate oyster-associated viruses has been extensively studied [306-309]. A 5-min
HHP treatment at pressure 400-MPa and 0 °C was established as an effective approach
to bring murine norovirus-1 to undetectable levels in oysters [308]. HAV can also be
effectively inactivated from oyster tissues using HHP. Calci et al. (2005) could achieve a
PFU reduction >3 log10 with a one-minute treatment at 400 megapascals [306]. It is
important to note that temperature, matrices’ pH, and salinity have a great effect on the
efficiency of pressure mediated HAV inactivation [307].
Another recent development in the field of molluscan shellfish safety is the
application of super critical CO2 (scCO2), a known antibacterial substance widely used
in the food industry to reduce the load of oyster-associated bacteria. Two conditions,
100 bar and 37 °C for 30 minutes and at 172 bar and 60 °C for 60 minutes, were
reported as able to induce 2-log and 3-log reductions in the oysters’ aerobic plate count
respectively. No significant change in the physical appearance, smell, or texture was
recorded (Figure 5-10) [310].
As previously stated, V. vulnificus and V. parahaemolyticus are major seafoodassociated health concerns. In recent years, there has been a tremendous amount of
effort to design approaches to reduce their load, especially in molluscan shellfish. One
of the latest innovations in this field is the introduction of a “weak acidic electrolyzed
water” based approach [311]. Quan et al. (2010) have demonstrated that weak acidic
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electrolyzed water possesses outstanding antibacterial potency against Vv and Vp,
especially when compared to sodium hypochlorite (NaClO), a commercial sanitizer
[311].

Untreated oysters

Oysters treated with scCO2 at 37 ˚C for 40 minutes

Figure 5-10. Appearance of oysters before and after a 40 minute exposure to
scCO2.
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A chlorine dioxide (ClO2) based approach was also recently introduced.
According to Wang et al. (2010) a 6-hour treatment with 20 mg/L of ClO2 is enough to
disinfect oyster tissues contaminated with Vp. These authors particularly recommend
this method because it is cost-effective; it also has the potential of increasing seafood’s
shelf life (~12 days)

[312]. In addition, E. coli O157:H7, S. typhimurium, and L.

monocytogenes, other pathogens of importance regarding seafood safety, have proven
sensitive to this type of treatment.
Scombrotoxin. Because of the large number of associated outbreaks,
scombrotoxin can be viewed as the most dangerous seafood-associated health hazard
[218, 219]. To store fish at low temperatures is generally considered sufficient to
prevent the growth of causative bacteria. Unfortunately, such conditions cannot always
be respected, especially during retail processes. Phuvasate and Su (2010) proposed an
alternative to low temperature storage applicable under these circumstances, namely
the use of Electrolyzed Oxidizing (EO) water and ice. According to these authors, the
load of several histamine-producing bacteria on food surfaces and fish skin can be
significantly reduced simply by using electrolyzed oxidizing water and ice. Conditions
reported as effective using salmon and tuna’s skin were, for EO water, 100 ppm
chlorine for 120 minutes, and for EO ice, 100 ppm chlorine for 24 h [313]. Experts now
agree, electrolyzed oxidizing water possesses a great potential as far as seafood safety.
Its use is recommended not only because it is environmentally friendly, safe, and cost
effective but also because its application is quite straightforward. Its antibacterial effects
against several other seafood-associated bacteria have been reported. A few examples
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are E. coli O157:H7, L. monocytogenes, as well as Salmonella enteritidis,
Campylobacter jejuni, Enterobacter aerogenes, and S. aureus [314].
Bio-preservation of seafood. To add various chemicals to seafood in order to
reduce its bacterial load or inhibit the growth of unwanted bacteria is an option that
many have proposed as a solution to some seafood safety issues. Regrettably,
consumer

acceptance

of

these

products

is

not

always

guaranteed.

As

chemical/preservative-free, ready-to-eat seafood products are gaining in popularity
alternatives to the use of chemicals have emerged, and an example is bio-preservation.
Recently there have been a few innovations in this field. An example in this case is the
proposed use of Carnobacterium divergens M35 and divergicin M35 in an effort to rid
seafood from one of its most persistent bacterial contaminants, namely L.
monocytogenes [315]. Matamoros et al. (2009) characterized several strains of lactic
acid bacteria that can be used to this end as well. These bacteria (Lactobacillus
fuchuensis,

Leuconostoc

gelidum,

Lactococcus

piscium,

and

Carnobacterium

alterfunditum) showed inhibitory potential against seafood spoiling and pathogenic
bacteria [316]. Pinto et al (2009) also reported two bacteriocins produced by lactic acid
bacteria (Enterococcus faecium and Pediococcus pentosaceus) that can be used to this
end [317].
Irradiation and other recent breakthroughs. Several other cutting edge
technologies designed to help deal with seafood-associated health issues have been
introduced in recent years. A few examples are X-ray, gamma ray, and electron beam
irradiation based technologies. Gamma irradiation (0.5, 1, 2, and 5 kGy) and electron
beam irradiation have recently proven an effective non thermal approach to reduce the
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load of V. parahaemolyticus as well as several other seafood-associated contaminants,
namely L. monocytogenes and S. aureus, in a raw seafood dish (oyster Jeotkal).
Organoleptic properties were not negatively affected by the irradiation. In this particular
case, gamma irradiation appears a better alternative to electron beam irradiation [318].
The beneficial antibacterial effects of electron-beam irradiation applied to another
seafood dish (salted and seasoned short-necked clam) were reported in 2009 by Kim et
al. It is important to note that, in this case, no change in sensory qualities was observed.
A significant microbial inactivation (coliform bacteria, aerobic bacteria, yeast and mold)
was reported [319]. Similar results were achieved with cold-smoked salmon [320]. This
technique appears to be a better alternative to HHP in regards to sanitization of coldsmoked salmon. In fact, while both approaches (Irradiation at 2 kGy and HPP: 450 MPa
for 5 min) yielded a safer final product, the visual aspect of HHP-treated, not Irradiationtreated, salmon was negatively affected. The microbial load of both products did not
exceed 6 log10 cfu/g after 35 days storage at 5 °C [320].
X-ray irradiation has also been investigated for use in improving seafood
microbiological quality. Several recent publications have demonstrated its beneficial
effects on V. parahaemolyticus, V. vulnificus (shrimp contaminants). It is important to
note that several other shrimp-associated bacterial contaminants, namely E. coli,
Salmonella enterica, and Shigella flexneri, were inactivated as well [321, 322].
High Hydrostatic Pressure (HHP) was also reported as an excellent alternative to
reduce the level of Listeria in fish. According to Gudbjornsdottir et al. (2010), a 700–
900MPa treatment of 10 s is sufficient to reduce the load of L. innocua to undetectable
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levels. This experiment was completed with cold-smoked salmon. In this case, though
there was no lipid oxidation, some variations in color and microstructure of the final
product were noted [323]. The potential of HHP to rid mackerel from parasites, such as
the nematode Anisakis simplex, was also recently reported. In this particular case, a
complete inactivation of the larvae in the fish tissue was achieved at 300 MPa after a
five-minute exposure [324].
Another recent report has proposed using CO2 in packaging fish. Schirmer et al.
(2009) proposed using CO2 combined with various organic acids: citric acid (3% w/w,
pH 5) and acetic acid (1% w/w, pH 5) in packaging fresh fish, as an effective way to
improve its quality and shelf life. This combination has proven efficient at completely
inhibiting bacterial growth in naturally contaminated salmon stored at 4 °C for 14 days.
Monitored bacteria were Enterobacteriaceae, lactic acid bacteria, and sulphur reducing
bacteria. Sensory analysis was not completed by these authors [325].
A better alternative to rid shrimp from V. parahaemolyticus was recently
introduced. The use of chlorine is the current approach to reduce the level of shrimpassociated pathogenic bacteria. Unfortunately, health issues such as bronchitis and
pulmonary edema in workers have been reported. Norhana et al. (2009) proposed an
even simpler approach to deal with shrimp-associated bacterial pathogens. These
authors show that washing shrimp with acidic fruit juice, namely bilimbi (Averrhoa
bilimbi) or tamarind (Tamarindus indica L.) was also an effective way to significantly
reduce its load of bacteria [326]. In 2007, Chaiyakosa et al. reported another safer
alternative to reducing the load of V. parahaemolyticus in shrimp, namely the use of
Chitosan [327]. Another author reported this same substance as an effective means of
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bringing safer salmon to consumers. Packing cold-smoked salmon in chitosan-coated
plastic films containing 4.5 mg/cm2 sodium lactate or either a combination of 4.5 mg/cm2
sodium lactate plus 0.6 mg/cm2 potassium sorbate or 2.3 mg/cm2 sodium lactate plus
500 IU/cm2 nisin was found to be beneficial. It was established that for seafood
conditioned using this approach and stored at low temperature (~ 4 ºC), L.
monocytogenes’ growth was inhibited for at least six weeks [328].
6.

Future directions and conclusions
From pathogenic bacteria, parasites, and viruses of all sorts, to life threatening

biotoxins, the range of chemical and biological contaminants present in seafood is
broad in scope and challenging to manage. Despite years of efforts from regulatory
authorities and the scientific community, the public at large is still at risk of dangers
associated with seafood consumption. For several years now, seafood has ranked
foremost as the most significant source of food-borne disease outbreaks of known
origin. Contributing factors are numerous and represent key points upon which urgent
action, from regulatory authorities and the scientific community is required. Special
attention should be paid to deleterious agents that have been associated with the
largest number of outbreaks in the past years. In the U.S. for instance, major threats
were scombrotoxin, responsible for 36% of all reported seafood-borne outbreaks from
1990 to 2006, followed by ciguatera (responsible for 21% of outbreaks), bacteria
(especially Vibrio spp) responsible for 24% and finally noroviruses, which cause about
10% of all outbreaks reported during this same period [218]. It is important to note that
these same agents pose serious problems in other parts of the world, as well.
Scombroid fish poisoning, for instance, is also a serious problem in countries like Japan
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and the U.K. [242]. Vibrio spp, especially V. parahaemolyticus, have been reported as a
major problem in several Asian countries [254]. A recent study, a 2005 – 2008 survey of
shellfish (mussels, clams and oysters), showed that norovirus is a problem in Italy, as
well [329].
The task of ensuring consumers protection against the dangers of seafood is
shared by several groups.

These include (1) regulatory authorities, which depend

heavily on the scientific community, and are in charge of the promulgation and
enforcement of laws and regulations, (2) establishments involved in the harvest,
processing, storage, and retail of seafood, and (3) consumers themselves. Failures and
flaws at various levels of the current safety management system explain why seafood
has been a persistent issue for the past few years. A certain number of defects in the
seafood regulatory system of the U.S. for instance are presented in a 2008 report of the
Center for Science in the Public Interest (CSPI). Mentioned shortcomings are the
“voluntary recall” approach currently in place, added to financial issues. CSPI sees in
the limited budget allocated to the FDA (Figure 5-11), a serious hindrance to its
efficiency. This can be a serious hindrance, for instance, when it comes to law
enforcement. CSPI reports an extremely low inspection rate of food processing
companies by the FDA, a rate that is insignificant compared to the USDA’s [218].
Currently,

in

the

U.S.,

there

are

approximately

13,400

seafood-processing

establishments. The FDA reports having inspected only 3,066, 2,830, and 2,456 during
the fiscal years 2004, 2005 and 2006 respectively.
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Figure 5-11. Graphical representation of some limitations in the current federal
food safety regulatory system with signficant impact on seafood safety
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Financial limitations are not the only obstacle to full efficiency of regulatory
agencies. The unavailability of effective technological tools that could either help rid
seafood from hazardous entities/substances, or assist regulatory authorities in effective
risk assessment and management during various control programs is also critical.
Without effectual detection methods, efficient law enforcement is nearly impossible.
Though numerous approaches applicable to virtually all seafood-associated health
hazards have been proposed so far, several gaps remain.
This is the case of biotoxins for instance, which alone were responsible for 63%
of all reported seafood-borne diseases from 1990 to 2006. Because they are extremely
resistant to various post-harvest processing techniques, as far as assuring seafood
safety, preventive measures are a better option. More effective detection tools are thus
critically needed in order to reduce the current incidence of biotoxin-linked seafoodborne illnesses. Presently, in this field, there is still a need for cost-effective, rapid,
sensitive, specific, and straightforward methods that can be operated by untrained
personnel on a routine basis.
Though several approaches to toxin detection in seafood have been proposed so
far, and even significant progress made recently (Table 5-7), animal-based assays and
liquid chromatography, techniques that have their share of shortcomings, are still the
official methods (Table 5-4)
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Animal bioassays for instance, are fit to assess the overall toxicity of a sample
but cannot give insight on the nature of the toxin(s) involved. Moreover, these assays
are time consuming, of limited accuracy and controversial (ethics). As stated previously,
liquid chromatography, on the other hand, when coupled with effectual detection
methods, is valuable at accurately identifying the nature and concentration of the
incriminated toxin(s). However, it is important to note that, chromatography-based
methods are lengthy and not cost-effective; heavy equipments and trained specialists
are needed. Better methods have been proposed, but, to our knowledge, none has
been approved by regulatory authorities for routine use. Though these new methods
present some clear advantages, it is important to point out that they also possess some
weaknesses. Among these are difficulty of application on a routine basis, the necessity
for heavy equipment, and the complexity of protocols and generated data, just to name
a few.
There are flaws in current approaches to control scombroid fish poisoning and
ciguatera. In the case of scombroid fish poisoning for instance, there is still a need for
more effective alternatives to control Histamine-Producing Bacteria (HPB). Current
recommendations of the FDA involve rapid cooling (≤ 40 ˚F) after visceration (for larger
fish) upon death. Unfortunately, this approach possesses a few shortcomings. It is
important to note that not all HPB are mesophiles. Several studies showed that
histamine can be produced even at low temperature by physchrophilic HPB [242, 330].
Ciguatera was second to scombrotoxin as the most likely cause of seafood-borne
disease outbreak from 1990 to 2006. Though ciguatera is such an issue in the U.S.,
“there are neither standards, nor an official method” that applies to Ciguatera Fish
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Poisoning (CFP) in this country [238]. Innovations, regulation-wise, in this regard are
obviously critical. Current efforts with respect to CFP prevention involve various toxinmonitoring programs, education, alongside with bans on the sale and capture of fish
most likely to cause poisoning (Europe, Australia).
Bacteria were next to toxins as the most prevalent cause of seafood-borne
illnesses during the past decade. Fortunately, in this case, there are currently several
approved Post-Harvest-Processing (PHP) approaches aimed at reducing their load in
seafood. These included IQF (Individually Quick Frozen), HCP (Heat Cold
Pasteurization), and HHP (High Hydrostatic Pressure). Though these techniques have
revolutionized the industry of oysters, for instance, there is still room for improvement,
especially because oysters do not survive such processing [331]. In terms of shelf life,
this can be an issue. To store, HHP-, IQF- and HCP-treated oysters at low temperatures
is, unfortunately, not enough to solve the issue. Prapaiwong et al. (2009), studying
variations in the bacterial load (total aerobic bacterial counts) of HHP-treated oysters
stored at 4 °C for instance, determined that the bacterial count of processed products
can rise quickly during storage and can even reach ~ 107 CFU/g in just 7 days [332].
Moreover, long-term storage presents the disadvantage of increasing the final
production cost. Post-harvest-processing techniques non lethal to oysters would be,
without the shadow of a doubt, a better alternative. Mahmoud and Burrage (2009c)
reported X-ray irradiation as a better approach for reducing the load of oystersassociated V. parahaemolyticus because oysters are able to survive even extremely
high X-ray doses [333]. Oysters have also been shown to be able to survive scCO2
exposure, making it an attractive tool for further exploration [310].
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Norovirus is another major seafood-associated health hazard. Major gaps in the
current system are regulatory and scientific. Despite the clear threat posed by this virus,
not much effort has apparently being exerted regulation-wise. As mentioned by Terio et
al. (2010), “there is no virological standard for bivalve shellfish in European legislation”
[329]. Though several approaches to the detection of norovirus in seafood have been
proposed so far, much still needs to be done; an area in need of improvement is the
development of more efficient methods of viral RNA extraction. RNA extraction is a
critical step in several virus detection protocols. RNeasy Kit was recently presented by
Husman et al. (2009) as a most useful alternative for viral RNA extraction after
comparing five such approaches side by side. A modified paramagnetic silica-based
guanidium extraction based technique was also developed recently [334, 335].
Other challenges faced in norovirus detection are related to the virus’ genetic variability
and scarcity in samples. Interferences of seafood matrix, mainly, the presence of
inhibitory substances, also represents a serious obstruction [335]. An effective TaqMan
RT-PCR based approach for quantification of genogroups I and II norovirus, which
presents the advantage of overcoming background inhibitory effects, was introduced
recently by Gentry et al. (2009) [336]. An effective and more sensitive multiplex RT–
PCR-based approach to norovirus and rotavirus detection in oysters was also
introduced recently [337].
There is no doubt that the development of effective technologies able to
surmount each and every one of these challenges will aid efforts to reduce outbreak
incidents of seafood-borne infections attributable to viruses.
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Chapter 6 : REDUCING OYSTER-ASSOCIATED
BACTERIA LEVELS USING SUPERCRITICAL FLUID
CO2 AS AN AGENT OF WARM PASTEURIZATION
Running Title: SUPERCRITICAL CO2 EFFECTS ON OYSTER’S BACTERIAL
CONTAMINANTS
Published in the International Journal of Food Microbiology, 2010, 138 (1-2):63-70
Authors: Meujo DA, Kevin DA, Peng J, Bowling JJ, Liu J, Hamann MT

ABSTRACT - An innovative approach to Post-Harvest Processing (PHP) of oysters is
introduced focusing on the effects of supercritical carbon dioxide (scCO2) on bacterial
contaminants trapped in the digestive system of oysters. Oysters were exposed to
scCO2 under two conditions: (1) 100 bar and 37 °C for 30 min and (2) 172 bar and 60
°C for 60 min. Using FDA standard guidelines for food analysis, variations in the Aerobic
Plate Count (APC) were assessed. It was established that exposing oysters to CO2 at
100 bar and 37 °C for 30 min and at 172 bar and 60 °C for 60 min induced 2-log and 3log reductions in the APC respectively. The decrease in the microbial load as a result of
treatment with scCO2 was found to be significant (P=0.002). A release of adductor
muscles from the shell was noted in oysters treated at 172 bar and 60 °C for 60 min;
this was not the case for oysters treated at 100 bar and 37 °C for 30 min. A blind study
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allowing sensory analysis of treated vs. untreated oysters was also completed and no
significant change in the physical appearance, smell, or texture was recorded. In this
paper, we also report the effect of scCO2 on several bacterial isolates, including a
referenced ATCC strain of a non-pathogenic Vibrio (Vibrio fischeri) as well as several
other bacterial isolates cultured from oyster' tissues and found to share biochemical
features common to pathogenic Vibrio strains. A complete inactivation (minimum 7-log
reduction) was achieved with these latter bacterial isolates. A 6-log reduction was
observed with V. fischeri.

1. Introduction
As a direct consequence of filter-feeding in often heavily contaminated water,
oysters can be loaded with pathogenic microorganisms. These microorganisms are
absorbed concomitantly with nutrients and accumulate in the gastrointestinal (GI)
system of oysters. Hepatitis viruses (A and E), Salmonella, Shigella spp., Escherichia
coli, Vibrio spp., Clostridium perfringens, C. botulinum and Yersinia enterocolitica are
some of the microbes that have been reported as part of this pathogenic microflora
[265, 338, 339]. Since oysters are often consumed raw, these pathogens are a serious
concern. These microorganisms have been associated with a wide range of mild to
severe foodborne illnesses. Of pathogens that contaminate the GI system of oysters,
Vibrio spp (especially V. parahaemolyticus (Vp) and V. vulnificus (Vv)) are of greater
concern [338, 340, 341]. Among immunocompromised patients, especially those with
chronic liver disease, V. vulnificus strains have been strongly associated with severe
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and life-threatening conditions.V. vulnificus is the second leading cause of seafoodrelated fatality in the US [257, 259].
Pathogenic microorganisms are not the only concern associated with oyster
consumption. Other risks include toxic metals, biotoxins and chemical environmental
contaminants. These also accumulate in the GI system and tissues of oysters and have
been associated with food poisoning outbreaks [235].
Until recently, all attempts to reduce the incidence of oyster-related foodborne
illnesses were centered on consumer education. Other efforts to minimize consumer
exposure to oyster-associated pathogens included natural depuration and harvesting
restrictions. Despite these efforts, in 2002, Potasman et al. reported a worrisome
increase in the number of outbreaks of bivalve-associated infections primarily from
oysters, from 3 reports in the 1970s to 22 during the 1990s. The large majority of these
outbreaks were due to raw oyster consumption [265].
The emergence of innovative FDA approved Post-Harvest Processing (PHP)
technologies such as Individual Quick Freezing (IQF), introduced in 1989, Heat–Cool
Pasteurization (HCP), introduced in 1995, and High Hydrostatic Pressure (HHP),
introduced in 1999, have revolutionized the industry of seafood, particularly in regard to
oysters. These technologies, which are currently commercially available, have made it
possible to bring safer raw products to consumers. An end product of high quality (fresh
taste and superior appearance) is the major advantage of Individual Quick Freezing
(IQF), Heat–Cool Pasteurization (HCP) and High Hydrostatic Pressure (HHP)
processing. These processing techniques also reduce the level of V. vulnificus to non240

detectable levels (i.e., < MPN/g). The level of spoilage bacteria is significantly reduced
aswell. Unfortunately, oysters cannot survive any of the above PHP technologies [331].
In terms of shelf life, this can be an issue and thus it is mandatory to store HHP-,
IQF- and HCP-treated oysters at low temperature; long term storage is expensive.
Several other methods are under development including approaches using X-ray and
Gamma radiation as cold pasteurizing agents.
In the present paper, we introduce an original and promising approach to postharvest processing of oysters: warm pasteurization of oysters using scCO2 (CO2 at a
temperature and pressure above its critical point). The antimicrobial potential of dense
CO2 was first reported in 1951 by Fraser while working with E. coli [342]. Extensive work
has since been completed and currently, the bactericidal potential of scCO2 is wellestablished over a wide range of pathogenic microorganisms. ScCO2 has been
documented to effectively inactivate viruses (HIV-1, Sindbis virus, polio Sabin type I
virus, and pseudorabies virus [PRV]), yeast (Saccharomyces cerevisiae), as well as
vegetative and sporal forms of various bacteria (Salmonella, S. aureus, listeria, E. coli,
Pseudomonas fluorescens, etc.) [343-346]. So far, however, there has been no report
on the effect of scCO2 on Vibrio spp.
There are also several reports of studies related to the kinetics of inactivation of
bacteria in food products (e.g., milk, fruit juice, herbs, ground beef, etc.) using scCO2
[345-347]. However there is no reported attempt to assess whether treating oysters with
scCO2 could have a positive impact on the wide range of pathogenic bacteria which
populate their GI system.
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The present studies address several key questions in regards to oyster
pasteurization by scCO2. First, the effects of scCO2 was evaluated in vitro on bacterial
cultures of a non-pathogenic strain of Vibrio used here as a model for Vibrio spp (Vibrio
fischeri ATCC® 7744™) and several bacterial isolates from an oyster homogenate.
Second, the effect of scCO2 on the bacterial community trapped in the oyster GI system
was studied. Finally, using a panel of thirteen participants, a sensory analysis of fresh
untreated oysters versus scCO2-treated oysters was completed in a blind survey.
2. Material and Methods
2.1.

Bacterial strains
Referenced bacterial strains used to assess the effect of scCO2 on bacteria in

vitro were V. fischeri (ATCC® 7744™) and E. coli (Migula) Castellani and Chalmers
(ATCC® 25922™). V. fischeri was grown and maintained on either Luria Bertani Salt
(LBS) medium (1% [wt./vol.] bacto tryptone [DB], 0.5% [wt./vol.] bacto yeast extract [BD,
Franklin Lakes, NJ], 2% [wt./vol.] NaCl, 0.3% [vol./vol.] glycerol, 50 mM Tris–HCl [pH
7.5]) [348], or BOSS medium (3% [wt./vol.] NaCl [Fisher Scientific], 0.1% [wt./vol.]
Glycerol [Sigma Aldrich], 1% [wt./vol.] bacto peptone [DB], 0.3% [wt./vol.] beef extract,
[pH 7.3]; [349].

E. coli was grown and maintained in Bacto nutrient broth [Difco

Laboratories, Detroit, MI], 23 g/L.
2.2.

Oysters
Oysters were purchased from a seafood distributor in Memphis, TN, USA. These

oysters were harvested on 04/13/09, properly maintained and delivered to our facility on
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4/20/09. After arrival, the oysters were stored whole on ice overnight and our
experiments were carried out the following day. Oysters were presumed alive unless the
shell's adductor muscles were permanently released, in which case the oysters were
discarded. Concerning morphology and size, the oysters were a mixture of “bananashaped” and “good-quality shaped” oysters; “goodquality shaped” oysters constituted
the majority. The morphology classification was performed according to procedures
previously published by Lee et al., 2004 [350]. The length of the oysters varied from
small (7.5 cm) to large (13 cm).
2.3.

Supercritical unit and treatment of oysters using supercritical CO2
The SFT-150 SFE system (Supercritical Fluid Technologies, Inc.) (Figure 6-1)

was used for all scCO2 treatments. The internal surfaces of the SFT-150's treatment
chamber were sterilized with a 70% ethanol solution and allowed to dry at room
temperature. The samples prepared for treatment were placed into the chamber which
was then hermetically sealed. The liquid carbon dioxide source was opened filling the
chamber and venting for 5 s to purge the chamber of any air. An external air source was
utilized to supply the SCT-150's pneumatic compressor which increases the chamber's
internal pressure. An external air pressure gauge was utilized to control the pneumatic
compressor. The SCT-150's internal pressure was maintained and monitored via the
fine-control valves and internal pressure displays located on the SCT-150 unit. Oysters
were sampled in groups of 10–13 and placed in porous bags (Filter Specialists, Inc.,
[FSI] Michigan City, IN) which were placed into a 4 L capacity chamber. The oysters
were exposed to scCO2 under two different conditions: 100 bar for 30 min at 37 °C and
172 bar for 60 min at 60 °C. After treatment, the chamber was carefully vented, the
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oysters removed, and their microbial load (APC) was assessed alongside untreated
oysters.

Julabo chiller

Figure 6-1. Standard bench-top SFT-150 (bottom) and schematic of supercritical
sterilization apparatus (top).
(1) Filter. (2) Bulkhead. (3) Relieving Regulator. (4) CO2 Pre-chiller. (5) Liquid CO2 pump. (6)
Preheater. (7) Vessel. (8) Sterilization unit.

2.4.

Microbiological analysis of treated vs. untreated oyster samples
For microbiological analysis, each group of oysters was divided into three sub-

samples which were analyzed independently. Each oyster's surface was carefully
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cleaned with 70% ethanol solution and dried under a bacteriological hood using a paper
towel. Oysters were opened aseptically in order to separate the flesh and interstitial fluid
from the shell. The flesh and interstitial fluids were macerated in a sterilized blender for
about a minute in an equal volume of Butterfield's phosphate-buffer to yield an oyster
homogenate (dilution 1:2). A dilution of 1:10 was prepared by transferring 20 g of this
homogenate into 80 mL of Butterfield's phosphate-buffered dilution water. Subsequent
10-fold dilutions were prepared. One mL of each dilution was pipetted into separate,
duplicate, appropriately marked Petri dishes. About 12–15 mL plate count agar (cooled
to about 45 ± 1 °C) was added to each plate and the agar was allowed to solidify. The
plates were incubated promptly for 48 ± 2 h at 35 °C.
As a positive control a group of 12 oysters was split into three subgroups, placed
in self-sealing sterilization pouches, and autoclaved (30 min at 121 °C and 18–20 psi).
At the end of the sterilization process using the same procedure described above, the
APC was assessed and confirmed to be zero.
2.5.

Statistical analysis
All oysters' experiments were replicated twice and assessments of APC counts

were run in triplicate for each replicate (n = 2 × 3). Mean values ± standard deviations
were used to plot the corresponding graph.
The test of the hypothesis that the bacterial load in treated vs. untreated oysters
was significantly different was done by application of the Mann–Whitney U test to
groups of log means of each set of two within sample replicates. The difference
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between the set of treatment group log means and the set of untreated group log means
was found to be significant when P < 0.05.
2.6.

Biochemical characteristics of bacteria isolated from oyster tissue
Several bacterial colonies were isolated from the oysters' tissues (treated

oysters); Gram staining, catalase tests, oxidase tests, mobility tests and fermentation
profiles were completed for each isolate. The catalase reaction was completed with 3%
H2O2. The ability of isolates to ferment specific carbohydrates was determined using
phenol red broth (enzymatic digest of casein [1%], supplement sugar [0.5%–1%],
sodium chloride [0.5%], phenol red [0.0018%], final pH: 7.4 ± 0.2 at 25 °C) to which
specific carbohydrates (glucose, sucrose, lactose or mannitol) were added. Oxidase
reagent droppers [0.5 mL of a 1% aqueous solution of N, N, N′, N′-tetramethyl-p
phenylenediamine dihydrochloride] were used for the oxidase test. Some isolates were
also cultured on the Vibrio selective thiosulfate-citrate-bile salts-sucrose (TCBS) agar
(yeast extract [0.5%], proteose peptone No. 3 [0.1%], sodium citrate [1%], sodium
thiosulfate [1%], oxgall [0.8%], saccharose [2%], sodium chloride [1%], ferric
ammoniumcitrate [0.1%], bromothymol blue [0.004%], thymol blue [0.004%], and agar
[1.5%]) (Table 6-2).
2.7.

Effects of scCO2 on bacteria isolated of oysters tissues
Four bacteria isolates possessing basic biochemical characteristics common to

pathogenic Vibrio sp (i.e., Gram negative, catalase positive, oxidase positive and growth
on TCBS agar) were cultured overnight at 35 ± 2 °C in ISP2. Ten milliliters of each
culture was pipetted into 50 mL Sterile Corning® centrifuge tubes. A hole was made in
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the cap of these tubes to allow the flow of scCO2 into the tube. Dry sterilized filtered
paper was used to cover the hole. Two such culture tubes were prepared for each of the
four isolates. These were placed together in the 100 mL vessel of the unit of the
Supercritical Fluid Technologies, Inc., SFT-150 SFE system and treated with scCO2 at
100 bar and 37 °C for 30 min. Bacterial counts were estimated by plate spread
technique using ISP2 or plate count agar; serial dilutions were completed in each case
and these plates were seeded with 100 µL of treated or untreated culture
2.8.

Kinetics of inactivation of two ATCC referenced Gram negative bacteria V.

fisheri and E. coli by scCO2
For each experiment, 2 mL of a freshly grown culture of E. coli and V. fischeri
contained in a 15 mL Sterile Corning® Centrifuge tube (Corning Incorporated, Big Flats,
NY), was introduced in the 100 mL vessel of the unit; a hole was also generated in the
plug-sealed cap of the centrifuge tube to allow the flow of scCO2 into the tube. The
experiment was completed under three different pressures (100, 150, and 200 bar) at
37 °C with the purpose of evaluating the effects of pressure variation on the sterilization
potential of CO2; exposure times were 5, 10, 15 and 20 min. The initial load was
estimated by plate count (E. coli) or by using a calibration curve (V. fischeri). At the end
of each experiment, the number of surviving bacterial cells was counted by plate spread
techniques [351]. Briefly, a fourfold serial dilution of each test culture was made in a 96
well-plate format. A few wells were selected for the bacterial count process via
spreading 25 µL of the content of the given wells or dilution on the surface of a plate
containing BOSS or nutrient agar; the bacterial count per well was repeated twice and
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the average value was considered as the final count. The experiment was repeated to
confirm the previously observed trend (n = 4).
2.9. Sensory assessment
The sensory analysis of oysters treated by scCO2 was assessed by a panel of 13
people. The features evaluated included physical appearance, smell, and texture of
oysters; the oysters were not tasted. Because they were not trained panelists, these
panelists were presented with standards (Figure 6-4) that would assist them in the
grading process. There were two such standards; the first was labeled as “fresh” and
the second as “spoiled.” The first standard was a freshly shucked, untreated oyster
while the second was an oyster that was left at room temperature for about two days
(enough to allow it to develop the mild odor associated with spoiled oysters). Each
panelist was asked to comparatively examine the physical appearance, smell, and
texture of these standards after what they were led to the oyster stations where five
groups of oysters were aligned side by side. One of these groups included untreated
oysters while the rest included oysters treated under a variety of conditions ([20 min,
100 bar, 37 °C], [50 min, 100 bar, 37 °C], [50 min, 200 bar, 37 °C], and [20 min, 200 bar
37 °C]). These oysterswere labeled using simple codes: X1, X2, X3, X4 or X5 (blind
study). The panelists were informed that one out of these five groups was made of
standard/untreated oysters. The panelists were then asked to evaluate the physical
appearance, smell, and texture of the oysters as closely resembling our standard for
“fresh” or our standard for “spoiled”. A third option, “intermediate” was also offered. A
score of two (2) was allocated for the adjective “fresh” (the most desirable). A score of
zero (0) was allocated for the adjective “spoiled” (the least desirable). Finally, a score of
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one (1) was allocated for “intermediate.” (Table 6-1) The overall “freshness score” for
each given oyster was the sum of scores it received for its texture, physical appearance,
and smell. This freshness score varied from 0 to 6. To be judged acceptable, an oyster
must have obtained an overall score ≥ 3.
Data from all the 13 panelists were pooled for each group of oysters and an
overall scorewas assigned per the group; this was the mean value of scores achieved
by individual oyster of each particular group.

Table 6-1. Guide used in grading oysters (treated and untreated): blind study

3. Results
3.1. Microbiological analysis of treated and untreated oyster samples
Oysters sampled in groups of 10–13 oysters were treated with scCO2 under the
following two conditions: 100 bar, 30 min, 37 °C and 60 min, 172 bar, 60 °C. After
exposure, the effect of scCO2 on the aerobic microbial load (APC) that contaminates the
GI system of these oysters was assessed using the FDA recommended approach to
food analysis (n = 6). The microbial load (Aerobic Plate Count) present in the GI system
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of untreated oyster samples was determined using this same approach and estimated
to be 1.8 × 107 CFU/g of oyster meat (EAPC).
It was estimated that exposure of oysters to CO2 (100 bar, 30 min, 37 °C) led to a
significant decrease (P = 0.002) in the load of oysters' bacterial contaminants. This
treatment induced a 97.6% reduction in the microbial load that contaminated their GI
tract corresponding to a 2-log reduction. A similar result was observed in previous
experiments with oysters exposed to scCO2 at 100 bar, 40 min, and 37 °C (data not
shown). The residual load of bacteria in these scCO2-treated oysters was estimated to
be about 4 × 105 CFU/g (EAPC) (Figure 6-2).
A greater bacteria inactivation level was observed with oysters exposed to 172
bar, 60 min and 60 °C. In this case the APC reduction was estimated to be 99.9%,
which corresponds to a 3-log reduction. This translates into reducing the initial load of ~
1.8×107 CFU/g (EAPC) of oyster meat to 3.3×104 CFU/g.
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Inactivating Effect of scCO2 on Bacteria that
Contaminate the Gut of Oysters

Aerobic Plate Count (APC) CFU/g o f Oyster
Homogenate (Log Scale)

P= 0.002

1.00E+08
1.00E+07
1.00E+06

***

1.00E+05
1.00E+04
1.00E+03
1.00E+02
1.00E+01
1.00E+00

Untreated

Treated

Figure 6-2. Inactivating effect of scCO2 on bacterial contaminant of oyster.
Oysters were thoroughly cleaned and treated at 100 bars, 30 mins and 37 ˚C. The oysters were
separate in 3 groups shucked in aseptic environment; the amount of APC was then estimated
using FDA recommended approach to food analysis. This whole experiment was repeated twice
for an “n = 6 (that is 2 * 3). Untreated Oysters were processed in a similar manner. The APC was
estimated twice also for an n = 6 that is (2 * 3)
*** Statistically significant difference

3.2. Effects of scCO2 on bacteria in vitro
As mentioned previously, V. parahaemolyticus and V. vulnificus are key players
in quality control programs for raw oysters. We anticipate assessing the effect of scCO2
on these microorganisms (in vitro and in vivo) in future studies. In the present
document, we have evaluated the effect of scCO2 on a non-pathogenic strain, namely
V. fischeri which we used as a model for Vibrio sp. The kinetic of inactivation of V.
fischeri by scCO2 was studied under three different pressures conditions (100 bar, 150
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bar, and 200 bar at 37 °C); exposure times were 5, 10, 15 and 20 min. The effects of
scCO2 on oyster bacterial isolates possessing several key biochemical features
common to pathogenic Vibrio spp (namely V. parahaemolyticus and V. vulnificus) was
assessed as well.

Figure 6-3. Comparative Effects of scCO2 on V. fisherii and another Gram negative
bacterium (E. coli) in vitro
The kinetic of inactivation of two Gram negative bacteria by scCO2 was studied. Cultures of (A) V.
6
8
fisherii (3 x 10 CFU/mL) and (B) E. coli (5 x 10 CFU/mL) were exposed to sc CO2 at 100 bar,
150 bar and 200 bar for 5, 10, 15 and 20 minutes.
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3.2.1. Effect of scCO2 on bacterial isolates possessing some basic biochemical
characteristics common to pathogenic Vibrio sp (in vitro).
Ten milliliters of overnight cultures of oysters' bacterial isolates (Table 6-2) was
exposed to scCO2 (100 bar, 37 °C) for 30 min. The initial microbial load was estimated
to be higher than 2 × 107 CFU/mL of broth. A complete (100%) inactivation was
obtained for all cultures. No growth was observed even in plates seeded with 100 µL of
the undiluted sample (pipetted directly from the test tube) (Table 6-3).
This experiment was replicated and the number of survivals in each case was
estimated in triplicate. This corresponds, at a minimum, to a 7-log reduction.
Subsequent experiments helped to establish that a 30 minute-long exposure is not
required to achieve this level of inactivation; similar results were achieved with cultures
treated for only 10 min.
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Table 6-2. A few biochemical features of bacterial isolates obtained from treated oyster tissues
Isolate code

Gram

Catalase

Oxidase

Type

reaction

reaction

On TCBS

Growth

Colonies

Mobility

Colonies’
Color
conversion

Isolate #13*

-

+

+

+

Green

-

+

AF

centered
colonies
Isolate #18*

-

+

+

+

Green

+y

+*

AF

Isolate #30*

-

+

+

+

Green

+d

+*

AF

Isolate #36*

-

+

+

+

Green

+d

+*

AF

y

d

*

: conversion to yellowish color ; : conversion to darker (blackish) colonies ; +: Positive ; -: Negative ; did not ferment glucose, lactose or mannitol
, +* poor growth, AF: anaerobie facultative
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Table 6-3. Effect of scCO2 on bacterial isolates possessing some basic
biochemical characteristics common to pathogenic Vibrio sp (bacteria count 2E +
07 CFU/mL a)

Figure 6-4. Standards used for sensory analysis of untreated vs. treated oysters
A sensory analysis of untreated vs. scCO2 - treated oysters was completed. To grade the physical
appearance, smell, and texture of oysters, a panel of 13 people used two standards; the first standard
was that for “fresh” oysters and the second standard was that for “spoiled” oysters. (A) Standard for
“fresh” (B) Standard for “spoiled”

3.2.2.. Comparative effects of scCO2 on two ATCC referenced Gram-negative
bacteria: V. fisherii and E. coli - kinetic of bacterial inactivation
V. fischeri was reduced to a non-detectable level (6-log reduction) after only 5
min of exposure to scCO2; this occurred independently of pressure. V. fischeri appeared
far more sensitive to the effect of scCO2 when compared to E. coli, for instance. E. coli
is considered one of the most sensitive bacteria to this treatment [352]. The complete
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inactivation of E. coli (8-log reduction), under these same conditions, was achieved only
after 20 min of exposure to scCO2. Dillow et al. (1999) and also Smelt and Rijke (1992)
reported similar results [353, 354]. Along with this decrease in bacterial viability came a
decrease in the pH of the culture. This decrease in pH can suggest a possible
mechanism for the bacterial inactivation.
3.3. Sensory assessment
Treated and untreated oysters were evaluated side by side by a panel of 13
volunteers in a blind study. A score was assigned to oysters individually and as a group.
To be judged acceptable, an oyster or a group of oysters must have achieved an overall
score ≥ 3. From the data collected, it was concluded that oysters remain acceptable, as
far as their physical appearance, texture and smell, after exposure to CO2 ([100 bar for
20 min at 37 °C], [100 bar for 50 min at 37 °C], [200 bar for 50 min at 37 °C] and [200
bar for 20 min at 37 °C]). The group of treated oysters that received the best rating were
those treated at 100 bar for 20 min at 37 °C (score = 4.4). Ratings for the other groups
were also ≥ 3. The group of untreated oysters achieved a score of 4.9.
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Oyster treated at 100bar, 37°C
for 40minutes (Group1)

Untreated Oysters (group 1)
Untreated 1

Untreated 2

Oyster treated at 100bar, 37°C
for 40minutes (Group2)

Figure 6-5. Appearance of oysters before and after a 40 minutes exposure to
scCO2.
The effect scCO2 on the physical appearance of oysters is presented. Oysters were sampled in
small groups and introduced in a supercritical unit (SFT-150 SFE system -Supercritical Fluid
Technologies, Inc.) where they were exposed to scCO2 for 40 minutes. They were then shucked
and photographed. Temperature and pressure conditions were 37°C and 100 bar.

4. Discussion
Herein, we report that the level of bacterial inactivation (Aerobic Plate Count)
achieved with scCO2 (100 bar for 30 min at 37 °C or 172 bar for 60 min at 60 °C), is
comparable to that achieved with several FDA approved PHP for oysters, namely, HHP
(High Hydrostatic Pressure) and QF (Quick Frozen). In 2009, Prapaiwong et al. reported
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a comparable residual amount of bacteria in HHP- and QF-treated oysters. Oysters
included in their study were sampled from batches of treated oysters on their way to the
market. These authors reported a Total Aerobic Plate Count (TAPC) of 1.4 × 104 CFU/g,
1.6×104 CFU/g, and 3.3 × 104 CFU/g in HHP-treated oysters harvested during summer,
winter, and fall, respectively. They reported similar amounts of residual bacteria in QFtreated oysters. Untreated oysters harvested during these same periods reportedly
contained 3.5 × 105, 2.8 × 105, and 1.4 × 109 CFU/g for oysters harvested during winter,
fall, and summer, respectively [332]. Bacteria that survived these scCO2 treatments
were mostly Gram negative similar to what has been reported for HHP-treated and QFtreated oysters [332].
Twenty-four out of thirty isolates were identified as catalase positive, and
eighteen as oxidase positive. Once in culture however, these isolates (a random
selection of four) appeared to be extremely sensitive to the effect of scCO2. According
to Lin et al. (1994) [355], the complex physicochemical environment of food products
especially a high fat content can increase the resistance of vegetative cells to the effect
of scCO2 by limiting the penetration of CO2.
Each of the current three FDA approved PHP for oysters, namelyHHP, HCP, and
IQF, has its advantages and disadvantages. One of the major selling points of High
Hydrostatic Pressure (HHP), for instance, is the fact that it induces a release of
adductor muscles from oysters' shells. Whether the release of these adductor muscles
is truly a desirable effect is somewhat controversial. While it makes shucking oysters
afterwards easier, it is important to note that the permanent release of such muscles is
a clear indication that oysters did not survive the process which in terms of shelf life
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could be an issue. Prapaiwong et al. (2009) [332] studying variations in the bacterial
load of HHP-treated oysters stored at 4 °C, determined that the bacterial count can go
from an initial 1.6 × 104– 3.3×104 CFU/g (post-treatment residual load) to about 107
CFU/g in just 7 days.
Based on the Cold Storage Chart of the FDA [356], the quality of such oysters
can be maintained for a longer period of time (~ up to 3 – 6 months) provided they are
stored at ~ −17 °C. We were able to verify that such long term storage does not affect
the quality of oysters. In fact treated and untreated oysters used for our sensory study
were stored at ~ −17 °C before analysis.
The scCO2 approach stands out in this regard because the release of adductor
muscles from oysters can be monitored. Oysters in this case were treated under two
conditions, one that can be considered as mild (100 bar, 30 min and 37 °C) and another
that can be considered harsher (172 bar, 60min and 60 °C). Contrary to what was
observed at milder conditions (100 bar, 30 min and 37 °C), treating oysters at 172 bar
for 60 min at 60 °C, caused a release of adductor muscles from the shell. Oysters
exposed to the milder condition however did not release their adductor muscles and
retained their fresh-like appearance closely resembling the untreated ones (Figure 6-5).
On the other hand, the oysters treated at 172 bar, for 60 min at 60 °C though still watery
appeared slightly cooked or steamed—certainly a direct consequence of the high
temperature. This effect was most pronounced in another group of oysters treated at
this same condition and left in the scCO2 unit afterwards for about 45 min; this set of
oysters was excluded from our analysis.
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After processing, oysters that remain alive are undoubtedly a better alternative.
This is, for instance, the major selling point of several emerging PHP techniques,
namely those using X-ray and gamma irradiation as cold pasteurizing agents [357]. Xray and gamma irradiation are believed to exert their bactericidal effect by damaging the
bacterial DNA. Because of the high probability that oysters' DNA could sustain the same
damage, concerns have been raised concerning the shelf life of X-ray and gamma
irradiation-treated oysters. As mentioned previously, treating oysters at 100 bar for 30
min at 37 °C did not release the adductor muscles. We have good reasons to believe
that oysters can survive mild scCO2 treatments, such as 100 bar for 30 min at 37 °C.
During trial experiments, a few oysters treated under similar pressure and temperature
conditions for 40 min (Figure 6-5) and afterwards put in a flask filled with water were
actually able to open and close their shells (on contact with a hard object) for several
days. This was a clear indication that they had survived the treatment. The ability of
individual oyster to survive such high pressure and CO2 concentration varies with
individual health. The LD50 of scCO2 on oysters will be addressed in future studies.
The sensory experiments revealed that oysters treated at milder conditions retain
their acceptability. It is important to note that of all the groups of oysters included in this
analysis, none received a perfect score of 6 (not even the group of untreated oysters).
Two oysters from this group were graded as “spoiled.” Because of current facility
limitations, the only feature used to decide whether any given oyster is alive or healthy
(thus qualifying for inclusion into the study) is whether or not their shell is tightly closed.
While it is true that this feature is shared by live oysters when brought out of the water, it
is also true that some oysters, unhealthy or even dead, could share this feature. This
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constitutes a source of bias and explains why two spoiled oysters were found in the
group of untreated oysters. This justifies why, as stated above, at this point, it is difficult
to clearly assess the LD50 of scCO2 on oysters. Another difficulty and possibly a source
of bias, especially when it comes to sensory analysis studies, is the way our scCO2 unit
is built; this instrument was designed for scCO2 extraction; the lack of uniformity in the
treatment chamber could result in some oysters being overexposed.
Although the exact mechanism of the bactericidal action of CO2 is still unknown,
it has been proposed that the bacterial inactivation might occur as a result of
acidification of the medium or product being sterilized. This acidification occurs as a
result of CO2 interaction with water, an interaction which ultimately results in the
generation of H2CO3. H2CO3 exists in equilibrium with HCO3- this equilibrium is
responsible for the release of protons in the bacterial environment, thus decreasing pH.

.

([353])

Low pH can then induce structural changes in the membrane of bacterial cells.
These changes, in turn, will increase the permeability of the membrane to CO2, which
then can freely diffuse and accumulate in the bacterial cell, interfering with the normal
metabolism of these living cells and ultimately resulting in the death of the bacteria [347,
353]. There have been several other proposed mechanisms of bacterial inactivation by
scCO2, such as removal of vital constituent from cell membrane, induction of
intracellular electrolytes imbalance, and direct effect of CO2 on bacterial metabolism,
among others [345, 346].
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In conclusion, the scCO2 based approach to warm pasteurization of oysters is a
promising PHP technique. In the present document, it is established that scCO2 is as
effective as several current FDA approved standard approaches to PHP of oysters (e.g.,
HHP and QF) aimed at reducing the microbial load (aerobic flora) present in the GI
system of oysters. We believe that the scCO2 approach will also be as effective in
reducing the load of most problematic oysters-associated bacteria, namely, V.
parahaemolyticus and V. vulnificus. The bacteria used as a model for Vibrio sp., namely
V. fischeri showed an extremely high sensitivity to scCO2 and bacterial isolates cultured
from oysters' tissues and sharing common biochemical characteristics of V.
parahaemolyticus and V. vulnificus showed an extremely high sensitivity to scCO2, as
well.
As a PHP approach, the scCO2 based approach provides quite a number of
advantages over other emerging oyster PHP technologies. Large scale scCO2 based
technologies for food processing are already available commercially and used
industrially for processes such as coffee decaffeination. This represents a serious
advantage over gamma and/or X-ray based PHP techniques. The use of scCO2 in food
industry is well-established and safe; it can thus be predicted that acceptance by the
public will be easier. We have also completed a sensory analysis, and no significant
change was noted as a result of oysters having been treated with scCO2.
Finally, as mentioned in the introduction, microbial contaminants are not the only
health hazard associated with oysters. Other risks include biotoxins, toxic metal, and
chemical environmental contaminants. None of the currently proposed PHP treatments
(e.g., HHP, IQF, HCP, X-ray based approach, and gamma-based approach) can reduce
262

the load of toxic metal, biotoxins, and chemical environmental contaminants in oysters.
Though it is beyond the scope of this paper, it is important to note that the ability of
scCO2 to remove such contaminants from various biological substrates is wellestablished [358, 359]
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